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Smoking has been shown to be a major modifiable risk factor for bladder cancer. How-
ever, apart from distinguishing between current smokers and former smokers, not many 
detailed analyses have been performed on lifetime smoking behaviour and bladder can-
cer risk. Furthermore, smoking cessation after diagnosis of bladder cancer could improve 
bladder cancer prognosis, but this has not yet been studied prospectively over a longer 
period yet.
In this thesis, the current evidence on the association between smoking behaviour (dura-
tion, intensity, cessation, passive smoking exposure, cigarette type) and bladder cancer 
incidence and prognosis has been summarised through several meta-analyses. Further-
more, a prospective study on smoking and bladder cancer recurrence is described as well 
as a consortium study pooling data from 15 case-control studies to further decipher the 
interplay between smoking duration and intensity in determining bladder cancer risk. 
Considering all evidence described in the results chapters of this thesis, it is suggested 
that duration of exposure to cigarette smoke is most important in determining bladder 
cancer risk and possibly also recurrence. Also, there does not seem to be any association 
between exposure to environmental smoke and bladder cancer. To provide more insight 
in how smoking causes bladder cancer, future studies should consider the possible as-
sociation between molecular subtypes and smoking behaviours.
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Smoking as risk factor alone is estimated to be responsible for 60,000 new cancer cases 
(19,4% of all cancer cases) occurring in the UK in 2010 [1]. Of these cases, about one in 
six (10,000 people) are diagnosed with bladder cancer [2] and about half of these cases 
has been estimated to be attributable to smoking [3]. Worldwide, the estimated number 
of new cases of bladder cancer in 2012 was 430,000 and the number of deaths due to 
bladder cancer was 165,000 [4]. Moreover, the global prevalence of bladder cancer can 
be estimated at approximately 2,000,000, indicating that at any time there will be a very 
considerable number of patients requiring surveillance and treatment [4].  While smoking 
is mostly known as the primary risk factor for lung cancer, it is also an important contribu-
tor to the pathogenesis of bladder cancer. Although most of these cases can be attributed 
to cigarette smoking or occupational exposure to carcinogens [5], bladder cancer patients 
seem to be less aware of smoking being a primary risk factor when compared to patient 
knowledge on smoking and lung cancer [6,7].
In addition to increasing bladder cancer risk, there are also reasons to believe that lifetime 
smoking behaviour might have a negative impact on bladder cancer prognosis [8]. There 
is also evidence that passive smoking (also known as exposure to environmental tobacco 
smoke) increases bladder cancer risk [9], although the evidence is not as strong as for 
lung cancer [10]. Bladder cancer is known for its high recurrence and progression rates 
after initial treatment [11], which impact on quality of life [12] and generate high disease 
management costs that result in considerable economic burden [13]. Since an estimated 
18.4% of people smoke worldwide in more economically developed countries [14], re-
search on the influence of smoking on the bladder cancer risk and prognosis is a highly 
relevant and dynamic field of study.
the epidemiology of blAdder cAncer And smoking
Bladder cancer incidence is highest in more developed countries and about 75% of patients 
diagnosed are male [4]. Next to gender, several non-modifiable risk factors for bladder 
cancer have been identified, including age, family history, previous radio- or chemotherapy 
and long-term or repeated urinary tract infections [5]. Additionally, having a history of 
upper-tract urothelial carcinoma is also known to increase the risk of disease occurrence in 
the bladder as well as tumour recurrences or disease progression throughout the urothe-
lium [15,16]. Large regional differences (e.g. only 5% of the total bladder cancer incidence is 
from low human development index countries) seem to indicate that there are also various 
modifiable risk factors known to attribute significantly to the bladder cancer risk. Some of 
the most studied factors include exposure to smoking and dietary behaviour, and exposure 
to certain chemicals [1]. Among these, smoking is the leading preventable risk factor for 
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bladder cancer [3]. Although the number of smokers is declining in most countries, roughly 
15-20% of the population in Western countries and much higher percentages (especially in 
men) in large parts of Asia are estimated to smoke regularly [17] (Figure 1). Therefore, and 
because smoking behaviour from 20 years ago will continue to generate new cases, it is 
likely that the smoking will continue to cause a signifi cant number of bladder cancer cases.
Figure 1. Worldwide, age-standardized smoking rates in males. Units of age-standardised 
prevalence in proportions (0 to <0.1 = 0-10%, 0.1 to <0.2=10-20% etc.) Adapted from: Re-
itsma et al 2017 [17]. 
Generally, the incidence of bladder cancer is slightly decreasing over the past decades, 
probably due to the declining number of regular smokers in men living in countries with 
a high Human Development Index [4]. However, a study comparing two regional cohorts 
in the UK over a 20-year interval (1991-1992 versus 2005-2011) showed that the propor-
tion of cases being diagnosed who have ever been exposed to cigarette smoking has 
remained similar [18]. This indicates that the overall number of current or former smokers 
remained stable over time and that other factors in smokers such as smoking behaviour 
(e.g. duration or intensity) or cigarette contents (e.g. high tar concentration) might have 
been different between both regional cohorts. Nevertheless, differences between both 
cohorts might be explained by the coding system which changed from coding papillary 
tumours of uncertain behaviour and carcinoma in situ differently than malignant bladder 
tumours to coding these as malignant bladder tumours after 2000 in the UK. Accordingly, 
the paper also shows that the most recent cohort had a larger percentage of patients pre-
senting with multiple tumours (p<0.001), tumours of more than 2 centimetres in diameter 




behaviour in more detail in relation to bladder cancer incidence are warranted to better 
explain and predict bladder cancer trends in the future.
moleculAr pAthology of urotheliAl cArcinogenesis 
In developed countries, over 90% of bladder cancers are transitional cell carcinomas of 
urothelial origin, the other 10% originate from the glandular cells (adenocarcinoma) or 
from irritation and inflammation of the bladder lining (squamous cell carcinoma) [19]. 
Urothelial carcinoma is a type of solid malignancy that can be explained through muta-
tional changes in DNA [20]. Generally, there are two pathways to developing urothelial 
tumours most often referred to as the papillary and the non-papillary pathways [21]. 
Transformation of the superficial urothelial cells generally results in papillary tumours. 
Therefore, papillary tumours are mostly non-muscle-invasive and of low histologic grade 
at diagnosis, but still have a high probability of recurring and the potential for progres-
sion. Non-papillary tumours are solid tumours that form through severe dysplasia and are 
more often high-grade at diagnosis and more likely to progress through the bladder wall 
and metastasize [22]. Although the pathways seem distinct, there is also some overlap 
between both pathways, because 10-15% of the non-muscle-invasive papillary tumours 
might eventually progress to high-grade muscle-invasive carcinoma. 
Based on the evidence there is now on the molecular pathology of bladder cancer, it is 
believed that most urothelial carcinomas (both papillary and non-papillary) arise from 
early transformational changes that may affect large continuous areas of the urothelium, 
so-called field changes, giving rise to the synchronous and metachronous multifocality 
(i.e. multiple tumours in the urothelium) that is often observed. Such abnormal fields may 
have arisen from the progeny of a single transformed cell, and the subsequent tumours 
are genetically related and thus of monoclonal origin [23].
Alternatively, it is suggested that multiple tumours originate from independently trans-
formed areas of the urothelium giving rise to genetically unrelated (oligoclonal) tumours 
[24]. Learning more about the underlying molecular patterns leading up to bladder cancer 
is of high clinical importance as appropriate treatment should be applied based on the 
molecular type of tumours observed [24]. Recent efforts have identified several forerunner 
genes that could be predisposing factors for bladder cancer and predict carcinogenesis 
earlier. For example, the P2RY5 gene in which an allele (G172T), which causes loss of 
function of tumour suppressor gene RB1, was found to be carried by 100% of smokers in 
a large case-control study [25]. 
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Some factors like multifocality, pathological characteristics of the primary malignant tu-
mour (papillary, non-papillary) and possibly implantation of remnant tumour cells in the 
bladder dome after transurethral resection are factors associated with increased recurrence 
rates and possibly also progression to muscle-invasive bladder cancer [26]. Apart from 
several possible molecular pathways leading up to bladder cancer, the tumour location 
within the urothelium can also explain different responses to therapy. Muscle-invasive 
bladder tumours in the basal cells are mostly associated with more aggressive disease at 
presentation and show up-regulation of p53 target genes while luminal muscle-invasive 
bladder cancers often show FGFR3 and PPAR mutations and are more resistant to several 
types of neoadjuvant chemotherapy [27,28]. 
Data from The Cancer Genome Atlas (TCGA) initiative has proven that bladder cancer 
consists of many molecular subtypes with specific genetic alterations and differences 
in response to therapy [29]. Nevertheless, recently a molecular taxonomy for urothelial 
carcinoma called the “Lund taxonomy” [30] has been validated using TCGA data and, using 
an mRNA-based classifier, the taxonomy could distinguish between 7 major molecular 
subtypes to estimate survival rates [31]. Understanding molecular pathology helps improve 
clinical care, but can also be useful in explaining differences in bladder cancer risk or prog-
nosis for smokers, when future studies merge epidemiological data with molecular data. 
the Aetiology of smoking-relAted blAdder cAncer
One of the first mechanisms through which smoking was believed to be related to bladder 
cancer development was established in the 1950s when the “o-aminophenol hypothesis” 
of arylamine-induced human bladder cancer was proposed [32]. This hypothesis sug-
gests aromatic amines to be conjugated by the liver and excreted in the urine where 
it would liberate the carcinogen o-aminophenol [32,33], thereby causing DNA damage 
and potentially bladder cancer. Smokers are exposed to several carcinogenic compounds 
including tobacco-specific nitrosamines (TSNA), polycyclic aromatic hydrocarbons (PAH) 
and arylamines. Most of the current evidence points towards 2-naphtylamine and 4-ami-
nobiphenyl as being the most common aetiologic agents in bladder cancer [34,35]. 
Arylamines need metabolic activation to become mutagenic metabolites with ultimately 
carcinogenic potential [36]. The result of metabolic activation through N-oxidation are N-
hydroxylamines, which are extremely toxic and can bind to DNA and haemoglobin to form 
adducts [37]. For instance, 4-ABP haemoglobin adducts are increased in blood of smokers 
compared to non-smokers [38]. N-hydroxylamines are detoxified through conjugation 




excreted via the kidney and bladder. At the same time, these conjugates are hydrolysed 
in the urine because of its acidity, and may form highly electrophilic N-acetoxy deriva-
tives with possible further bio activation through N-acetyltransferases (NATs). Because 
of the conditions in the bladder the detoxified compounds are reactivated and damage 
the urothelial cells and form DNA adducts, which are congregated parts of DNA with 
carcinogenic chemicals. If these DNA adducts are not repaired before cellular proliferation 
occurs, fixation of mutations in proto-oncogenes and/or tumour suppressor genes may 
occur. Such irreversible mutations have the potency to change a normal cell into a malig-
nant phenotype. Therefore, having a phenotype associated with slow N-acetyltransferase, 
has been shown to be a risk factor for bladder carcinogenesis through modulating the 
metabolism of carcinogens in cigarette smoke [39]. 
blAdder cAncer diAgnosis And treAtment
At diagnosis, the commonest symptom of bladder cancer is visible or non-visible haema-
turia (blood in the urine), which prompts a direct referral to the urology department if vis-
ible [40]. Other important symptoms include noticeable changes in urinary frequency and 
urgency, as well as a burning sensation while urinating [40]. After diagnosis, bladder cancer 
can be broadly divided into two stage groupings which have some overlap in biology 
but differ in extent to which the tumour has grown and are therefore treated differently: 
non-muscle-invasive bladder cancer (NMIBC), previously also called “superficial” bladder 
cancer, and muscle-invasive bladder cancer (MIBC) [11,40]. Approximately 75% of all oc-
curring bladder cancers are non-muscle-invasive at diagnosis [41,42]. NMIBC includes high 
grade carcinoma confined to the innermost layer of the bladder (Tis), papillary tumours 
confined to the mucosa (stage Ta) and tumours which have invaded the lamina propria 
(stage T1) according to the most recent update of the TNM classification guidelines [43].
In addition to this general classification of bladder cancer the World Health Organization 
also proposes a more detailed classification of diseases in International Classification of 
Diseases (ICD) codes. Currently, in the 10th revision of the ICD codes, bladder cancer is 
coded as ICD code C67 with 9 sub-codes, indicating the exact location of the malignant 
neoplasm such as the dome of the bladder (C67.1) or the posterior wall of the bladder 
(C67.4). Before the year 2000, no international coding system was widely applied for blad-
der cancer, so it is possible that studies published before 2000 include bladder neoplasms 
that are not recognised in the ICD codes which were adhered to in later studies [44]. 
NMIBCs are generally treated by transurethral resection of the tumour using a cystoscope/
resectoscope, followed by a single shot of mitomycin C (MMC) and long-term cystoscopic 
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surveillance [11,45]. The European Association of Urology (EAU) updates guidelines on 
treatment recommended for patients showing different tumour characteristics frequently 
to ensure most effective treatment for every individual case. Currently, the EAU suggests 
three risk groups in which non-muscle-invasive bladder cancer patients can be catego-
rised. Low-risk tumours consist of primary, solitary, Ta, low grade, <3cm, no CIS tumours; 
high-risk tumours are T1, high grade (G3), carcinoma in situ or multiple, recurrent and 
large (>3cm) tumours. Intermediate-risk tumours are those that have some but not all 
characteristics of either a low or high risk tumour (e.g. Ta, but grade 2) [11]. Apart from 
these clinical characteristics, there are no widely-accepted or validated tissue-based or 
urine-based biomarkers to complement this risk stratification yet [46].
Commonly used additional treatment options are forms of adjuvant intravesical chemo-
therapy such as Bacillus Calmette-Guerin (BCG) recommended for high risk (of recurrence 
and/or progression) patients and MMC for intermediate-risk patients [11,45]. The TNM 
stage 2 identifies tumour invading the detrusor muscle, so all tumours staged TNM 2 or 
further are classified as MIBC, meaning that MIBC also includes TNM stage 3 (tumour has 
expanded through the muscle layer) and TNM stage 4 (tumour invades adjacent tissues 
such as the abdominal wall or other organs) [43]. Figure 2 shows all the stages of bladder 
cancer schematically (Figure 2) [20]. 
Figure 2. Bladder cancer stages and grades, showing the differences between non-muscle-
invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC). Adapted from 
Knowles et al., 2015 [20].
Standard treatment for MIBC is neoadjuvant chemotherapy, sometimes followed by radi-
cal cystectomy (i.e. removal of the bladder) [40,45]. However, since cystectomy is a major 




old [47], who represent a considerable proportion of the total bladder cancer population, 
there have been studies investigating alternative therapy options. For example, recently 
it has been shown that a combination of chemotherapy and radiotherapy can achieve 
long-term outcomes comparable to those of neoadjuvant chemotherapy and cystectomy 
in organ-confined disease (stage T2 and T3a) [48]. 
lifetime smoking behAviour And blAdder cAncer risk
The evidence on the harmful influence of smoking on cancer risk is consistent and 
convincing in showing that at least 12 different types of cancer are partially caused by 
smoking. Some of these cancers include cancer in the lungs, colon and rectum, head 
and neck, pancreas and kidneys [49]. Especially the evidence for smoking causing up to 
50% of bladder cancer cases is compelling [3]. Nevertheless, still many studies focus on 
the relationship between smoking and bladder cancer because of the potentially large 
public health benefits of smoking cessation and the large proportion of cases attributed 
to smoking. Despite the large number of studies that focus on smoking, there have 
been only few attempts to model lifetime smoking behaviour including all its aspects in 
one model. However, acquiring a more wholesome view of how smoking causes blad-
der cancer, could be of high importance in determining which group(s) of smokers are 
most at risk for the development of (bladder) cancer, thereby providing cues for tailored 
prevention and smoking cessation programmes. In addition, analysis on different mode of 
inhalation, type of tobacco [50] and cigarette contents might also provide more detailed 
information on the relationship between smoking and bladder cancer risk.
duration of cigarette smoking and bladder cancer risk
Longer lifetime exposure to increased levels of carcinogens in urine (e.g. from cigarette 
smoke) might lead to a higher cancer risk and those who smoke longer are at an increased 
risk of bladder cancer. Therefore, smoking duration is an important factor in establishing 
the risk of bladder cancer.
In a large meta-analysis published in 2000, bladder cancer patients who had smoked for 
more than 20 years had a 2.13-fold higher rate of developing bladder cancer compared to 
those who smoked less than 20 years [3]. A similar finding was shown in a pooled analysis 
of 11 case-control studies, all contained data on smoking duration [51]. Those who had 
smoked for 5 to 9 years did not show an increased risk of developing bladder cancer 
compared to non-smokers, whilst those who smoked for 60 years or more had a 6.14-fold 
increased risk (95% C.I.=4.10-9.20), showing a marked increase in bladder cancer risk with 
longer duration of exposure. Even though several studies investigating this relationship 
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appeared after 2000; no pooled analysis has been performed on smoking duration data 
since then. 
Furthermore, starting smoking at a younger age, also seems to increase the risk of blad-
der cancer. A meta-analysis based on 5 observational studies, showed that subjects who 
started smoking at an age under 20 (OR=1.26, 95% C.I.=1.12-1.42) had a higher propor-
tion of bladder cancer cases compared to those who started smoking after the age of 20 
[3]. Although, this effect may have been confounded by total duration of smoking, which 
is generally also longer when starting smoking at a younger age. 
smoking intensity and bladder cancer risk
Another important factor when establishing the relation between smoking and bladder 
cancer is “smoking intensity”. Smoking intensity is most often expressed in number of 
cigarettes smoked daily; however sometimes the total number of cigarettes smoked over 
a lifetime is also used as a measure of smoking intensity. Smoking intensity is generally 
highly correlated with smoking duration (i.e. those who smoke many cigarettes per day 
often also smoke for many years) [52]. Therefore, considering smoking intensity (or dura-
tion) alone to predict bladder cancer risk is mostly too restrictive.
Nevertheless, previous research on smoking intensity showed that the higher smoking in-
tensity leads to an increased bladder cancer risk. A pooled analysis showed that compared 
to non-smokers, smoking 1-20 cigarettes a day, regardless of the duration category, the 
risk of developing bladder cancer was increased by 2.17 (95% C.I.=1.75-2.70), while smok-
ing more than 20 cigarettes a day increased the risk by 2.79 (95% C.I.=2.00-390). This effect 
for smoking more than 20 cigarettes a day, was more pronounced among men compared 
to women (OR: 2.91 95% C.I.=2.09-4.06; OR: 2.57 95%C.I.=2.24-2.94, respectively). Bren-
nan et al. also investigated smoking intensity in the relation with the bladder cancer risk, 
and found that 1-2 cigarettes a day did not significantly increase risk, while smoking more 
than 40 cigarettes a day showed an increased risk of 3.08 (95% C.I.=1.74-5.47) [51]. 
pack-years of smoking, modelling lifetime smoking behaviour 
and bladder cancer risk
Pack-years, the number of years smoking 20 cigarettes each day, are often used for 
estimating the effect of lifetime exposure to cigarette smoke on (bladder) cancer risk. 
This combined measure of smoking intensity and smoking duration has been useful in 
showing that there is an increasing dose-response relationship with larger total exposure 
to cigarette smoke [52–54]. However, because 20 pack-years can indicate both a smoker 
who has smoked 20 cigarettes per day for 20 years as well as a smoker who has smoked 40 




bladder cancer risk. Therefore, models which can discriminate between smokers with long 
duration and shorter duration within the same pack-year categories have been developed 
and tested in several types of cancers [55–57], including bladder cancer [58,59]. The 
results from these studies across smoking-related cancers are consistent in showing that 
longer duration of smoking is more deleterious than a short, high intensity exposure when 
comparing cases and controls with equal pack-years. Nevertheless, this has only been 
investigated using various modelling approaches in a few bladder cancer case-control 
studies [51,58–60].
smoking cessation and bladder cancer risk
As with any potentially toxic exposure, reducing the exposure is expected to reduce harm. 
Similarly, smoking cessation reduces bladder cancer risk, although not immediately as it 
might take more than a decade to substantially reduce risk compared to someone who 
continues smoking.
There have been several observational studies investigating the effect of smoking cessation 
on bladder cancer risk. For example, the large NIH-AARP cohort, in which residents of eight 
states in California were followed between 1995 and 2006 and asked for their past smoking 
behaviour through questionnaires, showed that former smokers who stopped 1-5 years 
ago were still at a high bladder cancer risk (HR=3.32, 95%CI=2.84-3.89) compared to never 
smokers and resembled the risk of current smokers (HR=3.89, 95%CI=2.54-3.80). However, 
those who quit smoking more than 10 years ago were at a less increased bladder cancer 
risk (HR=1.93, 95%CI=1.73-2.14) compared to the risk estimate for current smokers [61]. 
These results suggest that the longer the smoking cessation, the lower the risk of develop-
ing bladder cancer. Estimates on years of smoking cessation and bladder cancer risk have 
also been pooled and confirm these findings. Nevertheless, a dose-response relationship 
between smoking cessation and bladder cancer risk has not been established as studies 
showing results on 20 or even 30-year smoking cessation have not been pooled yet. 
type of tobacco: cigarette, pipe and cigar smoking and bladder 
cancer incidence
While smoking in general is a risk factor for bladder cancer, the type of tobacco and by 
what device tobacco is inhaled are also suspected to influence risk. From a pooled analysis 
of six case-control studies from Denmark, France, Germany and Spain, it was suggested 
that the harmful effect of smoking on bladder cancer risk differs between different smok-
ing methods. It was shown that cigarette smokers were at the highest risk (OR=3.5, 95 
% C.I.=2.9 – 4.2) compared to non-smokers, while pure cigar smokers (OR=2.3, 95 % 
C.I.=1.6 – 3.5) and pure pipe smokers (OR=1.9, 95 % C.I.=1.2 – 3.1) were at a relatively 
lower, but still substantial, risk of developing bladder cancer compared to non-smokers. 
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However, these estimates were not adjusted for duration of smoking and are likely to be 
dose-dependent. Especially overall estimates for cigar smokers should have been cor-
rected by duration, because those smoking cigars for more than 40 years were also at 
a 3.8-fold increased risk (95% CI=2.1-7.1) compared to never smokers [50]. Because the 
electronic cigarette was only recently introduced on a large scale, there have not yet been 
population-based studies investigating e-cigarette smoking and risk of known smoking-
related diseases.
cigarette content, mode of inhalation and bladder cancer risk
While cigarette smoking has been a well-studied risk factor for bladder cancer in 
epidemiological studies, the impact of different tar, nicotine and CO (TNCO) contents of 
cigarettes is less often considered in observational studies. Studies have shown that with 
the introduction of the filter tip, the bladder cancer risk decreased by more than two-fold 
compared to non-filter cigarettes [62–65]. Also, two observational studies considered 
total tar and nicotine intake where one study showed a linearly increasing risk of bladder 
cancer with increasing tar intake [66] while the other showed no differences in bladder 
cancer risk between low-tar versus higher tar cigarettes [67]. With the current evidence, 
it remains unclear whether cigarette content can explain regional differences in bladder 
cancer incidence between more developed and less developed countries.
environmental tobacco smoking and bladder cancer incidence
Exposure to environmental smoking, also known as passive smoking, is known to be as-
sociated with slightly increased risks of smoking-related diseases such as lung cancer [10]. 
However, the evidence for bladder cancer is ambiguous. In a 2004 review, Zeegers et al 
concluded that there were not enough epidemiological studies published to confirm the 
mechanistically plausible link [68] between environmental smoking and bladder cancer 
risk [69], since there had only been one case-control study [70] and one cohort study 
[66] reporting on environmental smoking and bladder cancer risk. However, after 2004 
several epidemiological studies investigated the effect of environmental smoking on 
bladder cancer risk and have recently been summarised in a meta-analysis [9]. In this 
meta-analysis, all exposure to environmental tobacco smoking was pooled and not strati-
fied for childhood exposure or work-related exposure for example. However, these studies 
have different ways of estimating exposure to environmental smoke but, in common, 
they always gather data on smoking patterns of significant others, such as spouses or 
parents. Point estimates from these studies show differing results and therefore remain 
inconclusive. Therefore, updating this meta-analysis and stratified pooling of these data 





smoking And blAdder cAncer prognosis
Fewer studies have been performed investigating smoking behaviour in relation to blad-
der cancer prognosis. Most prognostic studies do not focus on the effect of smoking 
behaviour, for example cessation, after diagnosis on bladder cancer prognosis, but take 
lifetime smoking into account as a confounding factor in prognosis. However, the number 
of studies reporting hazard ratios (HRs) for smoking categories in bladder cancer prognosis 
has increased and the body of evidence suggesting a role of smoking status at diagnosis 
in prognosis is growing, especially in NMIBC [8,71]. Studies on bladder cancer prognosis 
focus mainly on three endpoints: a) bladder cancer recurrence, defined as a new episode of 
bladder cancer within the same disease stage, b) bladder cancer progression: when blad-
der cancer recurs as muscle-invasive after a primary non-muscle-invasive tumour and c) 
disease-specific survival, measured in death due to bladder cancer. Since the known large 
differences in prognosis, studies should always make the division between non-muscle-
invasive and muscle-invasive disease because of their large differences in prognosis [11,40]. 
smoking and non-muscle-invasive bladder cancer prognosis
No prospective studies on the association between smoking behaviour and NMIBC prog-
nosis have been performed. However, there is a considerable amount of evidence on the 
role of smoking behaviour before diagnosis in NMIBC [72–81]. Results from these, mostly 
retrospective multicentre or large cancer or hospital registries, are reviewed in several 
systematic reviews [8,71,82] and show that smoking before diagnosis, increases the risk 
of recurrence in NMIBC patients who are treated by transurethral resection of the bladder 
tumour. In addition, smoking also seems to increase the risk of progression after trans-
urethral resection, however the evidence is less robust [8]. Although the impact smoking 
cessation after diagnosis has on bladder cancer recurrence and progression or mortality 
is not clear yet, there are examples of successful smoking cessation interventions in urol-
ogy clinics [83] and patients have been shown to be more likely to quit smoking after a 
diagnosis of bladder cancer [84,85].
smoking and muscle-invasive bladder cancer prognosis
All studies until now on smoking behaviour and MIBC prognosis were in patient popula-
tions who were treated with radical cystectomy (i.e. removal of the bladder), possibly 
introducing bias since smokers often have more co-morbid conditions and therefore 
will likely have been excluded from such surgical cohorts [82]. Two systematic reviews 
concluded that there is some evidence that smoking behaviour before diagnosis influ-
ences MIBC prognosis [8,82]. A large (n=1,506) retrospective studies performed by Rink 
et al, compared local recurrence and mortality rates in heavy long-term smokers with 
light short-term smokers. Heavy smokers had higher rates of disease recurrence (HR=2.22 
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95% C.I.=1.62-3.02) and higher bladder cancer mortality rates (HR=2.07 95% C.I.=1.44-
2.99) compared to light smokers [86]. These results are corroborated by another large 
study (n=2,287) which observed statistically different (p=0.006) local recurrence rates 
for smokers (35.5%) compared to non-smokers (33.0%) and a risk estimate of 1.30 (95% 
C.I.=1.01-1.69) comparing disease-specific survival rates across smokers and non-smokers 
[87]. However, there are also studies which indicate that the effect of smoking on MIBC 
recurrence and survival is marginal. Boorjian et al. observed no association between 
tobacco use and urethral recurrence rate (HR=0.97 95% C.I.=0.70-1.35) in 1,506 bladder 
cancer cases [88]. A similar finding was observed by Lee et al. and showed no association 
between smoking and recurrence free survival (HR=0.91 95% C.I.=0.63-1.31) and bladder 
cancer specific survival (HR=0.94 95% C.I.=0.64-1.37) [89]. Recently, a meta-analysis on 
smoking status and bladder cancer mortality showed current smokers to be at a 1.53-fold 
(95%CI=1.12-2.09) increased risk of bladder cancer-related death compared to never 
smokers [90], however the studies included in this analysis contained both NMIBC and 
MIBC populations. Summarising, it is possible that smoking plays a role in MIBC; however, 
prospectively gathered data is needed to confirm the earlier observed results from retro-
spective studies. 
smoking and malignant potential of bladder cancer at diagnosis
Besides studies on the association between smoking and bladder cancer recurrence or 
mortality, there are also studies that have investigated how lifetime smoking behaviour 
could influence the clinical and pathological characteristics of bladder tumours at diag-
nosis. One case-control study reporting on the effect of smoking on tumour subtypes 
at diagnosis (low grade NMIBC, high grade NMIBC and MIBC) found that risk estimates 
for smoking were higher for high grade non-muscle invasive and MIBC compared to low 
grade NMIBC, indicating that smoking might even stronger increase the risk of more 
aggressive disease [91]. This hypothesis is further strengthened by results from the Blad-
der Cancer Prognosis Programme which found that current smokers developed larger 
tumours (mean difference: 0.48cm, 95% C.I.=0.04-0.91), showed a higher T stage (mean 
difference: 0.25 95% C.I.=0.08-0.41), developed more high grade tumours (mean differ-
ence: 0.15 95% C.I.=0.00-0.30) and were on average 4.0 years younger at diagnosis (95% 
C.I.=-5.9 to -2.0) compared to never smokers [92].
Aim And hypothesis of the thesis
The aim of the research presented in this thesis is to more thoroughly investigate the 
association between smoking behaviour and bladder cancer risk and prognosis, by delv-




factor. We hypothesize that i) smoking duration is most important in predicting risk of 
developing BC and that ii) smoking cessation after diagnosis could potentially improve 
BC prognosis.
generAl study design 
More detailed insight into the association between smoking and BC risk and prognosis 
is provided through both meta-analysis research and primary research from a prospec-
tive cohort study of bladder cancer patients (BCPP) and an international consortium of 
observational studies investigating bladder cancer risk (BLEND).
the bladder cancer prognosis programme (bcpp)
The West Midlands Bladder Cancer Prognosis Programme (BCPP) is one of the largest 
prospective cohorts of bladder cancer patients worldwide including approximately 1300 
NMIBC and MIBC patients at baseline. The study was initiated by the Cancer Research 
UK Bladder Cancer Group at the University of Birmingham. The Nottingham Multi-Centre 
Research Ethics Committee gave approval for the study (reference: 06/MRE04/65 and 
clinicaltrials.gov registration number: NCT00553215). The aims of this multi-centre (10 
hospitals) study are to; i) improve knowledge on prognosis by identifying (modifiable) fac-
tors that influence recurrence or progression of bladder cancer, ii) to develop a prognostic 
tool that could better predict these outcomes in patients and iii) to better understand 
bladder cancer patient behaviour and self-perceived impact of diagnosis and treatment 
[93].
Individuals who visited one the participating hospitals in the West Midlands between 
December 2005 and October 2011 with symptoms suspicious of bladder cancer were in-
cluded. Patients with previous cancer of the urethra, bladder, ureter, or renal pelvis within 
the last decade were excluded. Inclusion criteria to participate in the BCPP cohort study 
were being over 18 years of age, able to provide consent and being fit for cystoscopy 
and/or surgical biopsy/resection. To collect data on information on social-demographic 
information, dietary intake, smoking behaviour and other health-related lifestyle behav-
iours, social support and quality of life and medical and supplement usage history, all 
participants were asked to fill in a semi-structured questionnaire under supervision of 
a research nurse and Case Report Forms (CRFs) were also collected by research nurses. 
This was repeated 3 months after diagnosis and hereafter yearly until 5 years after inclu-
sion. Moreover, patients’ medical records were continuously examined for 5 years after 
inclusion to check for recurrence or progression events and information on clinical treat-
ment. After pathological assessment, some of the initially included participants (for whom 
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baseline data had already been collected by the research nurses) were not diagnosed 
with bladder cancer but with other non-malignant disease, such as bladder inflammation, 
so no follow-up data was collected for these participants. Results from this prospective 
cohort study are published in Chapter 7.
the bladder cancer epidemiology and nutritional determinants 
(blend) consortium
The BLadder cancer Epidemiology and Nutritional Determinants (BLEND) consortium cur-
rently consists of 19 case-control studies and 7 cohort studies, including data from the 
already pooled European prospective investigation into cancer (EPIC). Recruitment for the 
BLEND consortium is ongoing, but at this point there are 13,306 cases, 21,307 controls 
and 693,248 cohort members in the BLEND dataset. The aim of pooling these observa-
tional studies is to gain more knowledge on the impact of dietary patterns, nutrients and 
individual food items on bladder cancer risk [94]. 
Besides data on dietary intake and disease status, BLEND also provides data on smok-
ing behaviour, age, gender, family history of cancer and tumour staging. After receiving 
datasets from the participating studies, datasets were cleaned and recoded to the same 
codebook and appended to form the BLEND database. Food items were coded according 
to the Eurocode 2 Core classification version 99/2, which contains coding for 2,362 food 
items [95]. 
The large sample size of this consortium allows for reliable estimation of relatively small 
effect sizes which are to be expected when investigating the impact of single food items 
or dietary patterns on (bladder) cancer risk which is the aim of the consortium. Although 
larger effect sizes are to be expected for smoking, this large sample size also allows for 
the application of complex statistical models that need sufficient power to yield reliable 




outline of the thesis
This thesis consists of two parts; the first part describes 4 studies that investigate smoking 
and bladder cancer risk and the second part described 2 studies looking at the asso-
ciation between smoking and bladder cancer prognosis. First, a large meta-analysis was 
conducted to investigate smoking behaviour in relation to bladder cancer risk chapter 2. 
Chapter 3 adds to this meta-analysis in summarising evidence on exposure to environ-
mental tobacco smoke and bladder cancer risk, stratified by adult and childhood expo-
sure. In chapter 4, the impact of both smoking duration and intensity on bladder cancer 
risk was assessed and compared within the BLEND consortium. Chapter 5 describes the 
impact of cigarette content on bladder cancer risk, as investigated in the BCPP cohort in 
collaboration with the UK department of health. After this, the second part starts with a 
meta-analysis summarising results from studies investigating smoking status at diagnosis 
and bladder cancer prognosis is presented in chapter 6. Chapter 7 describes the first 
study with prospective data (BCPP) on smoking cessation after diagnosis in relation to 
bladder cancer recurrence. Finally, chapter 8 summarises all research done for this thesis 
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Smoking is a major risk factor for bladder cancer (BC). This meta-analysis updates previous 
reviews on smoking characteristics and BC risk, and provides a more quantitative estima-
tion of the dose-response relationship between smoking characteristics and BC risk. 
methods:
In total, 89 studies with 57,145 BC cases were included and summary odds ratios (SORs) 
were calculated. Dose-response meta-analyses modelled relationships between smoking 
intensity, duration, pack-years and cessation and BC risk. Sources of heterogeneity were 
explored and sensitivity analyses were conducted to test the robustness of findings.
results:
Current smokers (SOR=3.14, 95% CI=2.53-3.75) and former smokers (SOR=1.83, 95% 
CI=1.52-2.14) had an increased risk of BC compared to never smokers. Age at first expo-
sure was negatively associated with BC risk. BC risk increased gradually by smoking dura-
tion and a risk plateau at smoking 15 cigarettes a day and 50 pack-years was observed. 
Smoking cessation is most beneficial from 20 years before diagnosis. The population 
attributable risk of BC for smokers has decreased from 50% to 43% in men and from 
35% to 26% in women from Europe since estimated in 2000. Results were homogenous 
between sources of heterogeneity, except for lower risk estimates found in studies of 
Asian populations.
conclusions:
Active smokers are at an increased risk of BC. Dose-response meta-analyses showed a 
BC risk plateau for smoking intensity and indicate that even after long-term smoking 
cessation, an elevated risk of bladder cancer remains. 
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bAckground
Bladder cancer (BC) is estimated to be the ninth most incident cancer worldwide, with 
around 400 000 new cases per year; the disease accounts for a larger share of total cancer 
incidence in more developed regions (1). Cigarette smoking is a major risk factor for 
urothelial cell carcinoma (which also includes cancers of the renal pelvis and ureter) (2). 
Since recent studies estimated 22.8% of Europeans (3), 18.1 % of North Americans (4) 
and 52.9% of males from China (5) smoke, it is expected to remain an important BC risk 
factor in the near future. Studies investigating the association between smoking and BC 
risk were summarized in a meta-analysis 15 years ago (2) and several systematic reviews 
(6-8). However, further relevant studies have emerged since these reviews, allowing for 
more robust estimates, more detailed subgroup analyses, quantification of BC risk by 
dose-response investigations.
According to age- and gender-adjusted estimates from an earlier meta-analysis, those 
patients smoking at diagnosis (current smokers) had a 3.33-fold increased risk of develop-
ing BC compared to never smokers, and for former smokers the summary odds ratio (SOR) 
was 1.98; these age-adjusted risk estimates were comparable between males and females 
(2). Furthermore, BC risk increased with the number of cigarettes smoked per day and the 
number of years of smoking, although this was only assessed in a dichotomous way (e.g. 
1-20 cigarettes per day vs. >20 cigarettes per day) in this meta-analysis (2). 
The aim of this study was to provide an up-to-date estimation of the role of smoking in 
BC risk and to gain a more detailed quantification on several smoking characteristics (i.e. 
smoking intensity, duration and cessation) by performing dose-response meta-analyses. 
methods
search strategy
Both Medline and Embase online databases were used to search for epidemiologic studies 
on cigarette smoking and BC incidence. The search included the (MeSH) search terms 
“urinary bladder neoplasms”, “incidence” “risk”, “smoking” and “epidemiologic studies” 
in different combinations and resulted in a total count of 2 112 articles after removal 
of duplicates. Publications were excluded if they did not involve humans. Publications 
that did not provide useable data to calculate risk estimates and the associated 95% 
confidence intervals for smoking characteristics and BC incidence were excluded. Included 
publications provided risk estimates for at least one of the selected cigarette smoking 
characteristics, including: smoking status (never, former, current), age at first exposure, 
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daily cigarette consumption (intensity), duration of cigarette consumption, number of 
smoking pack-years and number of years since cessation. Publications reporting only on 
ever versus never smokers were excluded. Where a single study was described in several 
publications, the most recent publication was used for analysis. 
data collection
The Newcastle-Ottowa Scale (NOS) scale (9) was used to assess study quality and to 
extract information on possible sources of heterogeneity within individual publications 
by two of the authors (FvO and SJ). Information on the following variables was extracted 
and numerated in a dataset: year of publication, country and geographic area (North 
America, Europe, Asia, Africa, South America), anatomic site (bladder, upper tract uro-
thelium, renal pelvis), cigarette smoking assessment (interview or questionnaire), case 
and control source (hospital, population or both) and factors adjusted for in the analysis. 
The association between smoking and BC risk is expressed in odds ratios (ORs) for both 
case-control studies and cohort studies included in this review. Where possible, risk esti-
mate data was extracted directly from included articles and included both unadjusted and 
adjusted estimates. When direct risk estimates were not available, two-way contingency 
tables were constructed separately and unadjusted ORs and 95% confidence intervals 
were calculated. Since age and gender are major confounders of the association between 
smoking and BC, all included adjusted risk estimates adjusted for at least age and gender. 
For smoking duration, intensity, pack-years and cessation, risk estimates for smoking and 
BC risk were recorded per category, for example per 10 years of smoking duration, when 
data was available. Publications were excluded if the number of cases and/or controls or 
the number of person-years were not given. The definition of bladder cancer was broad in 
this study; this means we did not exclude studies that did not mention exact ICD codes of 
included bladder tumours in their papers, as this information is often lacking in publica-
tions. Therefore, it is likely that the included studies do not only include patients that were 
diagnosed according to ICD codes after 2000, but also a wider group of non-invasive 
disease. Studies that did not make clear whether cases showed non-muscle-invasive or 
muscle-invasive disease were also included.
statistical analysis
To investigate publication bias, funnel plots were constructed, plotting the logarithmically 
transformed ORs against the standard error of the associated log(OR) (10). The distribu-
tion of study risk estimates across the funnel plot was examined visually and Egger’s test 
for small study effects was performed to assess the degree of asymmetry (10). A random 
effects model was employed in all meta-analysis procedures. Between-study variance 
was estimated by I2 and subgroup analyses. Stata statistical software was used for all 
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analyses (version 13; Stata Corp., College Station, TX) and a p-value smaller than 0.05 was 
considered statistically significant in all analyses.
Summary ORs were estimated using classical meta-analysis for smoking status, age at 
first exposure (>20 years versus ≤20 years) and these results were obtained separately 
for men and women if data were available from the included publications. A cumulative 
meta-analysis was performed to investigate whether the association between smoking 
and BC incidence varied in time. Subgroup analyses were performed to explore differ-
ences in risk estimates between possible sources of heterogeneity, including geographic 
area, anatomic site, case and control source, study design and smoking assessment. The 
association of smoking duration, intensity, pack-years and cessation with BC risk was 
examined using a dose-response meta-analysis. The assigned dose for the dose-response 
analysis was determined by taking the median of each category (e.g. 15 cigarettes for 
category 10-20 cigarettes per day). Dose-response trends were estimated using both the 
variance weighted least squares (VWLS) and generalized least squares (GLS) regression 
methods (11). Since GLS is the most robust method which accounts for inevitable covari-
ance between study observations in a meta-analysis, the results from the GLS method 
are presented. Restricted cubic splines, which set knots at the 5th, 35th, 65th and 95th 
percentile, were used to investigate statistical non-linearity for all curves. Finally, popula-
tion attributable risk (PAR) of BC for current smokers compared to never smokers was 
estimated for Europe, North America and China using the overall pooled risk estimates 




For this meta-analysis, 99 articles that discussed cigarette smoking and BC incidence 
were identified between 1968 and 2015 based on their abstract. After full text evalua-
tion, 89 articles were included for full analysis (Figure 1). Study characteristics including 
year of publication, country, case/control source, smoking assessment and anatomic site 
are summarized in Table 1. Six articles were excluded after full-text evaluation due to 
insufficient NOS score, duplicate populations in several articles or not being published 
in English (101-106). Furthermore, three articles only presented data on ever smokers, as 
opposed to current and former smokers (107-109), and one cohort study did not present 
95% confidence intervals and omitted the case-control data to calculate these (110).
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Figure 1. Flowchart of study selection and exclusion criteria.
Of the 89 included studies, 72 were case-control studies (12-27, 29, 30, 32-38, 40-42, 44-
49, 51, 53-65, 68, 70-73, 76, 77, 79, 81-87, 89, 90, 92, 93, 95-99) and 17 were cohort studies 
(28, 31, 39, 43, 50, 52, 66, 67, 69, 74, 75, 78, 80, 88, 91, 94, 100). Three articles presented 
risk estimates from different study populations and were considered as separate studies 
in the analysis (9, 78, 84). In the case-control studies, cases were identified from hospitals 
(n=46) (13-15, 17-23, 26, 29, 33-38, 40, 41, 46, 49, 53, 54, 57, 58, 64, 65, 70-73, 76, 77, 81, 
83, 85, 86, 89, 90, 93, 96-99) or in predefined populations (n=24) (16, 24, 25, 27, 32, 35, 42, 
47, 48, 55, 56, 59-63, 68, 79, 82, 84, 87, 92, 95), and two studies used both hospital- and 
population-based cases (12, 30). Thirty-nine of the case-control studies recruited controls 
from hospitals (12-14, 16, 17, 19, 21-24, 26, 29, 33-37, 40, 41, 44-46, 49, 50, 53, 54, 57, 58, 
63-65, 68, 70, 71, 73, 74, 76-79, 81-83, 85-87, 89, 91-93, 96, 97, 99) and thirty-three case-
control studies recruited population controls (15, 18, 20, 25, 27, 30, 32, 35, 38, 42, 45, 47, 
48, 51, 52, 55-57, 59, 61-63, 68, 70, 72, 79, 82, 84, 87, 90, 92, 95, 98). Detailed information 
on cigarette smoking habits was assessed by interview (n=62) (12-18, 21, 23, 25-27, 29, 
30, 32-38, 40-46, 48, 49, 51, 53-55, 58, 59, 61, 62, 64, 65, 70, 72, 73, 77, 79, 81-87, 89, 90, 
92, 93, 95-99), questionnaire (n=26) (19, 20, 24, 28, 31, 39, 47, 52, 56, 57, 60, 63, 66-69, 71, 
74-76, 78, 80, 88, 91, 94, 100), and medical records (n=1) (50).
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publicAtion biAs And heterogeneity
Based on appraisal of funnel plots (Supplemental Figure 1), some publication bias (mostly 
large studies published) seemed to be present in studies that present unadjusted ORs 
(n=45). Publication bias seemed to be of less importance in studies presenting age and 
sex adjusted (n=11) and multiple-adjusted (n=13) ORs. The usefulness of funnel plots is 
greatly reduced when less than 10 studies are included. Egger’s test for small study effects 
demonstrated that there was no bias in the distribution of published results (p=0.150). 
Judging from I2 statistics there may have been heterogeneity (most I2 values between 70% 
and 90% for both classical- and dose-response meta-analyses), however when assessing 




Supplemental Figure 1. Funnel plots for (A) age and sex adjusted risk estimates, (B) multivari-
ate adjusted risk estimates and (C) all unadjusted risk estimates.
risk estimates from classical meta-analysis 
Table 2 summarizes both unadjusted and adjusted estimates for smoking status and age 
at fi rst exposure obtained from the classical meta-analysis. The adjusted SOR for current 
smokers compared to never smokers was 3.14 (95% CI, 2.53-3.75). Former smokers had 
a 1.78 (95% CI, 1.53-2.03)-fold increased risk of developing BC compared to never smok-
ers. This association was comparable between men (3.44, 95% CI=2.67-4.22) and women 
(3.56, 95% CI=2.76-4.36). When investigating all obtained estimates, the observed SORs 
remained comparable to the adjusted estimates. For age at fi rst exposure, 5 male-only 
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studies presenting age-adjusted risk estimates were pooled which resulted in a SOR of 
1.36 (95% CI=0.91-1.80) comparing males who started smoking before the age of 20 to 
those who had started smoking after the age of 20. Unadjusted SORs showed no effect of 
age at first exposure in females (0.99, 95% CI=0.31-1.68) as opposed to stronger associa-
tions for males only (1.34, 95% CI=1.02-1.68) and studies including both sexes (1.30, 95% 
CI=1.13-1.47).
risk estimates from dose-response meta-analysis
Dose-response curves estimated from studies reporting on smoking intensity (n=23) (25, 
30, 33-35, 37-40, 45-48, 57, 62, 67, 71, 78, 81, 82, 92, 99), pack-years (n=8) (34, 50, 61, 
71-73, 82, 94), duration (n=15) (25, 30, 38, 39, 47, 53, 59, 62, 67, 71, 75, 82, 92, 96, 99) and 
cessation (n=7) (25, 33, 38, 67, 72, 92, 94) and BC risk are depicted in Figure 3. The shape 
of both the intensity and pack-years curves is reminiscent of a logarithmic curve, show-
ing a rapid increase of BC risk before declining at a certain point. For intensity, BC risk 
increases only marginally from smoking more than 15 cigarettes a day, and likewise for 
pack-years from 50 pack-years onwards. The risk of BC increases almost linearly increases 
by smoking duration in years, although statistical tests for non-linearity showed that it 
is non-linear (p<0.05 at all investigated knots). Those who stopped smoking more than 
25 years prior to diagnosis were approximately at a 1.5-fold higher risk of BC compared 
Figure 2. Forest plot depicting crude summary odds ratios (SOR) for current smokers versus non-
smokers, by several possible sources of heterogeneity. The dashed line represents no effect and the 
solid line stands for the overall crude SOR of 2.96.
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to never smokers, whereas those who stopped smoking between 5 and 15 years prior to 
diagnosis were at a two-to threefold increased risk of BC compared to never smokers. 
There is a slight stagnation around 10 years of cessation, indicating a relatively small risk 
reduction between 5 and 15 years of smoking cessation. Nevertheless, this stagnation 
might also be explained as an artefact in the analysis, caused by the inclusion of only 
categorical data which did not span every possible value of smoking cessation in years 
as most included studies reported data on 10 years of cessation and none on 6 years for 
example.
sensitivity analyses
Subgroup analyses investigating the risk of BC of current smokers versus never smokers 
were performed to check for the influence of potential sources of heterogeneity (Figure 
2). Most subgroup estimates seemed to be consistent with each other and did not indicate 
heterogeneity. However, the SOR of 1.91 (95% CI=1.65-2.17) for the 7 included Asian 
studies was lower compared to both European (n=25, p=3.93*10-7) and North-American 
estimates (n=34, p=4.40*10-6). Of these 7 studies (including 2.760 cases), 4 investigated 
Chinese populations (84, 85, 93, 96), 2 investigated Japanese populations (18, 91) and 
there was one prospective study in a Korean population (69) to estimate the effect of 
smoking on BC risk. 
Across these 7 studies, estimates consistently indicated a two-fold increase of BC risk as 
opposed to the overall (and European and American) estimate of a three-fold increased 
risk of BC for current smokers compared to never smokers.
A cumulative meta-analysis, performed to check whether the risk estimate of BC for cur-
rent smokers compared to never smokers changed over time since (included publications 
appeared in print between 1968 and 2015) indicated that there was a slight increase 
of BC risk for current smokers versus never smokers over time (Supplemental Figure 2). 
However, when only considering multiple adjusted (at least adjusted for age and sex) 
estimates, there were no changes in estimated risk of BC (data not shown). 
In addition to the presented dose-response curves estimated by GLS regression using 
restricted cubic splines, other methods (VWLS, linear regression) did not show different 
results compared to GLS regarding the estimated regression slope for all investigated 
smoking characteristics. Furthermore, the shape of the dose-response curves did not 
change substantially by varying with positioning of knots using the cubic splines method 
or when applying a fractional polynomials approach for curve estimation. 
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Supplemental Figure 2. Cumulative meta-analysis results including ORs from all studies com-
paring BC risk between current smokers and non-smokers. The dashed line represents the 




In Europe, approximately 28% of males and 18% of females smoke (3), whereas in the USA 
these figures are estimated to be 21% and 16% (4). By combining these figures with the 
pooled risk estimates per continent from this meta-analysis PARs were calculated (Table 
3). The fraction of BC cases attributable to cigarette smoking is 43% for males and 26% for 
females in Europe and 34% for males and 30% for females in the USA. Unfortunately, no 
studies presenting gender-specific ORs were found for the Chinese population, however 
the PAR in the whole population seems smaller (20%) compared to both Europe and the 
USA, while the prevalence of smoking is larger in China (5).
Table 3. Population attributable risk (PAR) of bladder cancer per exposure to cigarette smoking in 
North-America, Europe and China
Men and women* No. of studies SOR Pe (smoking) PAR
North-America 13 3.08 0.18 27%
Europe 9 3.62 0.23 37%
China 4 1.87 0.28 20%
Men-only     
North-America* 8 3.55 0.21 34%
Europe** 13 3.67 0.28 43%
China 0 - 0.53 -
Women-only     
North-America* 8 3.72 0.16 30%
Europe** 13 2.92 0.18 26%
China 0 - 0.02 -
SOR=summary odds ratio; Pe=prevalence of exposure (smoking);  
PAR=population attributable risk 
* based on age-and sex-adjusted estimates only 
** based on both adjusted and unadjusted estimates
discussion
This meta-analysis summarizes the findings of 89 observational studies encompassing a 
total of 57 145 BC cases investigating the association between cigarette smoking and BC 
risk. 
smoking status and age at first exposure influence bc risk
Our findings support earlier reviews in indicating an increased risk of BC for cigarette 
smokers. Age at first exposure is negatively associated with BC risk, however no studies 
adjusted for smoking duration or smoking intensity as possible effect modifiers in the 
included publications. 
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dose-response relationship between smoking intensity and bc 
risk with a risk plateau at 15 cigarettes a day
Increasing smoking intensity (i.e. smoking more cigarettes per day) seems to be of less 
additional impact on BC risk when smoking more than 15 cigarettes a day. Perhaps sur-
prisingly, very heavy smokers (e.g. 50 cigarettes a day) do not experience a markedly 
increased risk compared to less heavy smokers. A similar relationship is observed for 
pack-years, but with a risk plateau at approximately 50 pack-years. These results are in line 
with experimental and molecular epidemiological studies in which saturation is observed 
of smoking-related DNA adduct levels in lymphocytes and lung cells at higher doses, 
leading to non-linear dose-response relationships (111). In the bladders of mice treated 
with the bladder carcinogen 4-aminobiphenyl (4-ABP), adduct levels in bladder-DNA and 
associated bladder tumours increased by dose at low doses, but saturation was observed 
at high doses (112). Similarly, in smokers, adduct levels (derived from the tobacco carcino-
gens Polycyclic Aromatic Hydrocarbons and 4-ABP) in blood cells plateaued at 20 ciga-
rettes per day (113), which is in concordance with the presently observed dose-response 
relationship in BC risk. Although these studies might provide some biological explanation 
for the observed risk plateau it is not replicated in other smoking-related cancers such 
as lung cancer (114), where the association seems to be linear, or head-and neck cancer 
where some studies show a similar risk plateau (115) but others indicate a linear associa-
tion (116). What might be reflected in the risk plateaus in the curves for bladder cancer are 
the reduced number of persons at risk of bladder cancer among heavy smokers, since they 
might have already died because of other smoking-related diseases such as lung cancer, 
cardiovascular disease or chronic obstructive pulmonary diseases. Nevertheless, more 
research is needed on the possible biological mechanism that underlies the observed 
association between smoking intensity and BC risk if there is any.
smoking cessation is most beneficial more than 20 years prior 
to diagnosis, but former smoking is still associated with a long-
term bc risk increase compared to never smokers
Many smokers believe that smoking cessation will cause their risk of several diseases to 
return to the risk of a non-smoker over a very short period (117). However, this analysis 
unambiguously shows that lowering BC risk after smoking cessation takes time. The 
beneficial effect of smoking cessation on BC risk is largest when having stopped smoking 
more than 20 years prior to diagnosis. Even then the risk of former smokers does not 
return to the risk of non-smokers. Even after 20 years of cessation, ex-smokers remain at a 
50% increased risk compared to those who have never smoked. Furthermore, there does 
not seem to be a substantial risk reduction between 5 and 15 years of smoking cessation 
prior to diagnosis. Although smoking cessation seems to be the only efficient mechanism 
to counteract smoking-induced pathogenic processes leading to cancer (118), these 
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results show that the malignant effects of exposure to tobacco-related carcinogens can 
linger for a lifetime in the bladder. The risk of BC per year of smoking increases gradually 
every year, indicating that smoking cessation programmes should aim to achieve smok-
ing cessation as early in life as possible to effectively decrease BC risk due to smoking. 
The presented dose-response curves might be useful aids for developing such smoking 
cessation strategies.
lower risk of bc for smokers in Asian compared to caucasian 
populations
All studies in Asian populations observed lower ORs compared to pooled estimates from 
Europe and the USA. A similar difference was observed in lung cancer, where a meta-
analysis showed a markedly lower pooled RR for smokers compared to never-smokers 
in Asian populations (pooled RR=5.52, 95% CI=2.83-10.78) compared to studies in Cau-
casian populations (pooled RR=9.94, 95% CI=5.92, 16.67) (119). Even though the exact 
mechanism behind this lower susceptibility for tobacco-related cancers in Asian popula-
tions remains unclear, there is some evidence that nicotine intake from cigarette smoking 
is lower and that therefore Asian populations might be less susceptible genetically to the 
harmful effects of tobacco smoke compared to Caucasian populations (120) or that the 
high number of never smokers exposed to passive smoking, especially in females, might 
play a role in explaining the weaker association between active smoking and bladder 
cancer in Asian populations (121). 
decreased population attributable risk (pAr) in Western 
countries for cigarette smoking in bc
The PAR calculated for Europe was noticeably lower compared to the estimated PAR from 
the 2000 meta-analysis (2), where it was estimated that 50% of male cases and 35% of 
female cases were attributable to smoking, as opposed to the 43% and 26% for men and 
women respectively which were estimated in the current meta-analysis. This indicates that 
the burden of smoking on bladder cancer incidence has decreased. Although we have no 
earlier PAR estimate for the USA, it is likely that a similar decrease in BC risk attributable 
to smoking has occurred during the past 15 years. These lower figures are due to the 
currently decreasing number of smokers in these populations (3, 4), since the risk of BC 
associated with smoking remains unaltered as we show in our cumulative meta-analysis. 
Even though the PARs were lower, the total number of worldwide incident BC cases only 
slightly decreased from 356 557 in 2002 (122) to 330 380 in 2012 (1), emphasizing the 
continuing importance of development of effective smoking cessation and prevention 
programmes. Interestingly, a pooled analysis from Nordic countries found very similar 
PARs (41% in males and 32% in females) to what we have observed now already in 1997 
(123), indicating that there might be meaningful differences in PAR even at a regional 
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level. Unfortunately, no PAR has been calculated previously for Eastern countries so 
we could not compare our estimated PAR for China to previous results. However, since 
smoking prevalence is still on the rise in China (5), it is highly unlikely that the PAR has 
decreased over the past years in China or other Eastern countries. 
bias and heterogeneity
Although the number of included studies was large, many articles did not present ad-
justed risk estimates. Since there was a difference in pooled OR between studies showing 
adjusted estimates compared to unadjusted estimates, we expect that not adjusting for 
at least age and sex might lead to underestimation of the strength of the association 
between smoking and BC incidence given the higher pooled OR for adjusted risk esti-
mates. In the dose-response meta-analysis, both adjusted and unadjusted risk estimates 
were included and there was no heterogeneity between studies caused by the number of 
factors adjusted for. 
In this meta-analysis, publication bias may have played a role since no attempts were 
made to include unpublished observations and several studies were excluded because of 
not meeting the selection criteria. However, since the number of included studies is very 
high, missing unpublished or excluded results will not have affected the presented risk 
estimates significantly. Additionally, when investigating funnel plots, the observed bias 
was bipolar (e.g. included both higher and lower estimates) and occurred mostly between 
larger studies. Since some degree of heterogeneity was likely to occur due to differences 
in study methodology (e.g. study population, design, smoking assessment) between the 
large number of studies included, a random effects approach to the meta-analyses was 
used. This approach allowed for more heterogeneity in studies beyond sampling error, as 
opposed to a fixed effects approach (124).
sensitivity analyses
Subgroup analyses showed that SORs were similar across several possible sources of 
heterogeneity, except for studies from Asian populations. A cumulative meta-analysis 
showed no time effect on the overall risk estimate of smoking for BC. Although several 
regression methods were used for dose-response curve estimation, there were no differ-
ences between the shapes of the estimated curves resulting from the different analyses. 
Also, varying the knots (which determine how the curves are estimated) did not cause 
major changes in the shape of the curves. Both observations lead to the conclusion that 




Because only 15 studies which adjusted for multiple factors (of which 8 adjusted their BC 
risk estimates for smokers for factors other than age and sex) were included, the pooled 
estimates obtained are not completely free of possible confounding due to other factors 
influencing BC risk. The number of studies adjusting for multiple risk factors was probably 
low because especially the more recently published studies often do not focus solely on 
smoking but only considered smoking status as a stratifying factor in their molecular 
analyses for example. Nevertheless, apart from smoking, only occupational exposure to 
carcinogens has been identified as a major risk factor for BC. Since estimation of oc-
cupational exposure to carcinogens requires specific data collection on job history which 
is often only done in studies focussing on occupation and BC risk, none of the included 
studies on smoking and BC adjusted for occupational exposure in the risk estimates 
presented in their papers. 
Additionally, most of the included studies were not clear on what classification for bladder 
cancer was used to indicate cases in the individual studies and merely stated broadly that 
a diagnosis of bladder cancer was needed for inclusion. Since the ICD coding, as well as 
the TNM classification, have changed over the approximately 45 years this meta-analysis 
spans, this might have caused some heterogeneity between the included risk estimates. 
Apart from not always showing data on tumour classification, studies included in this 
meta-analysis did not include sufficient data to stratify for important molecular aber-
rations which play a role in BC development. Studies on molecular determinants of BC 
development have unveiled TP53 mutation and chromosome 9 defects as frequent mo-
lecular aberrations in BC aetiology (125, 126). Also, glutathione S-transferase M1 (GSTM1) 
and N-acetyl transferase2 (NAT2) deficiency are both associated with increased bladder 
cancer risk and are together estimated to account for about 30% of bladder cancer cases 
in Caucasian populations (127). Recently, several single nucleotide polymorphisms (SNPs) 
associated with increased risk of BC have been identified on candidate genes such as 
fibroblast growth factor receptor 3 (FGFR3) and telomerase reverse transcriptase (TERT) 
(128). Some case-control studies focusing on molecular aberrations and BC also included 
data on smoking, however almost all the molecular studies found in our search did not 
present any useable smoking data for this meta-analysis.
conclusion
Our findings are in line with results from earlier meta-analyses and reviews indicating 
an estimated threefold higher risk of BC for cigarette smokers. Age at first exposure was 
negatively associated with BC risk. The proportions of BC cases attributable to smoking 
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(PARs) were noticeably lower than estimated in 2000 for both males and females, driven 
by the decreasing number of smokers in Western countries. Furthermore, we estimated 
dose-response curves providing a more graphic quantification of the impact of smoking 
intensity, pack-years, duration and cessation on BC risk which provide opportunities for 
development of smoking cessation- and prevention programmes which should aim for 
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3 A stratifi ed meta-analysis of the association between exposure to 
environmental tobacco smoke 
during childhood and adulthood and 
urothelial bladder cancer risk.
Frits H.M. van Osch, Sylvia H.J. Jochems, Anke Wesselius, 
Frederik J. van Schooten, Richard T. Bryan, Maurice P. Zeegers
Adapted from:





Active smoking is a major risk factor for urothelial bladder cancer (UBC). However, the 
evidence that exposure to environmental tobacco smoke (ETS) either in childhood or 
adult life is also associated with UBC risk is ambiguous. With this meta-analysis, we aim to 
summarise how exposure to ETS is associated with UBC risk. 
methods
In total, 11 studies (3 cohort studies, 8 case-control studies) were included in this meta-
analysis and summary odds ratios (SORs) for UBC risk were calculated for a total of 27.753 
never smokers who were exposed to ETS during childhood at home, during adulthood 
at home, or during adulthood in a work environment compared to never smokers who 
were never exposed to ETS. Sensitivity analyses were conducted to test the robustness of 
findings. 
results
Never smokers exposed to ETS during childhood (SOR = 1.04, 95% confidence interval 
(CI) = 0.82–1.26), during adulthood at work (SOR = 0.98, 95% CI = 0.78–1.18) or at home 
(SOR = 0.99, 95% CI = 0.83–1.15) were at a similar risk of UBC compared to never smokers 
who were never exposed to ETS. Results for males and females were similar. Also, when 
pooling all estimates during both childhood and adulthood, no effect was observed (SOR 
= 1.00, 95% CI = 0.89–1.10). 
conclusions
Although measurement of exposure to ETS was imprecise, there does not seem to be 
an association between UBC risk and exposure to ETS during childhood or adulthood. 
However, the current body of evidence mostly overlooks the duration and intensity of 
exposure to ETS.
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introduction
Cigarette smoking is a major risk factor for urothelial bladder cancer (UBC) and account-
able for a large proportion of UBC cases (1). On average about 18% of adults smoke 
tobacco daily, with variation between countries worldwide (2). Although the number of 
smokers has decreased recently, there are still a lot of individuals potentially exposed to 
environmental tobacco smoke (ETS). Although fewer cases of cancer can be attributed 
to exposure to ETS compared to active smoking, it is a type of exposure that can be 
prevented to a large extent.
A comprehensive Surgeon General’s report from 2006 on the health consequences of 
involuntary exposure to tobacco smoke in the United States described how homes and 
workplaces are the most common places for exposure to ETS, and that those with a 
relatively low income are more likely to be exposed to ETS (3). Moreover, a retrospective 
analysis of 192 countries showed that exposure to ETS was responsible for approximately 
1% of global mortality in 2004 (4). Interestingly, in both large-scale reports, the associa-
tion between exposure to ETS and UBC risk was not assessed, while associations with lung, 
breast, cervical and nasopharyngeal cancer are summarized (3). Although smoking is a 
major risk factor for UBC, the impact of exposure to ETS on UBC risk remains under-
reported compared to other smoking-related cancers.
A 2016 meta-analysis on exposure to ETS and the risks of developing cancers other than 
lung or breast revealed no significant association with UBC in cohort studies (OR = 0.99, 
95% confidence interval (CI) = 0.75–1.31), case–control studies (OR = 1.17, 95% CI = 
0.99–1.39) or all included studies (OR = 1.13, 95% CI = 0.98–1.30) (5). However, in this 
analysis childhood exposure was not assessed specifically, and not all studies that were 
pooled indicated whether exposure to ETS was at home (e.g., from a spouse or cohabitant) 
or at work. Moreover, there are several reports that exposure to ETS is common in both 
childhood and adolescents in for example the U.S. (6) and in adults in Greece (7). With our 
meta-analysis, we aim to provide and in-depth analysis of the effects of the exposure to 
ETS on UBC risk stratified by timing of exposure (childhood vs. adulthood exposure) and 
location of adulthood exposure to ETS (workplace or domestic exposure).
methods
literature search
Several online databases (Medline and Embase) were used to search for epidemiologic 
studies on exposure to ETS and UBC incidence. Search strategies included search terms 
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such as “urinary bladder neoplasms”, “incidence”, “risk”, “passive smoking”, or “exposure to 
environmental tobacco smoke”, and resulted in a total count of 110 articles after removal 
of duplicates. Additionally, cited articles in relevant reviews were checked to see whether 
any publications were missed. Articles were only included when they concerned human 
research on the association between ETS and the risk of UBC (primarily bladder cancer) 
and when risk estimates for UBC with 95% confidence intervals (CIs) were provided in 
tables or were potentially derivable from the text. 
data collection
All relevant papers published until December 2017 were assessed. In order to extract 
information on possible sources of heterogeneity and assess quality of included observa-
tional studies the Newcastle Ottawa scale (8) was applied to included publications by two 
authors (Frits H. M. van Osch and Sylvia H. J. Jochems). Data were either extracted directly 
from publications or ORs were estimated using manual calculation. When 95% CI’s had 
to be estimated an online tool was used (9). Exposure to ETS was defined as exposure 
to tobacco smoke from cigarettes, cigars or pipes which were smoked by someone else. 
If estimates for ETS exposure were only presented at different exposure levels the Excel 
spreadsheet described by Hamling et al. was used to obtain an overall risk estimate (10). 
To establish the effect of ETS on UBC risk, all relevant data on risk estimates of UBC for 
exposure to ETS was collected by two independent researchers (i.e., Frits H. M. van Osch 
and Sylvia H. J. Jochems). These include estimates on childhood and adulthood separately 
as well as combined lifetime exposure estimates. For the stratified analysis, the data had 
to strictly state where (at home, by a spouse, parent or other co-habitant or at work) and 
when (during childhood or adulthood) exposure took place for inclusion. Furthermore, 
data on year of publication, geographic area (North America, Europe, Asia, Africa, South 
America), exposure to ETS assessment (interview or questionnaire) and case and control 
source (hospital, population or both) was extracted.
statistical Analysis
A random effects meta-analysis was performed because some heterogeneity in true effect 
of exposure to ETS is to be expected between study populations who were exposed to dif-
ferent types of tobacco. Additionally, funnel plots investigating publication bias and the 
Egger’s test for small study effects were employed, as well as the I2 statistic describing the 
percentage of variation due to between-study heterogeneity. All analyses were performed 
stratified for timing of exposure (childhood or adulthood) and for location of exposure 
(domestic or at work). Adjusted ORs that were pooled had to be at least adjusted for age 
when taking the questionnaire and gender. Sensitivity analyses were performed by pool-
ing all different types of exposure to ETS in one analysis and by pooling only case-control 
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studies. All analyses were performed using Stata statistical software (version 14; Stata 
Corp., College Station, TX, USA).
results
study characteristics
Following full text evaluation, 14 articles initially met the inclusion criteria. None of the 
articles were excluded based on their quality assessment as all studies scored at least 7 
out of 9 on the Newcastle-Ottawa scale. Of these 14 articles, two were excluded because 
it was not explicitly mentioned what the nature (timing and location) of exposure to ETS 
was (11,12). Another study only showed results for urinary tract cancer and was therefore 
excluded (13). The remaining 11 publications, containing data from 12 populations, were 
included in our final analysis (Table 1). 
Studies were mostly from Western countries, except for one study from China (14). Three 
cohort studies (15–17) and eight case-control studies (14,18–24) were identified. Of these 
studies, the majority focussed on (urothelial) bladder cancer, although one study com-
bined all urothelial cancers (bladder, ureter, renal pelvis or urethra) (15). Furthermore, 
in the analysis domestic exposure to ETS data was pooled for any household members; 
studies which indicated spouses and other household members specifically were pooled 
to provide one risk estimate.
pooled results from stratified Analysis
Only seven studies reported estimates on childhood exposure to ETS. Pooling UBC risk 
estimates from these studies resulted in a summary odds ratio (SOR) of 1.04 (95% CI = 
0.82–1.26) (Figure 1, panel A) for both genders combined. There were also seven studies 
that provided estimates of UBC risk (both genders combined) for never smokers exposed 
to ETS at work compared to those who were never exposed to ETS at work, which also 
showed no significant differences in UBC risk (SOR = 0.98, 95% CI = 0.78–1.18) (Figure 1, 
panel B). 
Ten of the included studies estimated UBC risk for those exposed to ETS at home because 
of living with a spouse or any other cohabitant. Pooling the results from these studies 
resulted in a SOR of 0.99 (95% CI = 0.83–1.15), also indicating no significant impact on 






Figure 1. Meta-analysis results showing pooled risk estimates for urothelial bladder cancer 
(UBC) stratifi ed by timing (childhood or adulthood) and location (work-related or domestic) 
of exposure to ETS for males and females combined.
heterogeneity and publication bias
Heterogeneity between studies included in the analyses was very low, with an I2 of 0.0% 
(p-value > 0.05 in all three analyses) (Figure 1). Results were similar for males (Figure 2) 
and females (Figure 3). Although in men only, those exposed to workplace exposure to 
ETS seemed to have a lower risk of UBC (SOR = 0.69, 95% CI = 0.40–0.99). However, this 
was strongly driven by a low risk estimate obtained from one study (Figure 2). However, 
this further stratifi cation of the pooled risk estimates also showed the uncertainty in the 
analysis, for example in the broad confi dence intervals for UBC risk in those exposed to 
ETS during childhood in males (SOR = 0.86, 95% CI = 0.55–1.18) and females (SOR = 
1.04, 95% CI = 0.30–1.78). Generally, the pooled estimates for those exposed to ETS at 
home (panel C in Figures 1–3) were most stable (SORtotal = 0.99, SORmales = 0.88 and 
SORfemales = 0.94). 
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A.	Risk	of	UBC	– exposed	to	ETS	during	childhood B.	Risk	of	UBC	– exposed	to	ETS	at	work	(adulthood)
C.	Risk	of	UBC	– exposed	to	ETS	at	home	(adulthood)
Figure 2. Meta-analysis results showing pooled risk estimates for urothelial bladder cancer 
(UBC) stratifi ed by timing (childhood or adulthood) and location (work-related or domestic) 
of exposure to ETS for males only.
A.	Risk	of	UBC	– exposed	to	ETS	during	childhood B.	Risk	of	UBC	– exposed	to	ETS	at	work	(adulthood)
C.	Risk	of	UBC	– exposed	to	ETS	at	home	(adulthood)
Figure 3. Meta-analysis results showing pooled risk estimates for urothelial bladder cancer 
(UBC) stratifi ed by timing (childhood or adulthood) and location (work-related or domestic) 
of exposure to ETS for females only.
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Egger’s test for small-study effects indicated no publication bias by excluding estimates 
for smaller studies compared to larger studies in all three stratifi ed analyses (p > 0.05 for 
all three analyses). Funnel plots also showed that all extracted risk estimates were within 
expected range of standard error of the pooled estimate based on their study’s sample 
size (Supplemental Figure S1). When excluding risk estimates from the three included 
cohort studies and thus analysing only case-control studies, the SOR remained the same 
as in the overall analysis (SORchildhood = 1.01, 95% CI = 0.79–1.24, SORwork = 0.98, 
95% CI = 0.77–1.18 and SORhome = 1.02, 95% CI = 0.83–1.21), as shown in Supplemental 
Figure S2. Furthermore, when pooling all estimates of UBC risk regardless of timing or 
location of exposure to ETS there also did not seem to be any signifi cant impact of expo-
sure to ETS on UBC risk (SOR = 1.00, 95% CI = 0.89–1.10) or any heterogeneity caused by 
pooling estimates of exposure at different times in life (I2 = 0%, p = 0.978). Furthermore, 
as there are no biological reasons to assume that there is a substantial difference between 
exposure to ETS at work or at home during adulthood, an additional analysis pooling all 
risk estimates obtained during adulthood showed similar results as the stratifi ed analysis 
for males and females combined (SOR = 0.99, 95% CI = 0.86-1.11) and for males and 




Figure S1. Funnel plots showing risk estimates from individual studies relative to the pooled 
OR for both analysis on childhood exposure to ETS and adulthood exposure to ETS (both males 
and females).
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A.	Risk	of	UBC	– exposed	to	ETS	during	childhood B.	Risk	of	UBC	– exposed	to	ETS	at	work	(adulthood)
C.	Risk	of	UBC	– exposed	to	ETS	at	home	(adulthood)
Figure S2. Meta-analysis results showing pooled risk estimates for urothelial bladder cancer 
(UBC) stratifi ed by timing (childhood or adulthood) and location (work-related or domestic) of 
exposure to ETS for males and females combined, for case-control studies only.
A.	Risk	of	UBC	– men	and	women	exposed	to	ETS	during	adulthood B.	Risk	of	UBC	– men	exposed	to	ETS	during	adulthood
C.	Risk	of	UBC	– women	exposed	to	ETS	during	adulthood
Figure S3. Meta-analysis results showing pooled risk estimates for urothelial bladder cancer 





The results from this meta-analysis indicate no substantial effect of exposure to ETS dur-
ing either childhood or adulthood on UBC risk in never smokers. 
The heterogeneity among the included studies was very low and statistical power (as-
suming alpha = 0.05 and 1-beta = 0.80) sufficient to observe a SOR of at least 1.18 in all 
estimates during childhood (observed SOR was 1.04, 95% CI = 0.82-1.26) and 1.17 in all 
estimates during adulthood at home (observed SOR was 0.99, 95% CI = 0.83-1.15). We 
used statistical programme R to estimate the minimally detectable SOR when including 7 
(childhood) or 12 (adulthood at home) estimates from the currently included articles in a 
random effects meta-analysis (25). 
The pooled UBC risk estimates obtained on exposure to ETS are very likely influenced by 
recall bias (especially when estimating childhood exposure). It is often demonstrated that 
large, prospective studies that report results for exposure to ETS and lung cancer risk do 
not report corresponding results for UBC risk (5). Moreover, detailed information on the 
nature of exposure is often lacking. Studies rarely assess for how many years never smok-
ers were exposed to ETS and whether the active smoker smoked daily or only sporadically. 
Therefore, risk estimates in the included studies are certainly confounded by the length 
of exposure and the smoking behaviour of the active smoker(s) providing the exposure to 
the never smoking subject.
Some of the included studies on exposure to ETS and UBC risk (included in this meta-
analysis) have attempted to assess lifetime exposure to ETS and correct for length of 
exposure. Tao et al. described a combined index estimating lifetime exposure to ETS 
where different scores were added up for each member of the household that smoked 
(based on the number of cigarettes they smoked) and the hours of exposure to workplace 
ETS. The highest exposure category (5 or higher on a scale from 0–10) compared to never 
exposed never smokers showed an OR of 3.00 (1.24–7.26) (14). Jiang (2007) also estimated 
a cumulative index of ETS exposure (i.e., sum of childhood exposure and three levels of 
adulthood exposure (domestic, workplace and social). However, they showed no statisti-
cally significant associations with UBC risk either at intermediate exposure level (OR = 
1.61, 95% CI = 0.81–3.08) or at highest exposure level (OR = 1.28, 95% CI = 0.61–2.48). 
Also, Baris et al. found no association between a combined index of adulthood exposure 
with UBC risk (high versus low exposure OR = 0.9, 95% CI = 0.4–2.0) (22). Interestingly, 
adult men that did not smoke cigarettes or water pipe and were exposed to ETS both 
outside and at home gad a three times increased risk of UBC (95% CI = 1.5–5.9) compared 
to other nontobacco-using men who were not exposed to ETS in Egypt which as statisti-
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cally significant (23). Because of the different ways of calculating cumulative exposure 
(e.g., only in adulthood or different weights to scores concerning number of cigarettes 
smoked) these data could not be pooled. However, it is noticeable that all studies that 
estimated some form of cumulative exposure showed an increased UBC risk, often being 
statistically significant, and with higher risk estimates than any of the individual estimates 
pooled in Figure 1. More research is warranted in cumulative exposure to ETS to see 
whether those in the highest cumulative exposure categories during both childhood and 
adulthood might be at an increased risk of UBC.
Additionally, two studies that were not included in the meta-analysis because they only 
reported on lifetime exposure to ETS (so not childhood or adulthood specifically) or 
reported ORs for UBC risk for both ever smokers and never smokers who were exposed 
to ETS combined (12,16). In a Taiwanese case-control study the observed OR was 1.90 
(95% CI = 1.42–2.55) when comparing both never smokers and current smokers exposed 
to ETS to those who were not. In a separate analysis in only the never smokers exposed 
to ETS with low urinary arsenic levels the OR is not significant however (OR=1.72, 95% 
CI=0.75-3.94), so the relatively strong point estimate can probably be explained by the 
active smokers included in the primary analysis (12). In a large European-wide cohort 
study the estimated OR for UBC risk in those exposed to ETS compared to those who were 
not was 1.38 (95% CI = 1.00–1.90). Even though this estimate is probably overestimated, 
since both current smokers as well as never smokers exposed to ETS were considered in 
the exposed group (16). It would be meaningful to see more future research focussing 
on the effects of exposure to ETS in all subjects regardless of their smoking status like in 
these two studies and especially in current smokers who were also exposed to ETS.
Apart from the limited information that can be drawn from retrospectively gathered data, 
there are also possible confounders and effect modifiers that were not considered in the 
pooled studies. There is evidence of an interaction effect between arsenic methylation 
and exposure to ETS in determining UBC risk where only those with high total urinary 
arsenic level are at an increased risk of UBC (11,12), however both studies investigating 
this interaction were not included in the meta-analysis since they did not indicate what 
the timing and location of exposure to ETS was. Also, children of parents who smoke are 
more likely to start smoking themselves (26), possibly because nicotine receptors are also 
stimulated in the brain by second-hand smoke (27). Therefore, the never smokers that 
were exposed to ETS during childhood but never started smoking themselves are prob-
ably a biased reference group which is less susceptible to nicotine addiction compared to 
those who started smoking after being exposed to ETS. However, more research is needed 




The current evidence suggests no substantial association between UBC risk and exposure 
to ETS either during childhood or adulthood. Nevertheless, the measurement of exposure 
to ETS was biased since data was retrospectively collected and using different question-
naires in the included studies. More detailed information on duration and intensity of 
exposure to ETS is needed to answer the question whether there is also no association 
with UBC risk in high lifetime cumulative exposure to ETS categories or in ever smokers 
who were exposed to ETS.
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4 Tar, nicotine and carbon monoxide yield of UK cigarettes and the risk 
of non-muscle-invasive and muscle-
invasive bladder cancer.
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Ranti Fayokun, Nicholas James, Michael Wallace, KK Cheng, 
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Cigarette smoking is a major risk factor for bladder cancer (BC), however the impact of 
cigarette content remains unclear. This study aims to investigate tar, nicotine and carbon 
monoxide (TNCO) yields of different filtered cigarettes in relation to BC risk.   
methods
From the Bladder Cancer Prognosis Programme 575 non-muscle-invasive BC (NMIBC) 
cases, 139 muscle-invasive BC (MIBC) cases and 130 BC-free hospital-based controls (who 
visited the urology clinic with symptoms indicative of bladder cancer) with retrospective 
data on smoking behaviour and cigarette brand were identified. Independently measured 
TNCO yields of cigarettes sold in the UK were obtained through the UK Department of 
Health and merged with the BCPP dataset to estimate daily intake of TNCO.
results
BC risk increased by TNCO intake category for NMIBC cases (p for trend <0.050 in all 
multivariate models) with the highest OR observed in the >200mg/day category for 
tar (OR=3.00, 95%CI=1.36-6.63). For MIBC, the linear trend was only significant in with 
increasing tar intake (p=0.046) in multivariate models. No difference in risk is observed 
between smokers of low tar/low nicotine and high tar/high nicotine cigarettes compared 
to never smokers, neither for NMIBC (p=0.544) nor MIBC (p=0.449). 
conclusion
High daily intake of TNCO additionally increases both NMIBC and MIBC risk compared 
to low daily intake. However, since there is no difference in BC risk between low tar/low 
nicotine and high tar/high nicotine cigarette smokers it remains unclear whether smoking 
behaviour or TNCO yield of cigarettes explains this association. 
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bAckground
Active smoking is indicated as the most common risk factor for bladder cancer together 
with occupational exposure to carcinogenic chemicals and some diet-related factors (1,2). 
The impact of cigarette smoking has been quantified in a large number of studies, and a 
recent meta-analysis showed that current smokers have a three-fold increased risk of de-
veloping BC compared to never smokers (3). The relation between the amount of smoking 
and cancer risk has been investigated extensively, and is mostly characterised by smoking 
duration in years, smoking intensity in cigarettes per day, or pack years (an amalgamation 
of duration and intensity). 
However, the type of cigarette or cigarette composition is considered less often. Therefore, 
the evidence on the impact of different types of cigarettes, regarding the composition 
of the cigarette smoke, on BC risk remains weak. One case-control study has shown a 
decreased BC risk for filter versus non-filter cigarette smokers (RR=0.3, 95%CI not given, 
for filter-tip only cigarette smokers compared to non-filter-tip smokers) (4). However, 
this has not been shown consistently as another large case-control study showed no risk 
difference (OR=1.00, 95%CI 0.62-1.63) (5). Additionally, several case-control studies seem 
to suggest that smokers of black tobacco, which is hypothesised to contain more aromatic 
amines due to the long (about 8 weeks) air-curing process for the tobacco leaves when 
smoked compared to blond tobacco which is flue-cured (takes about 1 week and tobacco 
leaves are exposed to heat during the curing process instead of the lower temperature of 
outside), are at an approximately two-fold increased risk of BC (4–7). Two observational 
studies quantified BC risk for different intakes of tar and nicotine, of which one showed 
a linearly increasing trend in risk related to the amount of tar and nicotine and the other 
study showed no association between BC risk and cumulative tar intake (8,9). By introduc-
ing the filter tip, which changed cigarette design but not the tar and nicotine contents 
in most cases, smoking-related mortality has moderately decreased (10), although there 
are studies indicating that the levels of carcinogens in contemporary cigarettes might 
have become higher (11). Nevertheless, it remains unclear whether differences in cigarette 
content are related to meaningful differences in BC risk at population level. Therefore, we 
calculated the levels of tar, nicotine and carbon monoxide (TNCO) in mainstream smoke in 





This case-control study was conducted within the framework of the West Midlands Blad-
der Cancer Prognosis Programme (BCPP), an ongoing BC patient cohort study conducted 
in multiple centres in the West Midlands, United Kingdom. Further details of the BCPP are 
described elsewhere (12) and in chapter 1 of this thesis. In summary, the study population 
contained 1,544 adult individuals who were referred to one of the participating urol-
ogy centres because of symptoms indicative of BC (predominantly haematuria). Of these 
1,544 individuals, there were 1008 patients diagnosed with non-muscle-invasive bladder 
cancers (NMIBC), 275 muscle-invasive bladder cancer (MIBC) patients and 205 individuals 
were subsequently diagnosed as free from any form of cancer after histological tests at 
the urology clinic and selected as controls. Additionally, 57 patients were diagnosed with 
other primary cancers (e.g. prostate cancer) or had missing data on important staging 


































Figure 1. Flow chart of case and control selection from bladder cancer prognosis. BC, bladder 
cancer; BCPP, Bladder Cancer Prognosis Programme; MIBC, muscle-invasive bladder cancer; 
NMIBC, non-muscle-invasive bladder cancer.
Cases and controls whom did not provide data on cigarette brand and smoking status 
were excluded for analysis. Those who did not report data on cigarette brand were more 
often female (40% versus 21% in those reporting, chi-square p value <0.001), and slightly 
older (69.3 years versus 67.7 years, p=0.058). Of the 205 potential controls, 130 had a clear 
specifi cation of control status and provided data on smoking status and cigarette brand. 
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Of these 130 controls, 34 had benign papillomas, 25 a normal urothelium, 24 cystitis and 
20 urothelial inflammation. In addition, for 27 BCPP participants in the control group, the 
urologist did not provide a description apart from “no bladder cancer present” (Figure 1). 
All participants received a baseline questionnaire including questions to assess demo-
graphic characteristics, occupation and retrospectively characterise smoking and dietary 
behaviour.
tnco data from the uk department of health
In the UK, an approved and accredited laboratory appointed by the UK Department of 
Health periodically and independently analyses the yields of tar (T), nicotine (N) and 
carbon monoxide (CO) in smoke of random samples of cigarette brands sold in the UK 
according to the International Organisation for Standardisation (ISO) standards (13). This 
examination verifies the TNCO yields declared on cigarette packs by manufacturers and 
ensures that the TNCO yields of cigarettes on the UK market do not exceed the maximum 
allowed levels as set out in the relevant Tobacco regulation (10 mg/cig for tar, 1 mg/cig 
for nicotine and 10mg/cig for CO). This is a legal obligation in all Member States of the EU, 
and is set out in the UK in the Tobacco Products (Manufacture, Presentation, Presentation 
and Sale) (Safety) Regulations 2002 (Statutory Instrument 3041) (13). For tar, measure-
ments were made in line with ISO 4387 and for nicotine and CO, ISO 10315 and ISO 8454 
were used respectively, with the accuracy of measurements determined by ISO 8243 (14). 
By combining these data with the filter cigarette brand(s) currently or previously smoked in 
BCPP and the number of cigarettes smoked per day, daily intake of TNCO was estimated. 
Intake is a proxy measure for absolute TNCO exposure, since it is an estimation of the 
amount of TNCO that reaches the lungs which is also influenced by smoking behaviour 
(e.g. puff volume and whether the cigarette is smoked completely). Patients who smoked 
brands which were not in the UK Department of Health database were either excluded (88 
out of 602, 15%) or the TNCO values were based on the original packaging as determined 
by the manufacturer (40 out of 602, 7%). 
statistical analysis
From the BCPP questionnaire data daily TNCO intake was estimated through multiplying 
the number of cigarettes smoked per day (smoking intensity) with the TNCO levels. Based 
on these TNCO levels, cigarettes were classified as either low tar/low nicotine (tar<9 mg/
cigarette, nicotine <0.9 mg/cigarette) or high tar/high nicotine (tar ≥9 mg/cigarette, nico-
tine ≥0.9 mg/cigarette). Odds ratios (OR) and 95% confidence intervals (CI) estimating 
BC risk were calculated using logistic regression models. Potentially confounding factors 
included in multivariate analyses were restricted to age, sex, and smoking duration. Ide-
ally, smoking intensity would also be included as a possible confounder but this was not 
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possible due to collinearity issues because smoking intensity is used to estimate daily 
TNCO intake. Furthermore, data on occupation was sparse in controls (n=2 for controls, 
n=186 for NMIBC cases) so occupational exposure could not be included as a covari-
ate. Tests for linear dose-response trends in ORs between TNCO intake categories were 
performed by comparing logistic regression models with categorical variables for TNCO 
intake to models with a continuous variable for TNCO intake by using likelihood-ratio (LR) 
tests. 




Age at diagnosis (95% CI) 68.0 (67.1 - 68.8) 70.1 (68.2 - 71.9) 65.2 (63.0 - 67.5)
Sex (M/F) 442/133 99/40 91/39
Smoking status
Never 127 31 59
Former 299 67 45
Current 149 41 26
results
After exclusion of cases and controls in the analysis because of missing data on cigarette 
brand or the number of cigarettes smoked per day 575 NMIBC, 139 MIBC and 130 BC-free 
participants were included in the analysis. Figure 1 summarises the inclusion of partici-
pants for this case-control study recruited from the BCPP participants. Table 1 shows the 
baseline characteristics of the included NMIBC, MIBC and BC-free controls who were 
included in the analysis.
Table 2 shows linearly increasing dose-response relationships between daily tar, nicotine 
and CO intake and NMIBC risk compared to never smokers in both adjusted and unad-
justed models (p-values below 0.05 in all models). The adjusted logistic regression models 
show mitigated associations compared to the unadjusted model. The highest OR was 
observed in the highest intake category for tar (OR=3.00, 95%CI=1.36-6.63), although the 
95% confidence interval was wide. 
The results were similar when looking at MIBC risk albeit the 95% confidence intervals 
were wider due to the smaller number of MIBC cases (Table 3). Furthermore, the only 
increasing trend in a multivariate model was observed for daily tar intake (p=0.046) where 
the highest OR was 2.88 (95% CI=1.10-7.55).
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Furthermore, there does not seem to be a meaningful difference in BC risk between smok-
ers of low tar/low nicotine cigarettes and smokers of high tar/high nicotine cigarettes 
(p=0.544 for NMIBC and p=0.449 for MIBC). Additionally, smokers of low tar/low nicotine 
cigarettes did not smoke more filter cigarettes than high tar/high nicotine cigarette smok-
ers daily (p=0.516, data not shown).
Table 2. Adjusted and unadjusted odds ratios (OR) estimating NMIBC risk for daily tar, nicotine 
and CO intake and cigarette type comparing ever smokers to never smokers.
 Cases in cohort
Controls 
in cohort OR (95% CI) crude
OR (95% CI) 
multivariate 
adjusted model*
Never smoker 127 59 1.00 (reference) 1.00 (reference)
Ever smoker 448 71 2.93 (1.97-4.36) 2.14 (1.11-4.11)
Tar (mg/day)
<100 130 30 2.01 (1.22-3.33) 1.57 (0.78-3.15)
100-<200 154 21 3.41 (1.96-5.91) 2.73 (1.23-6.03)
>200 161 19 3.94 (2.23-6.94) 3.00 (1.36-6.63)
p-value for linear trend <0.001 0.007
Nicotine (mg/day)
<5 70 18 1.81 (0.99-3.30) 1.48 (0.69-3.18)
5-<10 93 16 2.70 (1.46-4.99) 2.02 (0.90-4.55)
10-<15 113 15 3.50 (1.88-6.51) 2.71 (1.15-6.41)
>15 169 21 3.74 (2.16-6.47) 2.85 (1.32-6.19)
p-value for linear trend <0.001 0.030
CO (mg/day)
<50 68 16 1.97 (1.06-3.69) 1.62 (0.73-3.56)
50-<100 71 14 2.36 (1.23-4.52) 1.69 (0.74-3.83)
100-<150 103 14 3.42 (1.81-6.47) 2.76 (1.15-6.61)
>150 203 26 3.63 (2.17-6.05) 2.75 (1.30-5.84)
p-value for linear trend <0.001 0.034
Ever smoker cigarette type
Low tar/low nicotine 52 7 3.45 (1.48-8.05) 2.80 (0.97-8.06)
High tar/high nicotine 396 64 2.87 (1.91-4.32) 2.14 (1.11-4.12)
p-value   0.667 0.544
*adjusted for age, sex and smoking duration
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Table 3. Adjusted and unadjusted odds ratios (OR) estimating MIBC risk for daily tar, nicotine 
and CO intake and cigarette type comparing ever smokers to never smokers.
 Cases in cohort
Controls in 
cohort OR (95% CI) crude
OR (95% CI) 
multivariate 
adjusted model*
Never smoker 31 59 1.00 (reference) 1.00 (reference)
Ever smoker 108 71 2.90 (1.71-4.91) 1.82 (0.79-4.21)
Tar (mg/day)
<100 33 30 2.09 (1.08-4.04) 1.31 (0.52-3.28)
100-<200 28 21 2.54 (1.24-5.18) 1.42 (0.51-3.99)
>200 44 19 4.41 (2.21-8.80) 2.88 (1.10-7.55)
p-value for linear trend >0.001 0.046
Nicotine (mg/day)
<5 19 18 1.89 (0.92-4.37) 1.30 (0.48-3.50)
5-<10 19 16 2.26 (1.02-5.00) 1.26 (0.43-3.70)
10-<15 19 15 2.41 (1.08-5.39) 1.34 (0.43-4.20)
>15 48 21 4.35 (2.22-8.52) 2.75 (1.07-7.11)
p-value for linear trend >0.001 0.105
CO (mg/day)
<50 18 16 2.14 (0.96-4.77) 1.40 (0.51-3.83)
50-<100 17 14 2.31 (1.01-5.30) 1.19 (0.39-3.60)
100-<150 12 14 1.63 (0.67-3.95) 0.96 (0.29-3.16)
>150 58 26 4.25 (2.25-8.01) 2.60 (1.03-6.56)
p-value for linear trend >0.001 0.061
Ever smoker cigarette type
Low tar/low nicotine 13 7 3.53 (1.27-9.77) 2.69 (0.73-9.84)
High tar/high nicotine 95 64 2.83 (1.64-4.84) 1.80 (0.77-4.18)
p-value   0.265  0.449
*adjusted for age, sex and smoking duration
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discussion
This study is the first to investigate all TNCO levels from cigarettes in relation to BC risk 
within a single study sample. Our results confirm the findings of another study, indicating 
a linearly increasing dose-response relationship for daily tar and nicotine intake. Addition-
ally, we showed a similar association with daily CO intake (8). Another study investigating 
cumulative tar intake did not show any association with BC risk (9). Our results indicate 
that especially the highest daily intake categories of TNCO values are associated with an 
increased risk of BC compared to the lower categories. 
Smokers persist in their smoking habits because of the addictive properties associated 
with nicotine intake. Nicotine is in itself not a strong carcinogen, but with each puff a 
smoker inhales a mixture of chemical carcinogens, including polycyclic aromatic hydrocar-
bons (PAHs), tobacco-specific nitrosamines (TSAs) as well as many other carcinogens, that 
can bind with DNA to form DNA adducts, which drive the carcinogenic process (15) For 
TSAs and PAHs, biomarker studies in smokers have shown corresponding 206 high levels 
of adducts to DNA and haemoglobin adducts, as well as for metabolites in urine (16-18). 
Further, nicotine might be involved in tumour cell proliferation through activation of Stat3 
and possibly also the PI3K/Akt/mTOR pathway (19), indicating that it might play a role in 
disease progression rather than in carcinogenesis itself, although the association with BC 
risk seems slightly less strong compared to tar. Tar from cigarette smoke is believed to 
be associated with cancer risk because it is a fraction that contains a high concentration 
of polycyclic aromatic compounds, oxidants and free radicals which all play an important 
role in inducing DNA damage, possibly leading to carcinogenesis (20). 
The results might be driven by the number of cigarettes smoked and to a lesser extent 
by TNCO values of cigarettes, since we did not observe any meaningful differences in 
BC risk between smokers of low tar/low nicotine and high tar/high nicotine cigarettes. 
More importantly though, this analysis was underpowered because of the low number 
of controls smoking low tar/low nicotine cigarettes (n=7) and therefore no conclusions 
can be drawn from this analysis. A post hoc power calculation, using statistical power 
programme G*Power 3 (21) and assuming an alpha of 0.05 and a power of 0.80, indicated 
that the smallest detectable OR for low tar/low nicotine smokers compared to never 
smokers was 2.86 for the crude analysis in NMIBC patients (the largest group), so the 
multivariate analysis also adjusting for confounders age, sex and smoking duration was 
clearly underpowered since including confounders would only increase the minimally 
detectable OR. Furthermore, the low statistical power of this comparison is also reflected 
in the wide 95% confidence interval (0.97-8.06). Future studies with sufficient statisti-
cal power should investigate whether smokers of low tar/low nicotine cigarettes do not 
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smoke more cigarettes than high tar/high nicotine cigarette smokers or whether they 
might alter their smoking behaviour (e.g. larger puff volume or more puffs) to increase 
nicotine intake (22), as has been observed in other studies. Our estimates of daily TNCO 
intake might be confounded by this compensation behaviour but could not be corrected 
for as detailed smoking behaviour data was not collected.
Furthermore, the controls were selected from the BCPP cohort in which all participants 
were under suspicion of bladder cancer at inclusion. Therefore, the control group included 
individuals with chronic urothelial inflammation (23) and benign papilloma (including 
some inverted papillomas) (24) which could be considered risk factors for BC develop-
ment. Hence, the presented ORs are probably underestimated because our control group 
is more similar to the case group than a hypothetical, completely healthy control group 
because of the presence of these risk factors. In addition to this, the control group is small, 
conclusion
High daily intake of TNCO increases NMIBC risk compared to low daily intake. However, 
it remains unclear whether smoking behaviour or cigarette type causes this association. 
More research with larger sample sizes is needed to corroborate these results and to shed 
light on whether smoking behaviour outplays cigarette content in determining BC risk.
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5 Modelling the complex exposure history of smoking behaviour in 
predicting bladder cancer: a pooled 
analysis of 15 case-control studies.
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BLEND consortium, Richard T. Bryan, Frederik J. van Schooten, 







Only few studies have modelled smoking histories by combining smoking intensity and 
duration to show what profile of smoking behaviour is associated with highest risk of 
bladder cancer. This study aims to provide insight into the association between smoking 
exposure history and bladder cancer risk by modelling both smoking intensity and dura-
tion in a pooled analysis.
methods
Data from 15 case-control studies included in the BLadder cancer Epidemiology and 
Nutritional Determinants (BLEND) study were used, including a total of 6,874 cases and 
17,727 controls. To jointly interpret the effects of intensity and duration of smoking, ex-
cess odds ratios (EOR) per pack-year were modelled by intensity continuously to estimate 
the risk difference between smokers with long duration/low intensity and short duration/
high intensity.
results
The pooled EOR model indicated that for a fixed number of pack-years, smoking for 
a longer duration at lower intensity was more deleterious for bladder cancer risk than 
smoking more cigarettes/day for a shorter duration. Similar patterns were observed within 
individual study samples.
conclusions
This pooled analysis shows that long duration/low intensity smoking increases bladder 
cancer risk more than short duration/ high intensity smoking within equal pack-year 
categories, thus confirming studies in other smoking-related cancers and demonstrating 
that reducing exposure history to a single metric such as pack-years is too restrictive. 
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introduction
Smoking is a significant modifiable risk factor for urothelial bladder cancer (UBC) and 
studies demonstrate a differential dose-response pattern for intensity and duration (1). 
Many studies have investigated smoking behaviour in relation to UBC, showing separate 
risk estimates for intensity, duration and pack-years; but only a few studies have modelled 
complex smoking histories including all aspects of exposure (2,3).
Most studies establishing the association between smoking exposure and various dis-
eases use cumulative exposure (i.e. pack-years) or adjust for it as a confounder when 
investigating smoking duration of intensity. However, more recently, consensus has been 
reached that modelling pack-years alone is not sufficient to identify possible mechanisms 
underlying such associations (4). Several researchers have discussed whether pack-years 
should be used to measure effects of smoking or whether pack-years can be useful in 
making biologically credible models that provide unbiased information on complex 
smoking exposure histories (4,5), and circumventing multicollinearity issues (6). Although, 
these issues have been a research topic for several decades for other diseases, they have 
been infrequently investigated in UBC research (7,8).
Two case-control studies in UBC both suggested that among equal pack-year categories, 
individuals who had smoked relatively fewer cigarettes per day for longer duration were 
at a higher risk of UBC compared to those who smoked more cigarettes per day over a 
shorter duration (2,3). In these studies, estimates of the excess odds ratio (EOR) per pack-
year were compared across categories of smoking intensity. Recently, similar models have 
been further developed and tested to also include time since smoking cessation (9). Using 
an alternative approach, two other case-control studies data also showed that duration is 
the over-riding factor in determining the risk of bladder cancer (10,11).
The aim of this study was to investigate the association between cumulative smoking 
exposure and UBC risk, in a uniquely large pooled sample of case-control studies.
methods
study data 
The BLadder cancer Epidemiology and Nutritional Determinants (BLEND) consortium 
currently consists of 19 case-control studies and 14 cohort studies investigating the asso-
ciation between lifestyle behaviours and UBC risk. For this analysis, we included 15 case-
control studies providing complete data on smoking behaviour, including; smoking status, 
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intensity and duration, These included 6,824 cases and 17,727 controls originating from 
Italy (11–13), Germany (14,15), Belgium (16), Sweden (17), Canada (18), the USA (19–24) 
and China (25). All smoking data were either collected through interview-administered 
questionnaires (n=6) or self-administered questionnaires (n=9). Further details on the 
methodology of this consortium have been described (26).
statistical analysis and delivery rate of exposure
A statistical approach described by Vlaanderen et al. was utilised (9). The pooled smoking 
data were divided into quintile categories of pack-years, years of smoking, cigarettes 
per day and time since smoking cessation (TSC). Odds ratios (ORs) for these categories 
were obtained using a multilevel random effect logistic regression model adjusting for 
study, age and sex as covariates. Subsequently, total pack-years were cross-classified 
by cigarettes smoked per day and years of smoking to estimate the ORs in combined 
exposure categories with never smokers as the reference group. Finally, we fitted an 
exponential model to estimate the EOR per pack-year by smoking intensity to investigate 
the independent effect of cigarette smoking duration and intensity of cigarette smoking 
on UBC risk. We used the model:
OR (d) = 1 + ßd x exp (g1 (n))
where the model was fitted using continuous pack-years (d), continuous intensity (n) and 
g1 as a 3-knot restricted cubic spline function of continuous smoking intensity (knots 
located at 20th, 50th and 80th percentile of the distribution of intensity of all smokers) 
and n is a subject’s smoking intensity. This model was applied to each of the 15 studies.
The results from such models describe delivery rate patterns of exposure to tobacco 
smoking in relation to UBC risk. The delivery rate is described through estimating how in-
creasing intensity or duration within a fixed number of pack-years influences UBC risk. For 
example, an inverse exposure rate effect for intensity would mean that the EOR/pack-year 
decreases with more cigarettes smoked per day, showing that within increasing intensity 
within fixed pack-years, and thereby automatically decreasing duration, decreases risk 
compared to those with a longer duration and lower intensity.
A sensitivity analysis was performed with data from 5 studies that provided detailed data 
on TSC by adding an extra 3-knot restricted cubic spline (knots at the 20th, 50th and 80th 
percentiles of the distribution of TSC of all former smokers) to the model, since incorpo-
rating TSC into these models might provide a better fit with the data (9). Additionally, 
different knot locations (at the 10th, 50th and 90th and 5th, 50th and 95th percentiles) 
were applied to assess the robustness of the associations. The fit of the models with 
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different knot locations were tested using the Akaike information criterion (AIC). 95% 
confidence intervals (CIs) for the EOR models were estimated through bootstrapping via 
1,000 replications of the original data. The 2.5th and the 97.5th percentile of the subse-
quent distribution are shown in the fitted model. To assess the level of heterogeneity 
underlying this EOR model, it was also repeated in individual BLEND study populations. 
results
smoking characteristics in included studies
Table 1 shows baseline characteristics for all included case-control studies. In most stud-
ies, at least 80% of current smokers at baseline smoked more than 10 cigarettes a day. The 
only study in which this proportion was much lower than the mean proportion for both 
current smokers (14%) and former smokers (4%) was the Swedish study, with 14% and 
4% respectively (17) (Table 1). Nine of the 15 studies demonstrated that 90% of current 
smokers had smoked for at least 20 years. This percentage was lower among former 
smokers (between 70% and 80%) (Table 1). One study from the USA (20) provided details 
on smoking behaviour among current smokers only.
risk estimates for smoking behaviour 
Based on the pooled results, current smokers had a higher UBC risk than never smok-
ers (OR=2.23, 95% CI=2.05-2.42) (Table 2). Tests for linear trend showed increasing risks 
across quintile categories of intensity, duration and pack-years (p-values<0.001). Further-
more, smoking cessation was related to a lower UBC risk compared to current smokers 
(Table 2), with an OR of 0.40 (95% CI=0.32-0.51) for those who had quit smoking more 
than 30 years before UBC diagnosis. UBC risk for those who had quit smoking 30 years 
prior to diagnosis was very similar compared to those who had never smoked (OR=1.04, 
95% CI=0.81-1.32).
delivery rAte pAtterns of exposure to smoking in 
relAtion to ubc risk
Fifteen ORs, with never smokers as reference category, were calculated in the analysis 
stratified by intensity quintile (Figure 1), whilst 20 ORs were estimated in the analysis 
stratified by duration quintile (Figure 2) because data were sparse in the intensity cat-
egories. None of the associations showed any departures from linearity (p>0.05 for all 
categories), which means that the EOR model as it is presented is valid in meeting the 
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CPD:	³30
Figure 1. Odds ratios (OR) for bladder cancer by cross-classifi ed categories of pack-years and 
quintile categories of number of cigarettes smoked per day (CPD). Lines indicate fi tted linear 
odds ratio models in pack-years, bars indicate 95% confi dence intervals. Pooled data was lim-
ited to never and current smokers.
The EOR per pack-year and 95% CI by continuous smoking intensity (cigarettes/day) 
resulting from the cubic spline model are plotted in Figure 3. Additionally, the slope 
resulting from the model including splines for TSC is also shown. The model excluding 
TSC had a slightly better fi t to the data (AIC=23,140) compared to the model including 
TSC (AIC=24,219), probably because the effect of TSC was heterogeneous between the 
few included studies. Both curves show an inverse delivery rate pattern, whereby with 
increasing cigarettes smoked per day the EOR per pack-year decreases, indicating that for 
equal pack-years, smoking for a longer duration is more strongly associated with UBC risk 
than smoking more cigarettes per day. As can be observed from the bootstrapped 95% 
CI, the plotted curve had the highest statistical power (highest number of participants) 
for individuals smoking between 10 and 40 cigarettes per day which included 79% of all 
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Figure 2. Odds ratios (OR) for bladder cancer by cross-classifi ed categories of pack-years and 
quintile categories of years of smoking. Lines indicate fi tted linear odds ratio models in pack-






















Figure 3. Estimated excess odds ratio (EOR) per pack-year for bladder cancer by cigarettes per day 
with bootstrapped 95% confi dence intervals. The dotted line indicates a model including an extra 
spline for time since smoking cessation. Triangles depict locations of the knots of the restricted cubic 
splines (20th, 50th and 80th percentile).
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Heterogeneity was small among the 10 individual studies in which EOR models were fi t 
with the original spline settings (Figure 4A). For three studies (12,21,23) the model did 
not fi t because of their data distribution (e.g. 19 cigarettes per day represented the 44th 
percentile and 20 cigarettes per day represented the 82th percentile of the data), and 
there was limited power within 2 studies (14,25) (too many levels of intensity with no 
cases). When moving the splines to positions fi tting the data distribution in the three 
studies with a different data distribution, the three added curves show a similar shape to 
the EOR curves from the 10 studies that were estimated with the original spline settings 
(Figure 5). Additionally, the EOR models within the 3 studies that included suffi cient data 
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Figure 4. Excess odds ratio (EOR) per pack-year by smoking intensity (cigarettes/day) stratifi ed 
by study. Model without time since smoking cessation spline (panel A) and model with time 
since smoking cessation spline (panel B). Study numbers refer to reference number within this 
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Figure 5. Excess odds ratio (EOR) per pack-year by smoking intensity stratifi ed by study, in-
cluding curves for three studies (15, 24, 26) that had to be fi t with alternative spline locations. 
Study numbers refer to reference number within this paper (see Table 1).
discussion
We have provided insight into the complex exposure patterns of lifetime smoking be-
haviour and the impact on UBC risk. We have shown an inverse delivery rate pattern 
indicating that, for equal pack-years of smoking, less cigarettes per day over a longer 
duration is more deleterious for UBC risk than smoking more cigarettes per day over a 
shorter duration. The results of this large pooled analysis of case-control studies are in 
line with data from previous case-control studies on UBC (2,3,11), which applied a similar 
model as well as results from a pooled analysis of 11 case-control studies which used a 
different modelling approach to assess duration and intensity simultaneously (10).
robustness of results
We applied the model as described by Vlaanderen et al, but a similar approach was fi rst 
described in a lung cancer study (27), known as the L-C (Lubin-Caparaso) model, which 
has also been applied in a pooled analysis of case-control studies on head and neck 
cancer (28) and in two individual UBC case-control studies (2,3). Alongside these models, 
Brennan et al described a different approach in 2000 which is based on stratifi cation of 
both duration and intensity and estimating ORs in all strata. They also observed that 
duration was more important in predicting UBC risk than intensity (10). 
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Similar ORs were observed for both women and men, although more men smoked at least 
10 cigarettes per day (86%) compared to women (73%), possibly explaining differences 
in risk estimates, in addition to the smaller sample of women in the included studies. 
Furthermore, observed ORs for smokers might be underestimated since the pooled OR for 
current smokers was markedly lower than observed in a large meta-analysis (1) (OR=2.23 
in the current sample vs OR=3.14 in the meta-analysis). This might be explained by some 
misclassification of smoking information collected through self-administered question-
naires in the 15 included studies or differences in data collection in the meta-analysis. 
Little heterogeneity in the range of predicted EORs per pack-year by cigarettes per day 
between the included studies was observed (Figure 4). However, some heterogeneity in 
magnitude of estimated EORs per pack-year remains between the studies, which may be 
explained by several factors such as geographical location (1) and calendar year in which 
cases and controls were recruited (29). Since only 5 studies provided sufficient data on 
TSC, this pooled analysis might not have had sufficient power to include TSC as an extra 
spline.
strengths and limitations of the eor model and interpretation 
of results
Although the EOR model can provide a more detailed insight into the association between 
smoking behaviour and disease risk, there are some other factors not in this model that 
also need to be considered. Since a more vigorous inhalation pattern has been shown to be 
associated with a higher UBC risk (30,31), the observed inverse delivery rate pattern might 
reflect differences in inhalation patterns among cigarette smokers. It is generally believed 
that light smokers inhale more vigorously compared to heavier smokers to achieve the 
same amount of nicotine consumption (32,33), therefore possibly confounding the risk 
estimates comparing heavy to light smokers. However, inhalation was not found to be a 
confounder of pack-years-adjusted cigarettes per day patterns in a lung cancer study (27). 
Data on inhalation patterns was not available for the study participants within BLEND.
Moreover, since no data were available on time periods during which study participants 
might have smoked less (or more) than their average estimated intensity we could not 
account for this. Also, the more deleterious effect of longer duration of smoking that we 
observed might be explained by these individuals smoking well after middle age, which 
is a critical period for avoiding cancer risk. Individuals who smoked more cigarettes per 
day but for a shorter period may have stopped smoking before middle age. Due to the 
retrospective nature of data collection in case-control studies including such detailed data 
on smoking behaviour would not have been possible in this pooled analysis; however, 
in prospective studies such periodical changes in smoking intensity could be accounted 
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for when applying the EOR models by adding TSC or time since moderation splines if 
data is gathered. This EOR model provides one of the most detailed UBC risk prediction 
following different durations and intensities of smoking. Nevertheless, there have been 
other methods to model smoking history in relation to cancer such as the comprehensive 
smoking index which also incorporates intensity, duration and time since cessation (34).
smoking intensity compared to duration in bladder 
carcinogenesis
Tobacco smoke contains many carcinogens that can contribute to carcinogenesis in the 
bladder. These carcinogens can form DNA adducts and, when multiple types of DNA 
adducts are combined, they contribute greatly to human cancer risk (35). Several studies 
have shown that nicotine-derived nitrosamine ketones (NNK), methyl and other DNA 
adducts are more frequently present in UBC patients who have smoked compared to 
those who have never smoked (36,37). Moreover, there is heterogeneity in the efficiency 
of DNA repair pathways between individuals; for example, those who have a slow N-
acetyltransferase phenotype have a higher risk of UBC when they smoke (38), and DNA 
repair processes can also be negatively influenced by smoking (39). This indicates that 
the DNA adduct pathway of UBC pathogenesis is important in smoking-related UBC. 
This is corroborated by our data showing that a longer exposure time to accumulate 
smoking-related DNA adducts, and thus resulting in a higher total burden of DNA ad-
ducts, contributes the most to a higher risk of UBC. The results from our study, as well 
as of other studies in UBC (2,3), lung cancer (9,27), and head and neck cancer (28), are 
consistent in showing that smoking behaviour characterised by long smoking duration 
at low intensity is associated with an increased cancer risk compared to a short duration 
at higher intensity. These results have major implications for prevention at public health 
level and can impact the public’s perception on smoking and health risks.  
conclusion
We have demonstrated that long duration/low intensity smoking behaviour is most 
strongly associated with UBC risk within equal pack-year categories in this pooled analysis, 
thereby confirming studies in two case-control studies on UBC as well as other smoking-
related cancers. Furthermore, with this model we found that reducing complex exposure 
history to a single metric such as pack-years is too restrictive, and future research should 
focus on interpretable ways to model complex cumulative exposures such as lifetime 
smoking behaviour.
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6 Signifi cant Role of Lifetime Cigarette Smoking in Worsening Bladder 
Cancer and Upper Tract Urothelial 
Carcinoma Prognosis: A Meta-Analysis
Frits H. M. van Osch, Sylvia H. J. Jochems, Frederik J. van Schooten, 
Richard T. Bryan, Maurice P. Zeegers
Adapted from:





Although cigarette smoking is a well-established risk factor for urothelial cancer (UC), its 
role in UC prognosis is still undetermined. This meta-analysis aimed to quantify the role 
of lifetime smoking history on bladder cancer recurrence, progression and survival, by 
pooling available data on non-muscle-invasive bladder cancer (NMIBC), muscle-invasive 
bladder cancer (MIBC) and upper tract urothelial carcinoma (UTUC).
materials and methods
A total of 24 studies, comprising data from 13,114 BC and 2,259 UTUC patients, were in-
cluded in this meta-analysis. Publication bias was addressed through Eggers test and the 
heterogeneity between studies was assessed by the I2 test statistic and subgroup analyses.
results
Current smokers at diagnosis are at an increased risk of developing local recurrences in 
NMIBC (HR=1.27, 95% C.I. = 1.09-1.46) and smoking MIBC patients are at an increased risk 
of dying due to BC (HR=1.23, 95% C.I. = 1.02-1.44). In the UTUC population smokers have 
both an increased risk of recurrence in the operative bed (HR=1.57, 95%C.I. = 1.19-1.95) 
and of dying due to UTUC (HR=1.53, 95%C.I. = 1.13-1.92). We did not identify significant 
heterogeneity between included studies.
conclusions
The body of evidence is limited due to the absence of prospective studies. However, 
the results from this meta-analysis unambiguously support the hypothesis that lifetime 
cigarette smokers are at an increased risk of developing a more malignant phenotype of 
urothelial carcinoma associated with worse prognosis. 
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bAckground
Smoking is a major risk factor for the development of urothelial cancer as has been shown 
repeatedly in several case-control and cohort studies (1). However, there has been little 
research into the influence of smoking status at diagnosis, and continuation of smok-
ing after diagnosis, on urothelial cancer recurrence, progression and survival. Several 
reviews have highlighted the potential effect that smoking status might have on disease 
recurrence in non-muscle-invasive bladder cancer (NMIBC) and possibly progression 
to muscle-invasive bladder cancer (MIBC) (2-4) as well as worse upper tract urothelial 
carcinoma (UTUC) prognosis (2, 5).
Lifetime smoking history seems to be associated with increased tumour size and aggres-
siveness of disease at first diagnosis (4, 6). However, it remains unclear whether this is also 
reflected in different clinical outcomes from urothelial carcinoma (UC), a definition which 
encompasses both BC and UTUC, for patients who are smokers compared to never smok-
ers. Although in lung cancer and oesophageal cancer, it has been shown that continuing 
smoking after diagnosis negatively affects oncological outcomes no studies have inves-
tigated smoking cessation after diagnosis yet for UC (3). Nevertheless, the association 
between current smoking at diagnosis and UC prognosis has been investigate in many 
(retrospective) studies (2, 3). 
An improved understanding of smoking and its role in UC prognosis, which is character-
ised by recurrence of disease, progression to muscle-invasive disease after initial treat-
ment or disease-specific death), has the potential to influence clinical decisions regarding 
UC patients and could possibly lead to evidence-based advice on smoking cessation in 
urology clinics (3). The most recent evidence on the relation between smoking and UC 
prognosis suggests that current smokers at diagnosis have higher NMIBC local recur-
rence rates compared to never smokers (2, 3). However, this association or the potentially 
significant association with disease progression has never been previously summarised in 
a meta-analysis.
This study aimed to quantify the role of lifetime smoking history on UC recurrence, pro-
gression and survival, by meta-analysis of available data on NMIBC, MIBC and UTUC. 
By quantifying the associations between lifetime smoking status and UC prognosis, this 
study will shed more light on whether smoking status should be incorporated in prognos-





Medline, Embase, Web of Science and Scopus were used to search for studies on cigarette 
smoking and bladder cancer recurrence, progression and bladder-cancer related mortal-
ity. The search was restricted to only include studies involving humans and there was no 
restriction on publication date. Search terms included the (MeSH) terms “urinary bladder 
neoplasms”, “neoplasm recurrence” “survival”, “smoking” and “epidemiologic studies” 
which resulted in 1,528 hits on possible articles to include after removal of duplicates. 
Studies were excluded when no hazard ratio (HR) for either recurrence-free, progression-
free or disease-free survival for smoking status (current and former versus never smokers) 
was given. Disease recurrence had to be specified as local recurrence for NMIBC and MIBC 
and as recurrence in the operative bed of the tumour for UTUC. Furthermore, only stud-
ies which regarded never smokers as the reference category for calculation of HRs were 
included. Moreover, only studies which provided information or stratified for received 
therapy were included to avoid misinterpretation due to the effects of different therapies. 
Figure 1. Flowchart of study selection and reasons for exclusion
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data collection
To assess the risk of bias and identify possible sources of heterogeneity within individual 
studies selected for full text evaluation the Newcastle-Ottowa assessment scale (NOS) 
for cohort studies was applied (7) by two of the authors (FvO and SJ). Several variables 
were extracted from included articles including year of publication, geographic area 
(North-America, Europe, Asia, Africa, South-America or worldwide collaborative studies), 
disease type (NMIBC, MIBC or UTUC), cigarette smoking assessment (questionnaire, 
interview or patient records), factors adjusted for and median length of follow-up time. 
HRs were obtained directly from included articles and were divided in recurrence-free 
(RFS), progression-free (PFS) and disease-specific (DSS) survival HRs. When bladders were 
resected in MIBC populations, recurrence-free survival was specified by loco-regional 
recurrence; recurrence at the margins of the surgical field or in the lymph nodes. NMIBC 
and MIBC were not further specified or analysed within the included studies, so it is likely 
that a range of different types of malignant neoplasms (e.g. different sub-codes of ICD 
code C67) are included in the pooled analysis. 
statistical analysis
HRs were pooled comparing RFS, PFS and DSS for current and former smokers to never 
smokers in NMIBC, MIBC and UTUC patients. Because HRs could differ between studies, a 
random effects model was used to model potential heterogeneity. The I2 test statistic was 
used to estimate between-study variance. Furthermore, meta-regression analysis was per-
formed to estimate the effect of possible sources of heterogeneity (smoking assessment, 
factors adjusted for, length of follow-up) on different outcome measures. Publication bias 
was explored by funnel plots and Egger’s test for small study effects for the different 
analyses performed (e.g. RFS, PFS & DSS) (8). Unfortunately, there was insufficient data 
to also stratify for gender. As sensitivity analysis, subgroup analyses were performed 
comparing pooled HRs across geographic area and length of follow-up quartile. Stata 
statistical software was used for all analyses (version 13; Stata Corp., College Station, TX).
results
study characteristics
In total, 24 studies were included in this meta-analysis; 11 for NMIBC (9-19) including 2 
trials on different intravesical chemotherapy schedules and 9 retrospective cohorts with 
a total of 7,210 cases, 7 retrospective cohorts for MIBC (20-26) investigating 2,259 cases, 
and 6 retrospective cohorts for UTUC (27-32) encompassing 5,904 cases (Table 1). During 
full-text evaluation 5 studies were excluded because of a lack of data in the study report 
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smoking status was given (38-42) or because the reference category was not comprised of 
never smokers (43-46) (Figure 1). All included studies were patient cohort studies, expect 
for two epirubicin trials in NMIBC (12, 13). Most studies which included HR estimates 
regarding smoking and UC prognosis were published after 2007. Smoking status was 
assessed either by a questionnaire (9-14, 18-20, 22, 26-32), reviewing patient records 
(15, 21, 23-25) or an interview (16, 17). All included study populations for NMIBC had 
undergone full transurethral resection of a bladder tumour (TURBT) with some recorded 
to have received Bacillus Calmette–Guérin (BCG) treatment (15, 16). For MIBC, only studies 
in which patient populations had undergone radical cystectomy (complete removal of the 
bladder) could be included, with some populations receiving (neo)adjuvant chemotherapy 
(20, 23-25). Although radiation therapy is becoming more common as an alternative to 
radical cystectomy (47, 48), no studies investigating associations between smoking and 
outcomes were found in radiation therapy patient populations. In included UTUC study 
populations all patients underwent nephroureterectomy. Moreover, there was no data on 
studies that investigated smoking behaviour post-diagnosis.
risk estimates for smoking status in nmibc
The pooled HR of 1.27 (95% C.I.=1.09-1.46) shows that current smokers at diagnosis are at 
a slightly increased risk of developing local recurrences compared to non-smoking NMIBC 
patients. A mitigated effect is seen in former smokers compared to non-smokers where 
the pooled HR is 1.13 (95% C.I.=1.00-1.25) based on 5,382 NMIBC cases. Similar (but not 
statistically significant) pooled HRs for PFS were obtained for both smokers (HR=1.21, 
95% C.I.=0.81-1.61) and former smokers (HR=1.13, 95% C.I.=0.81-1.45). Regarding DSS, 
only two studies investigating 925 NIMBC cases could be pooled and indicated no effect 
of being a current smoker at baseline (HR=1.01 (95% C.I.=0.93-1.10)). 
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risk estimates for smoking status in mibc
For RFS only one of the four included studies reported a signifi cantly increased risk of 
loco-regional recurrence in MIBC for current smokers at diagnosis (21), and two of three 
included studies showed an increased risk of local recurrence for former smokers (20, 21). 
Pooling these studies resulted in a pooled HR for recurrence of 1.09 (95% C.I.=0.78-1.40) 
for current smokers and a HR of 1.17 (95% C.I.=0.82-1.52) for former smokers compared 
to non-smokers at diagnosis. Current smokers at diagnosis seem to be at higher risk 
of dying due to BC compared to non-smokers (HR=1.23, 95% C.I. =1.02-1.44). A similar 
effect was observed for former smokers (HR=1.26, 95% C.I. =0.98-1.54). The HR for current 
smokers did not seem to differ between studies with different follow-up times.
Table 2. Pooled risk estimates for recurrence-free survival (RFS) and progression-free survival 
(PFS) in non-muscle invasive bladder cancer (NMIBC) 









events HR 95% CI
Smoking status
  Non-smoker 1.00 Reference 1.00 Reference
  Former smoker 7A 1903 1.13 1.00-1.25 4C 978 1.13 0.81-1.45
  Current smoker 10B 1723 1.27 1.09-1.46  6D 617 1.21 0.81-1.61
RFS=recurrence free survival, PFS=progression free survival, HR=hazard ratio, CI=confi dence 
interval
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Table 3. Pooled risk estimates for recurrence-free survival (RFS) and disease-specifi c survival 
(DSS) in muscle invasive bladder cancer (MIBC)









events HR 95% CI
Smoking status
  Non-smoker 1.00 Reference 1.00 Reference
  Former smoker 3A 360 1.17 0.82-1.52 3C 402 1.26 0.98-1.54
  Current smoker 4B 1206 1.09 0.78-1.40  6D 760 1.23 1.02-1.44
RFS=recurrence free survival, DSS=disease-specifi c survival, HR=hazard ratio, CI=confi dence 
interval
risk estimates for smoking status in utuc
No published studies on PFS for smokers in UTUC patient populations could be identifi ed. 
Current smokers at diagnosis were at a signifi cantly higher risk of both developing recur-
rences in the operative bed (HR=1.57, 95%C.I. =1.19-1.95) and dying due to UC (HR=1.53, 
95%C.I. =1.13-1.92). For former smokers, this effect was mitigated, both for RFS (HR=1.31, 
95% C.I.=0.85-1.78) and DSS (HR=1.20, 95% C.I. =0.80-1.61) (Table 4).
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Table 4. Pooled risk estimates for recurrence-free survival (RFS) and disease-specifi c survival 
(PFS) in upper tract urothelial carcinoma (UTUC)









events HR 95% CI
Smoking status
  Non-smoker 1.00 Reference 1.00 Reference
  Former smoker 4A 415 1.31 0.85-1.78 2C 331 1.20 0.80-1.61
  Current smoker 5B 482 1.57 1.19-1.95  2D 330 1.53 1.13-1.92
RFS=recurrence free survival, DSS=disease-specifi c survival, HR=hazard ratio, CI=confi dence interval
publication bias and heterogeneity between studies
Both statistically and visually (as judged from several funnel plots), the amount of bias 
between studies seemed negligible within all three different disease categories. However, 
a statistically signifi cant small study effect (p=0.041) was observed for the NMIBC studies 
investigating RFS, indicating a possibility of publication bias. Meta-regression analyses 
showed that no signifi cant heterogeneity was present due to mode of smoking assess-
ment, number of adjusted factors (mostly multivariable) or months of median follow-up, 
and I2 test statistics were all under 30% except for comparing the fi ve studies investigat-
ing RFS in UTUC (78%).
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sensitivity analyses
Subgroup analyses in studies investigating RFS in NMIBC patients showed no signifi cant 
heterogeneity between geographic areas or follow-up quartile in between studies (Fig-
ure 2). Additional inverse variance weighted regression analyses showed no signifi cant 
change in observed HRs with increasing median follow-up time continuously. Current 
smokers from Asian populations (16-18) seemed to be at a higher risk of developing local 
recurrences compared to American, European and worldwide populations, although these 
differences were not statistically signifi cant (p=0.452, p=0.447 and p=0.452 respectively). 
The results of all sensitivity analyses in both NMIBC and MIBC studies are summarised in 
Supplemental Table 1.
Figure 2. Forest plot depicting summary HR for RFS comparing current smokers vs non-smok-
ers in NMIBC (A) and disease-free survival in MIBC (B) by geographic area, time of follow-up 
quartile, study design and smoking assessment, respectively. Broken line represents no effect 
and solid line indicates overall pooled HR.
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Supplemental Table 1. All results from sensitivity analysis stratifying results on geographic 
area, follow-up quartile, study design and mode of smoking assessment for all studies investi-
gating RFS in NMIBC and DFS in MIBC. 
 NMIBC - RFS MIBC - DFS
Geographic area HR 95% CI
no. of 
studies HR 95% CI
no. of 
studies
North-America 1.25 0.93-1.58 3 1.28 0.96-1.61 2
Europe 1.25 0.80-1.70 3 1.66 0.90-2.43 1
Asia 1.74 1.23-2.26 3 0.94 0.58-1.30 1
Worldwide 1.22 0.99-1.46 1 1.30 0.87-1.73 2
Follow-up quartile       
1 1.56 1.01-2.12 2 - - 0
2 1.59 1.17-2.00 3 1.39 1.11-1.66 2
3 1.26 1.03-1.48 2 1.10 0.72-1.47 2
4 1.09 0.81-1.38 3 0.94 0.58-1.31 1
Study design       
Population-based 1.29 1.12-1.47 9 1.19 0.75-1.64 3
Institutional 1.18 0.61-1.74 2 1.26 1.02-1.51 3
Smoking assessment       
Hospital records 1.31 1.09-1.53 8 1.30 1.07-1.52 3
Questionnaire 1.04 0.73-1.36 1 1.14 0.70-1.58 3
discussion
This meta-analysis indicates a role for lifetime smoking behaviour in BC and UTUC prog-
nosis, showing an increased risk for disease recurrence and increased risk of death for 
current smokers at different stages of BC and UTUC. 
significantly higher local recurrence rates for smokers at 
diagnosis in nmibc
Previous reviews have already suggested that current smokers at diagnosis are at an in-
creased risk of developing local recurrences compared to non-smokers in NMIBC patient 
populations (2-4); however, this is the first study to quantify these risks at diagnosis. We 
observed an increased risk of developing local recurrences for current smokers compared 
to never smokers. Former smokers had a lower (but still increased) risk of developing 
local recurrences. These results are in-line with other studies indicating a potentially more 
malignant disease type for smokers at diagnosis (4, 6). The associations between smoking 
status at diagnosis and PFS were comparable to the RFS estimates, although not statisti-
cally significant. 
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In NMIBC, smoking appears to promote a recurrence phenotype but it is not associated 
with a progression/death phenotype. Mechanistically, there is thus likely to be an influence 
of smoking on the hallmark capabilities of BC such as self-sufficiency in growth signals 
and delimiting replicative potential (49, 50). Although evidence on the effects of smoking 
regarding BC prognosis is limited, including smoking status in panels of molecular mark-
ers (including e.g. p53, cyclooxygenase and vascular endothelial growth factor) has shown 
to improve prognostication in several studies (45, 51).
more deaths due to bc in smokers at diagnosis compared to 
never smokers in mibc
Compared to NMIBC there were considerably fewer studies investigating the role of 
smoking in MIBC prognosis, although one other meta-analysis also showed significantly 
increased BC mortality for current smokers compared to never smokers (RR=1.89 95% 
C.I.= 1.29-2.78) not adjusting for stage of disease in the analysis (52). We did not demon-
strate a relationship between smoking and RFS in MIBC patients; however, both current 
and former smokers at diagnosis are at a higher risk of dying due to BC compared to 
never smokers. There were also noticeably fewer studies investigating RFS compared to 
DSS in MIBC patient populations, emphasizing the need for more studies investigating 
RFS also in MIBC patients. Although there have not been specific studies investigating 
this association biologically or mechanistically, it is possible that the higher mortality due 
to bladder cancer for smokers can be attributed to a more malignant phenotype of BC at 
diagnosis, as suggested by other authors (4, 6). 
Regarding smoking and survival in MIBC, there are several malignant processes in which 
smoking is suspected to play a role and which might explain the observed association 
with poor survival. Smokers have been shown to have a significantly higher expression 
of Twist, a transcription factor regulating epithelial-mesenchymal transition which is an 
important event in tumour invasion (53). Also, positive expression of haeme-oxygenase-1 
(HO-1) may be dependent on smoking intensity as measured at diagnosis (54). A study 
by The Cancer Genome Atlas indicated that altered chromatin remodelling (which plays a 
role in gene expression and apoptosis) is a common event in MIBC (55), and has also been 
shown to be associated with smoking status in several in vitro studies (56, 57) and animal 
models (58). Moreover, it is probable that chronic exposure to cigarette smoke induces a 
phenotype of reduced sensitivity to cisplatin treatment, a well-known phenomenon in the 
management of MIBC (59). 
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significant associations between smoking and both rfs and 
dss in utuc patients
Interestingly, current smokers at diagnosis in the UTUC population were approximately 
at a 50% increased risk of both RFS and DSS compared to never smokers. Although the 
number of events was the smallest from the three meta-analyses performed, significant 
associations were observed. This indicates that also for UTUC patients, the risk of develop-
ing disease recurrences in the operative bed and dying due to UTUC is increased for 
smokers. Although similar associations are observed and many disease characteristics 
are shared, UTUC is a different disease than BC because there are several anatomical, 
biological and molecular-genetic differences (60). For example, microsatellite instability 
(MSI) and hypermethylation are more often observed in UTUC than in BC, which might 
lead to somatic inactivation of DNA mismatch repair genes representing a different 
pathway of initiating events (61, 62). Furthermore, the proportion of tumours that are 
invasive at diagnosis is about 50% for UTUC (63) whereas for BC these numbers are lower 
at approximately 20-30% (64), possibly explaining why the observed associations with RFS 
and DSS are stronger compared to those found in NMIBC and MIBC.
study limitations
One of the limitations of this study was the lack of prospective data on smoking behaviour 
after diagnosis. Even though current smokers at diagnosis could have quit smoking in 
the period prior to recurrence, dose-response meta-analyses show that smoking cessa-
tion only results in risk reduction at least 15 years before diagnosis, indicating a long 
latency effect of cigarette smoke in determining UC risk (unpublished results van Osch 
et al., manuscript currently under review). When considering recurrence as an incident 
event which usually occurs within 15 years of diagnosis, looking at lifetime smoking status 
at diagnosis could be a good proxy measure (with relatively high consistency between 
included studies for the effect of smoking on the development of recurrence). The same 
arguments hold for progression and UC mortality events. However, since UC is extremely 
heterogeneous biologically (65), studies prospectively investigating smoking within strata 
of molecular subtype and stage will provide a more thorough quantification of the effect 
of cigarette smoking in UC prognosis (and could additionally correct for smoking ces-
sation after diagnosis in analyses to further enhance the biological plausibility of these 
results). Furthermore, such studies will be better able to address the question of whether 
smoking status should be considered in predictive nomograms (e.g. EORTC or CUETO) to 
improve decision-making in BC treatment.
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conclusion
This meta-analysis supports the hypothesis that lifetime cigarette smokers are at an 
increased risk of developing a more malignant phenotype of UC. Smoking NMIBC and 
MIBC patients at diagnosis are at an approximately 25% increased risk of developing local 
recurrences and dying due to BC respectively. Furthermore, smoking UTUC patients are at 
an approximately 55% increased risk of both developing recurrences in the operative bed 
of the tumour and dying due to UTUC compared to never smokers. These results indicate 




 1. Zeegers M, Tan FE, Dorant E, van den Brandt PA. The impact of characteristics of cigarette 
smoking on urinary tract cancer risk. Cancer. 2000;89(3):630-9.
 2. Crivelli JJ, Xylinas E, Kluth LA, Rieken M, Rink M, Shariat SF. Effect of smoking on outcomes 
of urothelial carcinoma: a systematic review of the literature. Eur Urol. 2014;65(4):742-54.
 3. Simonis K, Shariat SF, Rink M. Smoking and smoking cessation effects on oncological out-
comes in nonmuscle invasive bladder cancer. Curr Opin Urol. 2014;24(5):492-9.
 4. Pietzak EJ, Malkowicz SB. Does quantification of smoking history correlate with initial blad-
der tumor grade and stage? Curr Urol Rep. 2014;15(7):1-6.
 5. Lughezzani G, Burger M, Margulis V, Matin SF, Novara G, Roupret M, et al. Prognostic fac-
tors in upper urinary tract urothelial carcinomas: a comprehensive review of the current 
literature. Eur Urol. 2012;62(1):100-14.
 6. van Roekel EH, Cheng KK, James ND, Wallace DMA, Billingham LJ, Murray PG, et al. Smoking 
is associated with lower age, higher grade, higher stage, and larger size of malignant blad-
der tumors at diagnosis. Int J Cancer. 2013;133(2):446-54.
 7. Wells G, Shea B, O’Connell D. The Newcastle-Ottawa Scale (NOS) for assessing the quality of 
nonrandomised studies in meta-analyses. Ottawa, ON—Ottawa Hospital Research Institute, 
2013. 2014.
 8. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, 
graphical test1997 1997-09-13 07:00:00. 629-34 p.
 9. Grotenhuis AJ, Ebben CW, Aben KK, Witjes JA, Vrieling A, Vermeulen SH, et al., editors. The 
effect of smoking and timing of smoking cessation on clinical outcome in non–muscle-
invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations; 2014: 
Elsevier.
 10. Wyszynski A, Tanyos SA, Rees JR, Marsit CJ, Kelsey KT, Schned AR, et al. Body mass and 
smoking are modifiable risk factors for recurrent bladder cancer. Cancer. 2014;120(3):408-
14.
 11. Rink M, Furberg H, Zabor EC, Xylinas E, Babjuk M, Pycha A, et al. Impact of smoking and 
smoking cessation on oncologic outcomes in primary non–muscle-invasive bladder cancer. 
Eur Urol. 2013;63(4):724-32.
 12. Serretta V, Altieri V, Morgia G, Di Lallo A, Carrieri G, Allegro R. Cigarette Smoking Status at 
Diagnosis and Recurrence in Intermediate-risk Non–muscle-invasive Bladder Carcinoma. 
Urology. 2013;81(2):277-82.
 13. Lammers RJ, Witjes WP, Hendricksen K, Caris C, Janzing-Pastors MH, Witjes JA. Smoking 
status is a risk factor for recurrence after transurethral resection of non–muscle-invasive 
bladder cancer. Eur Urol. 2011;60(4):713-20.
 14. Segal R, Yafi FA, Brimo F, Tanguay S, Aprikian A, Kassouf W. Prognostic factors and outcome 
in patients with T1 high-grade bladder cancer: can we identify patients for early cystectomy? 
BJUI. 2012;109(7):1026-30.
 15. Sfakianos JP, Shariat SF, Favaretto RL, Rioja J, Herr HW. Impact of smoking on outcomes 
after intravesical bacillus Calmette–Guérin therapy for urothelial carcinoma not invading 
muscle of the bladder. BJUI. 2011;108(4):526-30.
 16. Gangawar R, Ahirwar D, Mandhani A, Mittal RD. Impact of nucleotide excision repair ERCC2 
and base excision repair APEX1 genes polymorphism and its association with recurrence 
125
Meta-analysis smoking and NMIBC prognosis
6
after adjuvant BCG immunotherapy in bladder cancer patients of North India. Med Oncol. 
2010;27(2):159-66.
 17. Chen C-H, Shun C-T, Huang K-H, Huang C-Y, Yu H-J, Pu Y-S. Characteristics of Female 
Non–Muscle-Invasive Bladder Cancer in Taiwan: Association with Upper Tract Urothelial 
Carcinoma and End-Stage Renal Disease. Urology. 2008;71(6):1155-60.
 18. Chen CH, Shun CT, Huang KH, Huang CY, Tsai YC, Yu HJ, et al. Stopping smoking might 
reduce tumour recurrence in nonmuscle-invasive bladder cancer. BJUI. 2007;100(2):281-6.
 19. Allard P, Fradet Y, Tetu B, Bernard P. Tumor-associated antigens as prognostic factors for 
recurrence in 382 patients with primary transitional cell carcinoma of the bladder. Clin 
Cancer Res. 1995;1(10):1195-202.
 20. Kim PH, Kent M, Zhao P, Sfakianos JP, Bajorin DF, Bochner BH, et al. The impact of smok-
ing on pathologic response to neoadjuvant cisplatin-based chemotherapy in patients with 
muscle-invasive bladder cancer. World J Urol. 2014;32(2):453-9.
 21. da Silva RD, Xylinas E, Kluth L, Crivelli JJ, Chrystal J, Chade D, et al. Impact of statin use 
on oncologic outcomes in patients with urothelial carcinoma of the bladder treated with 
radical cystectomy. J Urol. 2013;190(2):487-92.
 22. Lee C, Kim KH, You D, Jeong IG, Hong B, Hong JH, et al. Smoking and survival after radical 
cystectomy for bladder cancer. Urology. 2012;80(6):1307-12.
 23. Boström PJ, Alkhateeb S, Trottier G, Athanasopoulos PZ, Mirtti T, Kortekangas H, et al. Sex 
differences in bladder cancer outcomes among smokers with advanced bladder cancer. 
BJUI. 2012;109(1):70-6.
 24. Boorjian SA, Kim SP, Weight CJ, Cheville JC, Thapa P, Frank I. Risk factors and outcomes of 
urethral recurrence following radical cystectomy. Eur Urol. 2011;60(6):1266-72.
 25. Yafi FA, Aprikian AG, Chin JL, Fradet Y, Izawa J, Estey E, et al. Contemporary outcomes of 
2287 patients with bladder cancer who were treated with radical cystectomy: a Canadian 
multicentre experience. BJUI. 2011;108(4):539-45.
 26. Batty G, Kivimaki M, Gray L, Smith GD, Marmot M, Shipley M. Cigarette smoking and site-
specific cancer mortality: testing uncertain associations using extended follow-up of the 
original Whitehall study. Ann Oncol. 2008;19(5):996-1002.
 27. Kluth LA, Xylinas E, Kent M, Hagiwara M, Kikuchi E, Ikeda M, et al. Predictors of survival in 
patients with disease recurrence after radical nephroureterectomy. BJUI. 2014;113(6):911-7.
 28. Xylinas E, Kluth LA, Rieken M, Lee RK, Elghouayel M, Ficarra V, et al. Impact of smoking status 
and cumulative exposure on intravesical recurrence of upper tract urothelial carcinoma after 
radical nephroureterectomy. BJUI. 2013.
 29. Rink M, Xylinas E, Margulis V, Cha EK, Ehdaie B, Raman JD, et al. Impact of smoking on 
oncologic outcomes of upper tract urothelial carcinoma after radical nephroureterectomy. 
Eur Urol. 2013;63(6):1082-90.
 30. Gunay LM, Akdogan B, Koni A, Inci K, Bilen CY, Ozen H. Upper urinary tract transitional cell 
carcinoma: is there a best? Clin Genitourinary Cancer. 2013;11(1):39-44.
 31. Hagiwara M, Kikuchi E, Tanaka N, Matsumoto K, Ide H, Miyajima A, et al. Impact of smok-
ing status on bladder tumor recurrence after radical nephroureterectomy for upper tract 
urothelial carcinoma. J Urol. 2013;189(6):2062-8.
 32. Ehdaie B, Furberg H, Zabor EC, Ostroff JS, Shariat SF, Bochner BH, et al. Impact of smoking 




 33. Shiels MS, Gibson T, Sampson J, Albanes D, Andreotti G, Freeman LB, et al. Cigarette Smok-
ing Prior to First Cancer and Risk of Second Smoking-Associated Cancers Among Survivors 
of Bladder, Kidney, Head and Neck, and Stage I Lung Cancers. JCO. 2014;32(35):3989-95.
 34. Koch M, Hill GB, McPhee MS. Factors affecting recurrence rates in superficial bladder cancer. 
Journal of the National Cancer Institute. 1986;76(6):1025-9.
 35. Wakai K, Ohno Y, Obata K, Aoki K. Prognostic significance of selected lifestyle factors in 
urinary bladder cancer. Cancer Sci. 1993;84(12):1223-9.
 36. Tseng C-H. Insulin use and smoking jointly increase the risk of bladder cancer mortality in 
patients with type 2 diabetes. Clin Genitourinary Cancer. 2013;11(4):508-14.
 37. Wennersten C, Andersson G, Boman K, Nodin B, Gaber A, Jirström K. Incident urothelial 
cancer in the Malmö Diet and Cancer Study: cohort characteristics and further validation of 
ezrin as a prognostic biomarker. Diagn Pathol. 2014;9(1):189.
 38. Miyamoto H, Brimo F, Schultz L, Ye H, Miller JS, Fajardo DA, et al. Low-grade papillary 
urothelial carcinoma of the urinary bladder. Arch Pathol Lab Med. 2010;134:1160-3.
 39. Cheng L, Neumann RM, Weaver AL, Spotts BE, Bostwick DG. Predicting cancer progression 
in patients with stage T1 bladder carcinoma. JCO. 1999;17(10):3182-7.
 40. Simsir A, Sarsik B, Cureklibatir I, Sen S, Gunaydin G, Cal C. Prognostic factors for upper 
urinary tract urothelial carcinomas: stage, grade, and smoking status. Int Urol Nephrol. 
2011;43(4):1039-45.
 41. Gee JR, Jarrard DF, Bruskewitz RC, Moon TD, Hedican SP, Leverson GE, et al. Reduced blad-
der cancer recurrence rate with cardioprotective aspirin after intravesical bacille Calmette-
Guérin. BJUI. 2009;103(6):736-9.
 42. Michalek AM, Cummings KM, Pontes JE. Cigarette smoking, tumor recurrence, and survival 
from bladder cancer. Prev Med. 1985;14(1):92-8.
 43. Fleshner N, Garland J, Moadel A, Herr H, Ostroff J, Trambert R, et al. Influence of smoking 
status on the disease-related outcomes of patients with tobacco-associated superficial 
transitional cell carcinoma of the bladder. Cancer. 1999;86(11):2337-45.
 44. Ajili F, Kourda N, Karay S, Darouiche A, Chebil M, Boubaker S. Impact of Smoking intensity 
on Outcomes of Patients with Non Muscle Invasive Bladder Cancer Treated by BCG Im-
munotherapy. Ultrastruct Pathol. 2013;37(4):273-7.
 45. Mitra AP, Castelao JE, Hawes D, Tsao-Wei DD, Jiang X, Shi SR, et al. Combination of 
molecular alterations and smoking intensity predicts bladder cancer outcome. Cancer. 
2013;119(4):756-65.
 46. Rink M, Zabor EC, Furberg H, Xylinas E, Ehdaie B, Novara G, et al. Impact of smoking and 
smoking cessation on outcomes in bladder cancer patients treated with radical cystectomy. 
Eur Urol. 2013;64(3):456-64.
 47. James ND, Hussain SA, Hall E, Jenkins P, Tremlett J, Rawlings C, et al. Radiotherapy with or 
without chemotherapy in muscle-invasive bladder cancer. NEJM. 2012;366(16):1477-88.
 48. Stenzl A, Cowan NC, De Santis M, Kuczyk MA, Merseburger AS, Ribal MJ, et al. Treatment 
of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. Eur Urol. 
2011;59(6):1009-18.
 49. Bryan RT, Hussain SA, James ND, Jankowski JA, Wallace DMA. Molecular pathways in blad-
der cancer: part 1. BJUI. 2005;95(4):485-90.
 50. Bryan RT, Hussain SA, James ND, Jankowski JA, Wallace DMA. Molecular pathways in blad-
der cancer: part 2. BJUI. 2005;95(4):491-6.
127
Meta-analysis smoking and NMIBC prognosis
6
 51. Wang LC, Xylinas E, Kent MT, Kluth LA, Rink M, Jamzadeh A, et al. Combining smoking 
information and molecular markers improves prognostication in patients with urothelial 
carcinoma of the bladder. Urol Oncol. 2014;32(4):433-40.
 52. Cumberbatch MG, Rota M, Catto JW, La Vecchia C. The Role of Tobacco Smoke in Bladder 
and Kidney Carcinogenesis: A Comparison of Exposures and Meta-analysis of Incidence and 
Mortality Risks. Eur Urol. 2015.
 53. Fondrevelle ME, Kantelip B, Reiter RE, Chopin DK, Thiery JP, Monnien F, et al. The expression 
of Twist has an impact on survival in human bladder cancer and is influenced by the smok-
ing status. Urologic Oncology: Seminars and Original Investigations. 2009;27(3):268-76.
 54. Miyata Y, Kanda S, Mitsunari K, Asai A, Sakai H. Heme oxygenase-1 expression is associated 
with tumor aggressiveness and outcomes in patients with bladder cancer: a correlation with 
smoking intensity. Translational Research. 2014;164(6):468-76.
 55. Network CGAR. Comprehensive molecular characterization of urothelial bladder carcinoma. 
Nature. 2014;507(7492):315-22.
 56. Moodie FM, Marwick JA, Anderson CS, Szulakowski P, Biswas SK, Bauter MR, et al. Oxidative 
stress and cigarette smoke alter chromatin remodeling but differentially regulate NF-κB ac-
tivation and proinflammatory cytokine release in alveolar epithelial cells. The FASEB journal. 
2004;18(15):1897-9.
 57. Chen D, Fang L, Li H, Tang M-s, Jin C. Cigarette smoke component acrolein modulates 
chromatin assembly by inhibiting histone acetylation. Journal of Biological Chemistry. 
2013;288(30):21678-87.
 58. Marwick JA, Kirkham PA, Stevenson CS, Danahay H, Giddings J, Butler K, et al. Cigarette 
smoke alters chromatin remodeling and induces proinflammatory genes in rat lungs. Am J 
Respir Cell Mol Biol. 2004;31(6):633-42.
 59. Chang X, Ravi R, Pham V, Bedi A, Chatterjee A, Sidransky D. Adenylate kinase 3 sensi-
tizes cells to cigarette smoke condensate vapor induced cisplatin resistance. PloS one. 
2011;6(6):e20806.
 60. Green DA, Rink M, Xylinas E, Matin SF, Stenzl A, Roupret M, et al. Urothelial carcinoma of the 
bladder and the upper tract: disparate twins. J Urol. 2013;189(4):1214-21.
 61. Yates DR, Catto JW. Distinct patterns and behaviour of urothelial carcinoma with respect to 
anatomical location: how molecular biomarkers can augment clinico-pathological predic-
tors in upper urinary tract tumours. World J Urol. 2013;31(1):21-9.
 62. Azémar M-D, Comperat E, Richard F, Cussenot O, Rouprêt M, editors. Bladder recurrence 
after surgery for upper urinary tract urothelial cell carcinoma: frequency, risk factors, and 
surveillance. Urologic Oncology: Seminars and Original Investigations; 2011: Elsevier.
 63. Kang CH, Yu TJ, Hsieh HH, Yang JW, Shu K, Huang CC, et al. The development of bladder 
tumors and contralateral upper urinary tract tumors after primary transitional cell carcinoma 
of the upper urinary tract. Cancer. 2003;98(8):1620-6.
 64. Kirkali Z, Chan T, Manoharan M, Algaba F, Busch C, Cheng L, et al. Bladder cancer: epidemi-
ology, staging and grading, and diagnosis. Urology. 2005;66(6):4-34.
 65. Knowles MA, Hurst CD. Molecular biology of bladder cancer: new insights into pathogenesis 
and clinical diversity. Nature Reviews Cancer. 2015;15(1):25-41.

7 The association between smoking cessation before and after diagnosis 
and non-muscle-invasive bladder 
cancer recurrence: a prospective 
cohort study
Disclaimer: this study was underpowered and therefore nothing can be 
inferred from the exploratory analysis presented in this dissertation
Frits H.M. van Osch, Sylvia H.J. Jochems, Duncan Nekeman, 
Sarah Pirrie, Anke Wesselius, Raoul C. Reulen, Nicholas James, 
D Michael A. Wallace, Frederik J. van Schooten, KK Cheng, 
Richard T. Bryan, Maurice P. Zeegers





Smoking is a major risk factor for bladder cancer, but the relationship between smoking 
cessation after initial treatment and bladder cancer recurrence has been investigated less 
frequently and not prospectively yet.
methods
722 non-muscle-invasive bladder cancer (NMIBC) patients (pTa, pT1 and CIS) from the 
prospective Bladder Cancer Prognosis Programme (BCPP) cohort, selected in the UK be-
tween 2005-2011, provided complete data on smoking behaviour before and up to 5 years 
after diagnosis. The impact of smoking behaviour on NMIBC recurrence was explored by 
multivariable Cox regression models investigating time-to-first NMIBC recurrence.
results
Over a median follow-up period of 4.21 years, 403 pathologically confirmed NMIBC 
recurrences occurred in 210 patients. Only 25 current smokers at diagnosis quit smoking 
(14%) during follow-up and smoking cessation after diagnosis did not decrease risk of 
recurrence compared to continuing smokers (p=0.352). 
conclusions
Although quitting smoking after diagnosis might reduce the risk of recurrence based on 
retrospective evidence, this could not be confirmed in this prospective study because the 
number of NMIBC patients quitting smoking before their first recurrence was too low.
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introduction
Bladder cancer (BC) is estimated to be the ninth most frequent cancer worldwide with 
approximately 400,000 newly diagnosed cases per year [1]. Compared to other cancers, 
mortality rates are generally lower for BC [1] since the majority of BCs diagnosed are non-
muscle-invasive bladder cancers (NMIBC) [2]. However, NMIBC often recurs [3] and has 
a risk of progressing to muscle-invasive bladder cancer (MIBC) [4], events which impact 
on the quality of life of the patient [5] and generate high disease management costs [6].
Although smoking is an established risk factor for BC, its effects have been less frequently 
investigated in relation to BC prognosis [7–10]. Although many studies investigated ef-
fectiveness of treatment for NMIBC and MIBC with regard to recurrence, progression and 
mortality, most studies did not investigate the effect of smoking or other factors modifi-
able by patients on BC prognosis [11]. Nevertheless, the number of studies also reporting 
hazard ratios (HRs) for BC recurrence by smoking status at diagnosis has increased recently 
and the current body of evidence consistently shows that there is a small association 
between smoking and BC recurrence when comparing current smokers to never smokers 
at diagnosis [10,12]. However, the impact of smoking cessation after BC diagnosis on 
recurrence and mortality has not yet been quantified prospectively [13]. Studies have 
investigated the impact of smoking cessation within one year after diagnosis on BC recur-
rence, showing a slight decrease in risk of recurrence [14,15], and one study indicating 
no effect of quitting after diagnosis on overall or bladder cancer-specific mortality [16].
The Bladder Cancer Prognosis Programme (BCPP) followed-up BC patients for five years 
post-diagnosis and investigated changes in smoking behaviour in relation to the course 
of the disease [17]. The principal aim of this study was to investigate whether smoking 
cessation post-diagnosis and smoking behaviour pre-diagnosis influences BC recurrence. 
methods 
the bladder cancer prognosis programme
This study was conducted within the framework of the West Midlands Bladder Cancer 
Prognosis Programme (BCPP), a cohort study in the United Kingdom. Details of the study 
are described elsewhere [17]. In brief, individuals were included between December 
2005 and October 2011 after referral to participating urology centres due to symptoms 
suspicious of BC and followed for a maximum of 5 years from diagnosis. Patients with 
previous cancer of the urethra, bladder, ureter, or renal pelvis within the last decade were 
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excluded. The study was ethically-approved (06/MRE04/65) and all participants gave writ-
ten informed consent. 
data collection
At or around time of diagnosis, trained research nurses used semi-structured face-to-face 
interviews and questionnaires to collect data on social support, health-related quality of 
life, sociodemographics, medical history, and health-related behaviours including smok-
ing behaviour. Variables on smoking behaviour included current smoking status (never, 
former, current), duration (years of smoking), intensity (cigarettes per day), smoking 
cessation (in years) and tobacco type (filter, non-filter or rolled cigarettes, cigar or pipe). 
Monthly smoking status was also assessed retrospectively by postal questionnaires that 
were sent out to participants yearly until the end of follow-up. 
smoking status at diagnosis and during follow-up
A combined smoking status variable was created indicating continuing smokers, former 
smokers who consistently abstained, never smokers, former smokers who started smoking 
again, and current smokers who quit smoking post-diagnosis. Patients were considered 
quitters when they abstained consistently, so smokers who quit for 3 months and then 
started again were considered as continuing smokers. Furthermore, for each participant 
that reported smoking cessation during follow-up it was confirmed whether this occurred 
before or after their first recurrence. If patients quit smoking after their first recurrence, 
they were considered as continuing smokers in the time-to-first recurrence analysis.
population at risk
Of the 1,550 cases who agreed to participate, 231 were subsequently identified as not 
having BC. Patients who presented with MIBC (n=275) disease at diagnosis were excluded 
from analysis because they are fundamentally different from NMIBC with regard to re-
currence. Patients with squamous or adeno-carcinomas of non-urothelial origin or with 
bladder cancer as secondary carcinoma were excluded (n=41). In addition to patients 
presenting with Ta and T1 tumours, carcinoma in situ (CIS) tumours were included (n=16) 
since they have an increased risk of recurrence [18]. In total, 846 (84%) of these patients 
had provided data on smoking behaviour at diagnosis and during follow-up and remained 
under follow-up within the cohort study. Of the included 846 NMIBC patients, there were 
116 patients with unknown recurrent tumour stage. These 116 unconfirmed events were 
excluded for other analyses as well as 8 cases who had radiotherapy (on suspicion of 
being MIBC cases) resulting in a NMIBC patient population at risk of recurrence of 722. 
No systematic guidance or tools were provided to enable patients to quit smoking after 
diagnosis, so care as usual was applied by all participating urologists.
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statistical analysis
BC recurrence was defined as a new tumour that was the same stage as the primary 
tumour (Ta or T1) but also when a primary Ta patient had a T1 recurrence. Patients that 
progressed from T1 to T2 disease were not counted as a recurrence but as a progression 
event. Unfortunately, there were not enough events to also consider biological progres-
sion within this sample of NMIBC patients, as defined in the BCPP cohort [19]. Therefore, 
this study only focussed on confirmed recurrence events and patients who experienced a 
progression event were censored in the survival analysis when the progression event was 
diagnosed.
The impact of smoking behaviour on BC recurrence was explored by Cox regression 
models—with time since initial transurethral resection of the bladder tumour (TURBT) as 
the time-metric—investigating possible differences in likelihood of a first recurrence. We 
explored two different Cox regression models: one adjusted for age at diagnosis and sex 
(model 1) and one additionally adjusted for BC stage, grade, tumour size and number 
of tumours at diagnosis (model 2). This set of confounders was chosen since they are 
markers of NMIBC prognosis and are factors that contribute to European Association of 
Urology (EAU) risk stratification for clinical decisions [20]. Moreover, they are potentially 
associated with smoking behaviour at diagnosis [21]. Consequently, conditional risk set 
modelling was applied to investigate time between multiple recurrent events and analysis 
time was reset at each event [22]. For this analysis, reresection of tumours was added to 
model 2 as a confounder. The proportional hazards assumption was checked in all models 
using Schoenfeld residuals. Cumulative incidence functions (CIF) corrected for competing 
risks (death) were made [23].
Furthermore, the differences in mean number of recurrences over 5 years between never 
smokers, former smokers and continuing smokers were compared using a multivariable 
ANOVA model correcting for pairwise comparisons using Tukey’s HSD. There were not 
enough BC-related death events (45) or confirmed progression events (19) to allow for 
separate analyses. A similarly low number of progression events has been observed in a 
large (n=718) NMIBC patient sample before [24].
NMIBC patients who died before the end of follow-up (n=157) were censored at time 
of death and patients who underwent cystectomy (n=15) were censored at the date of 
cystectomy (13). Other patients were considered lost to follow-up when the date on which 
patients were last seen in the hospital for bladder cancer-related therapy or the date on 





number of recurrences and characteristics of population at risk
All 722 patients at risk of recurrence were followed over a median period of 4.21 years 
(IQR = 2.64-5.00 years). The majority of patients (506, 70%) were followed for at least 3 
years. Over this period of follow-up, 210 NMIBC patients experienced at least one con-
firmed recurrence event. These 210 NMIBC patients accumulated a total of 403 confirmed 
recurrence events in the cohort. 
Most cases were male (79%) and around the age of 70 (Table 1). Furthermore, continuing 
smokers seemed to be underrepresented in the low EAU risk group (12%), those who quit 
smoking seemed more likely to be younger and female, and continuing smokers seemed 
more likely to present with multiple tumours at diagnosis (Table 1). In the multivariate 
models, 26 patients were not included in the analysis due to missing data on age (n=7), 
number of tumours at diagnosis (n=15) and tumour size (n=4). Because participants were 
recruited from multiple centers, patients were treated by multiple urologists with different 
individual thresholds to perform certain therapies. Therefore, not all patients were treated 
exactly according to the EAU guidelines [20], which is often the case in actual clinical 
practice [25]. 
Associations between smoking behaviour pre-and post-
diagnosis and bc recurrence
Although HR estimates for smoking cessation pre-diagnosis indicated a protective 
association with BC recurrence, the p for linear trend was not statistically significant 
(ptrend=0.126) and therefore the association cannot be considered as strong (Table 2). 
No association between smoking status and risk of recurrence was observed in the multi-
variable model (Table 2). Interestingly, when compared to continuing smokers (HR=1.04, 
95% CI=0.65-1.66) HRs were similar for those who quit smoking (p=0.352) and former 
smokers who started again post-diagnosis (p=0.431) (Table 2). Additionally, the cumula-
tive incidence function shows that cumulative incidence of BC recurrence was lowest for 
former smokers and never smokers (Figure 1).
135







































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































BCPP – smoking cessation and BC prognosis
7
Figure 1. Cumulative incidence functions with correction for competing risk (death) indicat-
ing cumulative incidence of fi rst recurrence per category of smoking status in NMIBC patients 
treated with TURBT.
Only 25 smokers (14%) of the 174 current smokers originally recorded at diagnosis quit 
smoking at any point during follow-up. Three quitters were excluded for full analysis for 
not having information on their date last seen and another fi ve had missing data regard-
ing the invasiveness of their recurrent events. Of the 480 former smokers at diagnosis, 
172 (36%) started smoking (any form of tobacco) again post-diagnosis in all included 846 
NMIBC patients. Exposure to environmental tobacco smoke during childhood (HR=1.17, 
95%CI=0.81-1.68) or adulthood (HR=1.02, 95%CI=0.76-1.36) did not seem to have any 
impact on time to fi rst recurrence (Table 2).
Table 3 shows HRs for time to fi rst recurrence by smoking intensity, duration and pack-
years. No linear trends were observed although the highest categories showed the highest 
point estimates for both smoking intensity and pack years. For smoking duration, the HRs 
were divergent and did not indicate any trend (ptrend=0.729) at all.  
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Table 2. Cox regression analysis investigating smoking status at diagnosis, smoking behaviour after 
diagnosis, smoking cessation and passive smoking regarding risk of recurrence in NMIBC patients 
treated with TURBT.
 Age & sex adjusted Multivariable model*
 HR 95% CI
number of 
events / 




Smoking status  
Never smoker 1.00 ref 29/103 1.00 ref 28/99
Former smoker 0.79 0.51-1.24 61/266 0.78 0.48-1.24 59/254
Continuing smoker 1.17 0.75-1.83 62/186 1.04 0.65-1.66 61/180
  
Former smoker who started 
again** 1.04 0.65-1.64 51/150 0.87 0.53-1.41 49/146
Current smoker who quit 
smoking*** 1.25 0.52-3.00 6/17 1.47 0.63-3.41 6/17
Smoking cessation (in years) 
****   
<20 years 0.81 0.46-1.43 15/48 0.82 0.46-1.46 15/47
21-40 years 0.76 0.53-1.08 57/208 0.74 0.51-1.08 54/200
>40 years 0.67 0.44-1.02 39/155 0.71 0.46-1.09 38/148
   
p for trend 0.070   0.126   
Exposed to passive smoking 
during childhood?   
No 1.00 ref 36/142 1.00 ref 35/138
Yes 1.23 0.86-1.75 173/576 1.17 0.81-1.68 168/554
Exposed to passive smoking 
during adulthood?   
No 1.00 ref 74/261 1.00 ref 74/261
Yes 1.03 0.77-1.38 135/454 1.02 0.76-1.36 135/454
* All estimates adjusted for age, sex, stage, grade, tumour size and number of tumours
** Former smoker who started again and current smoker who quit smoking not included in former smokers 
at diagnosis
*** Smokers who quit after their first event are considered as current smokers
**** Reference category = current smokers at diagnosis, estimates also include former smokers who started 
again after diagnosis
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Table 3. Multivariable Cox regression analysis concerning the association between smoking 
pack-years, intensity and duration (recorded at diagnosis) with time to first recurrence in 
NMIBC patients treated with TURBT.
 Age & sex adjusted Multivariable model*








       
Never smoker 1.00 ref 29/103 1.00 ref 28/99
       
Pack-years       
1-9 packyears 0.86 0.53-1.42 36/141 0.81 0.48-1.37 34/134
10-19 packyears 0.95 0.54-1.67 22/81 0.92 0.51-1.65 22/80
20-29 packyears 0.93 0.49-1.77 15/58 0.81 0.42-1.60 15/57
30-39 packyears 0.70 0.35-1.43 11/55 0.60 0.30-1.22 11/53
>40 packyears 1.28 0.76-2.14 30/86 1.14 0.66-1.97 29/83
       
p for trend 0.365   0.688   
Smoking intensity (cigarettes/
day)       
1-9 cigarettes 0.83 0.50-1.38 32/128 0.81 0.47-1.38 30/122
10-19 cigarettes 0.75 0.45-1.28 31/140 0.61 0.35-1.07 31/138
20+ cigarettes 1.24 0.79-1.96 55/167 1.16 0.72-1.85 54/160
       
p for trend 0.112   0.198   
Smoking duration (in years)       
1-9 years 1.03 0.52-2.05 12/45 0.97 0.48-1.95 12/43
10-19 years 0.94 0.54-1.62 22/83 0.85 0.48-1.50 21/78
20-29 years 0.79 0.45-1.39 21/87 0.79 0.44-1.44 20/85
30-39 years 1.08 0.61-1.89 26/88 0.93 0.52-1.66 25/85
40+ years 1.00 0.60-1.64 36/127 0.88 0.52-1.49 36/124
       
p for trend 0.917   0.729   
* All estimates adjusted for age, sex, stage, grade, tumour size and number of tumours at diagnosis
When considering multiple events that have occurred in patients (Table 4) the HRs are 
similar to the time to first recurrence analysis (HR for continuing vs never smokers is 
1.10, 95%CI=0.72-1.69). However, continuing smokers seemed to have experienced more 
recurrences than never smokers on average over 5 years on average, however not signifi-
cantly (0.64 vs 0.45, p=0.308).
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Table 4. Conditional risk set model investigating time between multiple recurrence events in 





events / patients 
at risk
Mean number of 
recurrences over 5 
years (95% CI)
Smoking status
Never smoker 1.00 ref 43/99 0.45 (0.28-0.63)
Former smoker 0.71 0.47-1.08 108/254 0.45 (0.33-0.57)
Continuing smoker 1.10 0.72-1.69 116/180 0.64 (0.47-0.81)
    
Former smoker who started again 0.89 0.56-1.43 108/146 0.82 (0.57-1.06)
Current smoker who quit smoking** 0.85 0.35-2.04 18/19 0.84 (0.10-1.58)
* All estimates adjusted for age, sex, stage, grade, tumour size, number of tumours and reresection of recur-
rent tumour
** Smokers who have quit after their first event (n=2) are also included
discussion
smoking cessation post-diagnosis and bc recurrence & clinical 
implications
The reported HRs give reason to believe that quitting smoking does not influence the 
likelihood of NMIBC recurrence over 5 years when compared to continuing smokers in 
our sample. However, the number of quitters in our prospective sample was small which 
complicates drawing conclusions for this group. Another (retrospective) patient cohort 
study which assessed smoking cessation post-diagnosis concluded that quitting smoking 
significantly reduced risk of recurrence (HR=0.45, 95% CI=0.25-0.83, comparing quitters 
to continuing smokers), however the proportion of quitters (~43% of current smokers 
at diagnosis) was also considerably larger [14]. In another retrospective cohort study, 
Fleshner et al concluded that it remained unclear whether smoking cessation at time of 
diagnosis is beneficial with regard to BC recurrence [15] although Aveyard et al. estimated 
that the Fleshner study shows a HR of 0.71 (95% CI=0.48-1.05) when comparing quitters 
to continuing smokers[26], which is similar to the estimate observed in the study by Chen 
et al. Taken together, the limited evidence at this point seems to indicate that quitting 
smoking at or closely after diagnosis could reduce risk of recurrence. However, even 
across several smoking-related cancer sites such as lung cancer where this association 
is stronger, evidence to imply a strong, causal relationship between smoking behaviour 
after diagnosis and recurrence is still limited [27] so more prospective research is needed.
Considering the prolonged latency period for the development of BC after exposures [2], 
it is credible that the association between altering smoking behaviour post-diagnosis and 
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likelihood of a first recurrence or multiple recurrences over 5 years is not as strong as 
the association between smoking and carcinogenesis. Similarly, epidemiological evidence 
suggests that pre-diagnostic smoking cessation does not immediately lower the risk of 
BC [28], also indicating a longer latency period than 5 years. Furthermore, it is considered 
that a first BC recurrence is often the result of incomplete resection and/or tumour cell 
re-implantation, and that genuine new tumour formation only plays a more important 
role in later recurrences [29]. It is therefore reasonable to suggest that, because of the 
DNA-damaging effects of cigarette smoke [30], modifying smoking behaviour may only 
influence later recurrences and possibly those that may occur beyond the follow-up 
period of 5 years reported here.
Notwithstanding the results from our study, when considering the impact of comorbidi-
ties on overall survival in BC patients [31] which include several smoking-related diseases 
[32] and other evidence indicating beneficial and significant results of post-diagnostic 
smoking cessation in retrospective studies [14,15], it is evident that smoking cessation 
should be encouraged for NMIBC patients at diagnosis.
It is striking that only 14% of current smokers at diagnosis in our sample quit smoking 
post-diagnosis. There are examples of succesful smoking cessation interventions in urol-
ogy [33], and several studies found that when patients were diagnosed with BC they were 
more likely to quit smoking [34,35]. Therefore, urologists should continue to improve 
smoking cessation counselling in newly diagnosed NMIBC patients and to be current on 
the available tools to improve smoking cessation figures. Moreover, more intervention 
clinical research investigating smoking cessation programmes in NMIBC patients is war-
ranted.
smoking behaviour pre-diagnosis & exposure to environmental 
tobacco smoke
Smoking cessation was most beneficial, with regard to reducing the risk of recurrence, the 
longer before diagnosis it happened compared to continuing smokers. This was the stron-
gest association observed in our study and has been observed in other studies as well, 
although not consistently [12]. Other results were in line with earlier studies investigating 
smoking status at diagnosis and BC recurrence as well, by indicating a slightly increased 
risk of recurrence in NMIBC patients for current smokers compared to never smokers in 
a meta-analysis [10]. 
Another recent study not included in the aforementioned meta-analysis shows similar 
HRs (HR=1.49, 95%C.I.=0.95-2.33) for current smokers at diagnosis [8]. However, when 
including this study and our study (data from continuing smokers) in the meta-analysis 
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the pooled HR barely changes from 1.27 (95%CI=1.09-1.46) to 1.26 (95% CI= 1.12-1.40) 
[10], indicating a significantly increased risk of recurrence for current smokers at diagnosis 
compared to never smokers. Possibly, the lack of association for continuing smokers in 
this study can be explained through multiple synchronous tumours being present at 
diagnosis in epithelial tumours. This theory of “field cancerization” proposes that (pre-)
malignant transformation of cells has already occurred at different sites across the urothe-
lium, explaining why (changing) smoking exposure will not have a large impact on disease 
prognosis [36]. 
Additionally, given that recent reviews indicate no considerable heterogeneity between 
studies that do not show an association between environmental tobacco smoke and risk 
of BC, it is unlikely that we would have shown any substantial association with BC recur-
rence either [37,38].
Because no substantial association between smoking status pre-diagnosis and BC recur-
rence was observed in adjusted models it is possible that the tumour characteristics 
associated with BC recurrence (stage, grade, tumour size, number of tumours) included 
as confounders in these models overshadow the effects of smoking behaviour in deter-
mining risk of BC recurrence [21] and possible also mortality since no association between 
quitting smoking after diagnosis and all-cause or bladder-cancer-specific mortality was 
observed in a large retrospective cohort study[16]. Moreover, since current smokers at 
diagnosis in our cohort have been associated with having a higher stage, higher grade 
and larger tumour size compared to never smokers [39], smoking behaviour might play 
a more crucial role in determining risk of recurrence already before diagnosis through 
promoting unfavourable tumour characteristics associated with BC recurrence at diag-
nosis, although in a Dutch cohort of 323 UBC patients there was only a weak association 
between smoking intensity and increased risk of a more aggressive tumour type [40]. 
strengths and weaknesses
Despite the prospective nature of our study there were some limitations restricting the 
analyses. Due to the relatively short follow-up of this study, long term effects of smoking 
cessation post-diagnosis could not be assessed and the number of deaths due to BC in 
the NMIBC patients within our cohort was too low for Cox regression analysis. Also, it was 
not possible to obtain detailed information on adjuvant therapy for all patients, so differ-
ences in adjuvant therapy could not be considered in the statistical analysis. Additionally, 
we did not correct for biomarkers of BC recurrence such as mutations in the FGFR3 or 
TP53 genes [41], although they might work together with smoking intensity in predicting 
BC outcome [42]. 
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Furthermore, one of the caveats of using only self-reported questionnaire data to assess 
smoking exposure was likely demonstrated in our sample of NMIBC patients. The large 
proportion (about 1 in 3) of former smokers pre-diagnosis who reported to have started 
smoking again post-diagnosis is implausible and is probably observed due to misclas-
sification of either the questionnaire at baseline or during follow-up. A high misclassifica-
tion rate (47%) when comparing self-reported data on smoking behaviour to cotinine 
values in blood was also shown in another sample of bladder cancer patients undergoing 
surveillance [43]. Preferably, future studies should consider more reliable ways of verifying 
smoking exposure through biochemical analysis.
Unfortunately, at the start of the study we did not anticipate this small proportion of 
quitters after diagnosis which is why the analysis concerning quitters is underpowered. 
conclusion
Although quitting smoking after diagnosis might reduce probability of recurrence based 
on retrospective evidence, the number of NMIBC patients quitting smoking in our pro-
spective study was low. Based on the current evidence, smoking cessation pre-diagnosis 
seems to have the largest impact on reducing risk of recurrence after NMIBC diagnosis. 
More prospective studies with adequate sample size are required to further investigate 
the possible effect of smoking cessation after diagnosis of NMIBC. 
Disclaimer: this study was underpowered and therefore nothing can be inferred from the 
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The aim of this dissertation was to provide detailed evidence on the association between 
smoking behaviour pre-and post-diagnosis and bladder cancer risk and prognosis, 
contributing to a more thorough understanding of how smoking is related to bladder 
cancer. The hypotheses for this thesis were that smoking duration is more important than 
intensity in predicting risk of developing BC and that smoking cessation even after BC 
diagnosis could have a beneficial effect on BC prognosis. To investigate these hypotheses, 
the current body of evidence was summarised first by using a meta-analysis approach. 
Second, the observed knowledge gaps were filled by analysing data from both the pro-
spective BCPP cohort of bladder cancer cases and the BLEND consortium of observational 
studies on bladder cancer risk.
summAry of mAin findings
This thesis can be divided in two parts; the investigation of the relationship between 
smoking and a) bladder cancer risk (chapters 2 to 5) and b) bladder cancer prognosis 
(chapters 6 & 7).
The extensive meta-analysis presented in chapter 2, showed a threefold higher risk of BC 
for cigarette smokers, which is in line with results from earlier meta-analyses and system-
atic reviews. Interestingly, however, the proportions of BC cases attributable to smoking 
(PARs) were noticeably lower (43% compared to 50% in males) than estimated in 2000, 
possibly driven by the decreasing number of smokers in Western countries. Furthermore, 
the meta-analysis showed that those who have quit smoking for more than 35 years 
are still at an increased risk of bladder cancer compared to never smokers (OR=1.48, 
95%CI=1.39-1.58). 
In chapter 3 all available evidence on the association between exposure to environmental 
tobacco smoke (ETS) and bladder cancer risk were combined. Results from this meta-
analysis showed no substantial association between exposure to ETS, either during child-
hood or adulthood, and bladder cancer risk. However, detail on the smoking behaviour of 
active smokers to whom never smokers were exposed in these studies was often lacking. 
Therefore, it was not possible to identify whether there were groups of participants in 
studies that were highly exposed to ETS from a heavy smoker, and possibly showing 
different results than those exposed to a less heavy active smoker.
The unique collaboration between the UK Department of Health and the BCPP cohort 
study made it possible to investigate tar, nicotine and CO content of different brands of 
cigarettes smoked by BCPP participants. Results showed that increasing daily intake of tar, 
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nicotine and CO linearly increases the risk of non-muscle-invasive bladder cancer linearly 
compared to a lower intake (chapter 4). Nevertheless, individual smoking behaviour might 
differ regarding the number of cigarettes smoked and depth of inhalation, which in turn 
might be correlated with cigarette type, possibly confounding this association. 
In chapter 5, the effect of smoking duration and intensity on bladder cancer risk was 
analysed by making use of the BLEND data.  This pooled data from 15 case-control studies 
confirmed that smoking duration is the overriding factor in determining bladder cancer 
risk. Since this study showed very strong evidence that smokers should stop as early as 
possible to substantially reduce risk of bladder cancer, this result might have a major 
impact on future prevention programmes/interventions.  
The meta-analysis in chapter 6, which summarises results from studies investigating the as-
sociation between smoking status at diagnosis and bladder cancer prognosis (recurrence, 
progression and death) showed that bladder cancer patients who smoke at diagnosis are 
at an approximately 25% increased risk of recurrence and dying due to bladder cancer. 
Unfortunately, all included studies in this meta-analysis were retrospective in nature and 
therefore did not consider smoking cessation after diagnosis. Therefore, chapter 7 aims to 
fill this gap in knowledge by prospectively following non-muscle-invasive bladder cancer 
patients in BCPP. However, the proportion of quitters after diagnosis was very small (14%) 
and therefore conclusions concerning smoking cessation after diagnosis were limited.
interpretAtion of mAin findings
smoking behaviour (intensity, duration and cessation) and 
bladder cancer risk
Although it has been known for decades that smoking is a major risk factor for bladder 
cancer [1], and that those who have the highest cumulative exposure (e.g. total number of 
cigarettes smoked over a lifetime) are at the highest risk of developing bladder cancer [2], 
the exact dose-response relationship between smoking behaviour (intensity, duration and 
cessation) and carcinogenesis remains disputable [3,4]. With the dose-response curves 
based on the meta-analysis research presented in chapter 2 of this thesis [5], an overview 
is provided for the association between different smoking behaviours and bladder cancer 
risk. Currently, this is the most detailed summary to date. Nevertheless, results might be 
biased by the fact that it could not be considered that smoking duration and intensity 
are highly correlated because those who have smoked many years are often also heavier 
smokers. Because of this high correlation, the individual curves do not predict risk based 
on the number of cigarettes, but rather only show the strength of association between 
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smoking intensity and duration and bladder cancer risk separately. More detailed data 
collection on smoking behaviour would be needed for moving towards individual risk 
prediction.
In an attempt to go beyond a classical epidemiological estimation of the association 
between smoking behaviour and bladder cancer risk and the identification of factors 
related to smoking behaviour, a state of the art technique was used to model pack-years 
together with smoking intensity in chapter 5. Here, it was found that smoking duration is 
the overriding factor in determining bladder cancer risk, indicating that the length of the 
period that a person smoked is more important than the number of cigarettes smoked 
during that period. Although risk in the lowest pack-year categories is still low for those 
with a relatively long duration as can be seen in supplemental Figure 1 in chapter 5. In 
addition, different cigarette types (heavy and light) and their contents were investigated 
on their association with bladder cancer in chapter 4 [6]. Although bladder cancer risk 
was increased for high total intake of tar, nicotine and CO, no difference between high 
tar and low tar cigarettes could be shown because of the low statistical power in this 
analysis. Especially due to the small number of controls smoking light cigarettes (n=7) the 
minimally detectable OR was smaller than the observed point estimate and not reliable. 
Furthermore, it could not be distinguished whether these associations were possibly con-
founded by smoking behaviour such as increasing inhalation volume when smoking light 
cigarettes, which is shown to be a prevalent compensation mechanism in light smokers 
[7]. In addition to these different aspects of smoking behaviour and the use of different 
cigarettes that could explain differences in bladder cancer risk between smokers, the 
current evidence on the association between exposure to environmental tobacco smoke 
and bladder cancer risk was also summarised by timing of exposure in chapter 3. For 
this, however, no noticeable association could be observed, although a power analysis 
showed that the current meta-analysis was able to detect a SOR of 1.17 to 1.18 with 
the current number of included studies [8]. Nevertheless, given the low heterogeneity 
between study results, where most studies found risk estimates very close to 1.00, it is 
unlikely that repeating this meta-analysis when more study estimates are available in the 
future will detect any meaningful (e.g. a SOR of 1.10 or less) impact of exposure to ETS on 
bladder cancer risk. 
In summary, the research presented in this thesis shows that different smoking behaviours 
(i.e. smoking duration and intensity) determine bladder cancer risk. Notably, a longer 
smoking duration is important in increasing risk, but also cigarette contents or inhalation 
pattern could potentially modify risk. 
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Overall, smoking initiation should be prevented at any age, but for those who already 
smoke all results in this thesis strongly imply that smoking cessation should happen as 
early in life as possible. Nevertheless, ex-smokers will likely always be at an increased 
bladder cancer risk compared to never smokers. Therefore, prevention efforts should 
focus on preventing smoking initiation in childhood, an approach which is already ap-
plied commonly [9]. This will likely have the largest effect on decreasing incident cases 
of smoking-related cancers on a population level since those who start smoking at a 
young age are often also longer exposed to cigarette smoke [10]. Many efforts have been 
taken to reduce smoking worldwide and it is encouraging to see the number of smokers 
decrease overall [11]; however, many countries still struggle with a high prevalence of 
smoking, especially in men (e.g. >50% of men in China [12] and >40% of men in Turkey 
[13]). 
smoking and bladder cancer prognosis
Bladder cancer is one of the most expensive malignancies because of the high recurrence 
rates and ongoing surveillance and treatment costs [14]. Therefore, it is highly relevant to 
investigate (modifiable) risk factors that could decrease the risk of recurrence in bladder 
cancer patients. Since smoking is the major risk factor for bladder cancer development, 
most studies on identifying modifiable risk factors for bladder cancer recurrence also 
focus on smoking, yet only retrospectively.
The pooled analysis of retrospective studies investigating smoking status and bladder 
cancer prognosis, described in chapter 6, indicates that current smokers at diagnosis of 
bladder cancer are at an increased risk of recurrence (in non-muscle-invasive patients) 
and of dying due to bladder cancer (in muscle-invasive patients) [15]. This is in line with 
results from a previous meta-analysis, providing evidence that smoking cessation before 
diagnosis reduces the risk of dying due to bladder cancer [16]. The observed risk estimates 
for recurrence were not as strong as for bladder cancer risk (e.g. approximately 3 times 
higher risk for current smokers at diagnosis compared to never smokers, while current 
smokers have an approximately 1.25-fold increased risk of recurrence). This difference in 
strength of association between risk of primary tumour and risk of recurrence might be 
explained by the theory of “field cancerization”. This theory proposes that (pre-)malignant 
transformation of cells has already occurred at different sites across the urothelium before 
diagnosis, explaining why (changing) smoking exposure after diagnosis will not have a 
large impact on disease prognosis [17].
Since all available studies on smoking and bladder cancer prognosis were retrospective, 
the impact of smoking behaviour on bladder cancer recurrence was investigated prospec-
tively within the BCPP cohort. Unfortunately, the number of patients who had stopped 
153
BCPP – smoking cessation and BC prognosis
8
smoking during follow-up was too low to assess the impact of smoking cessation on the 
recurrence of bladder cancer (chapter 7). The number of quitters after diagnosis found in 
BCPP was surprisingly low when compared to other observational studies. In California, 
for example, 48% of the smokers diagnosed with bladder cancer quitted smoking and it 
was also shown that the most important reasons for cessation were diagnosis of bladder 
cancer, as well as the advice of the urologist [18]. Other studies also showed that brief 
interventions (such as continued advice on quitting or congratulating people on abstain-
ing) applied by clinicians in the urology clinic can be effective in increasing the number 
of bladder cancer patients quitting smoking [19,20]. Since the number of quitters in BCPP 
was very low, it is highly recommended that urologists in the West Midlands area give 
smoking cessation advice or apply novel brief interventions to increase cessation rates in 
bladder cancer patients from the West Midlands.
Taken together, the current evidence indicates that smoking cessation before diagnosis 
has a larger impact on reducing risk of recurrence and mortality due to bladder cancer 
than smoking cessation after diagnosis. Nonetheless, smoking cessation after diagnosis 
should also be promoted in the urology clinic since the diagnosis of bladder cancer is a 
life-changing event that might trigger smokers to quit successfully. Moreover, smoking 
cessation might not only help in reducing risk of recurrence for bladder cancer, but can 
also prevent many smoking-related co-morbidities that occur often in bladder cancer 
patients [21]. 
methodologicAl considerAtions
misclassification of active and passive smoking exposure
Obtaining information on smoking behaviour from self-reported questionnaires often 
leads to underreporting of current smoking status [22]. In our study within the BCPP cohort 
(chapter 7), there was a considerable number of bladder cancer patients with presumably 
conflicting data on smoking behaviour. Where at baseline these patients reported to have 
never smoked, they reported smoking at the first follow-up measurement. Moreover, 
about 1 in 3 former smokers also seemed to have “started” again after 3 months. Although 
misclassification was not ascertained within BCPP, a previous study that compared urinary 
cotinine levels to self-reported smoking history in 145 bladder cancer patients, showed a 
misclassification rate of 33% for current smoking status [23]. Therefore, the results shown 
in chapter 7 are likely biased and underestimate the true effect of continuing smoking, 
especially through misclassification of current smokers at diagnosis [24].  
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The same misclassification could also have led to biased results in chapter 3, in which the 
exposure to ETS was assessed among never smokers. If again, a substantial proportion 
of the never smokers are former or current smokers, the strength of association might 
have been underestimated as the contrast between case and control group is possibly 
smaller than it could have been without any misclassification [25]. Nevertheless, since 
most reported studies on exposure to ETS and bladder cancer risk showed no statistically 
significant effects, this possible misclassification only makes it more likely that there is no 
substantial effect of exposure to ETS on bladder cancer risk.
interpretation of statistical models and implications of selection 
of confounders
In this thesis, results from several types of statistical models such as Cox regression 
models (chapter 7) or excess odds ratio (EOR) models (chapter 5) are presented. Cox 
regression analyses time-to-event data and there are several different options to reset 
survival time if multiple events occur. For example, within the Cox regression models 
used in BCPP in which multiple recurrence events were investigated, the risk of a second 
recurrence was estimated by calculating the time since the first event occurred (Chapter 
7). Another option, however, is to consider time since diagnosis for every event that might 
occur, accumulating person-time at risk for second or third recurrences as if the previ-
ous recurrences did not happen, but adjusting for the other recurrences statistically [26]. 
The interpretation of the results from these two different methods would be different, 
since in the second scenario more time is counted for a second event than in the first. 
Nevertheless, applying both methods for estimating the risk of recurrence for continuing 
smokers compared to never smokers did not show different results within BCPP (HR=1.10, 
95%CI=0.72-1.69 using the first method and HR=1.20, 95%CI=0.67-2.13 using the second 
method). Therefore, the rationale for using a specific statistical approach should always be 
clear and will help researchers in interpreting results in the correct way that follows from 
the data that is behind it [27].
Similarly, when building a statistical model adjusting for a certain set of confounders, 
researchers aim to obtain unbiased estimates of a causal effect between exposure and 
outcome. However, since epidemiological risk estimates are based on comparing averages 
or probabilities between groups, causality can only be inferred from a population level 
[28]. This is problematic for the process of selecting relevant confounders because within 
a study sample, confounders are selected on their relevance from a population perspec-
tive. Also, confounders could be correlated with each other introducing bias where there 
was none [29]. Therefore, theoretical frameworks have been developed to also assess the 
interplay between selected confounders to estimate which variables should be included 
in the model and which ones probably only introduce more bias [29]. This directed acyclic 
155
BCPP – smoking cessation and BC prognosis
8
graph method was used to formulate the final model in the Cox regression analysis pre-
sented in chapter 7.  
In summary, motivating choices for statistical models, selection of confounders and sub-
sequent correct interpretation of results in papers is of paramount importance to maintain 
a high standard of interpretable research, especially in observational studies where many 
possibly confounding variables are not controlled.
implicAtions And impAct of results
The results of this thesis clearly and irrefutably show that the duration of exposure to 
cigarette smoke is the most important factor for the development of bladder cancer 
Although the current evidence is limited, it is also plausible that a longer duration of 
exposure to cigarette smoke before diagnosis could possibly increase the chances of a 
type of bladder cancer with a worse prognosis in those with relatively impaired DNA 
repair mechanisms, because more opportunities for smoking-related DNA damage occur 
[30]. More importantly, even those who stopped smoking for more than 30 years are still 
at an increased risk of bladder cancer compared to never smokers. Therefore, the results 
from this thesis mainly implicate that smoking prevention programmes in children should 
be promoted to decrease the burden of bladder cancer in the future. Since the propor-
tion of smokers in many countries is still above 15% [11], promoting smoking cessation 
will also have a considerable impact on decreasing the incidence of bladder cancer on 
a shorter term, although less drastically than preventing people from starting smoking 
at all. In addition to bladder cancer, smoking is also strongly associated with increased 
incidence and accounts for about 50% of mortality in many frequently occurring cancers 
[31]. Therefore, smoking prevention is not only important to reduce the burden of bladder 
cancer, but also on a much larger scale.
future perspectives
prospective studies – reliable estimation of exposure to 
cigarette smoke
It is evident from the meta-analysis presented in chapter 6 and the prospective study pre-
sented in chapter 7 that more prospective studies on bladder cancer prognosis, gathering 
data on modifiable risk factors are needed to provide a better evidence based lifestyle 
advice that urologists could give to their patients to prevent bladder cancer recurrence. 
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An important issue that needs to be considered when designing a prospective study 
measuring smoking behaviour, is the under- or over reporting of unhealthy and healthy 
behaviour. To obtain reliable estimates on smoking status, future studies should consider 
determining cotinine levels in blood, urine or saliva instead of using self-reported ques-
tionnaires. 
Therefore, future prospective studies in bladder cancer prognosis should focus on reliable 
estimation of smoking status after diagnosis to definitively show what impact smoking 
behaviour can have on recurrence, progression and mortality.
smoking and the molecular heterogeneity of bladder cancer
Compared to most other common cancers, bladder cancer shows a large molecular 
heterogeneity compared to most other common cancers. The two major pathways with 
different molecular features that have been identified for the past two decades can gener-
ally be divided by showing hyperplasia and FGFR3 mutation or flat dysplasia and TP53 
mutation [32]. However, in recent years, many more sub-pathways have been suggested 
that could possibly explain differences in bladder cancer prognosis [33]. Since smokers 
present with different bladder tumour characteristics at diagnosis [34], future studies 
investigating smoking in relation to bladder cancer (prognosis) should also focus on 
explaining different molecular subtypes which might be associated with smoking.
modelling lifetime exposures, the future of epidemiology?
Establishing causal links between exposure and diseases has been one of the cornerstones 
of (bio)medical research for centuries. However, although epidemiology has identified a 
large proportion of major (causal) associations between exposure and disease over the 
past few decades, there is a need to reinvent itself as a research expertise to continue 
to contribute to understanding the causal associations between exposures and disease. 
In the past decades, epidemiology moved from the era of sanitary statistics, to an era 
focusing on infectious diseases towards chronic diseases and the “black box” paradigm 
[35]. At the beginning of the 1980’s the field of molecular epidemiology emerged that 
has contributed a lot to opening the black box between exposure and disease by relating 
genetic susceptibility, biomarkers of exposure and of biologically effect dose, to cancer 
risk [36]. At that time, researchers predicted that the black box era would lead into an era 
of eco-epidemiology, where biomedical techniques are integrated with classical epide-
miological methods [37], which is also what happened through genome-wide-association 
studies (GWAS) which emerged at the start of this century [38]. Currently, epidemiology 
is entering an era where new research methodologies need to be developed to analyse 
so-called “big data” (large databases of interlinkable datasets containing as much data 
as possible from every study participant [39]) and still obtain reliable and interpretable 
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results. A promising example of how complex exposure data can be approached is the ex-
posome approach. The exposome is defined as the conceptual framework of all exposures 
related to disease to which an individual is exposed during their lifetime [40]. In exposome 
wide association studies (EWAS), high throughput computational methods are applied to 
model the combination of all exposures related to disease simultaneously [41].
Hence, statistical methods like the EOR model (chapter 7) that can model highly correlated 
exposure variables simultaneously will likely be applied more often. As researchers can 
gather more data, the complexity of the analysis of the results also increases. Therefore, 
an important role for epidemiologists in the future will be in both applying and develop-
ing novel methodologies but, moreover, also be able to explain results from increasingly 
complex analyses to the public, clinicians and other public health professionals.
conclusion
The research presented in this thesis intended to comprehensively explain why smok-
ers get bladder cancer and how lifetime smoking behaviour could influence prognosis. 
Obviously, successful smoking prevention programmes will have the largest impact on 
reducing bladder cancer incidence. Nevertheless, the results across different studies 
indicate that for those already smoking, the total duration of exposure is most important 
in determining bladder cancer risk. Cigarette type and exposure to passive smoke seem 
to not have a significant impact on bladder cancer risk. Furthermore, smoking cessation 
before diagnosis will also help decrease the risk of recurrence for those who get bladder 
cancer most while more prospective research is needed to quantify the impact of smoking 
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Het doel van dit proefschrift was om meer inzicht te krijgen in de reeds bekende asso-
ciatie tussen rookgedrag en blaaskanker risico, alsmede prognose. Uit eerder onderzoek 
is bijvoorbeeld bekend dat rokers gemiddeld een driemaal zo hoog risico hebben op het 
ontwikkelen van blaaskanker, maar het is minder bekend hoe bijvoorbeeld sigaret-inhoud 
of de gehele blootstelling aan roken (o.a. aantal sigaretten per dag, rekening houdend met 
het aantal jaar) dit risico kan verhogen of verlagen. Er kan meer gerichte preventie plaats-
vinden als deze details meer bekend zijn en urologen kunnen hun blaaskanker patiënten 
uitleggen wat eventueel de voordelen zijn van stoppen met roken na de diagnose. De 
hypotheses van dit proefschrift waren dat de totale duur aan blootstelling aan roken 
belangijker is om risico te voorspellen dan het aantal sigaretten per dag en dat stoppen 
met roken na de diagnosis van blaaskanker de prognose positief kan beïnvloeden. Om 
deze hypotheses te kunnen onderzoeken, is eerst alle huidige literatuur onderzocht en 
samengevat door middel van meta-analyses en zijn de uit deze studies voorkomende 
openstaande vragen beantwoordt door analyse van data uit het prospectieve patiënten 
cohort BCPP en uit het internationale consortium van observationele studies naar blaas-
kanker genaamd BLEND.
samenvatting van de bevindingen uit dit proefschrift
Dit proefschrift kan onderverdeeld worden in twee delen; de onderzoeken naar de relatie 
tussen roken en a) blaaskanker risico (hoofdstuk 2 tot en met 5) en b) blaaskanker prog-
nose (hoofdstuk 6 en 7).
De uitgebreide meta-analyse die in hoofdstuk 2 wordt gepresenteerd, bevestigt het reeds 
bekende driemaal hogere risico op blaaskanker voor rokers op het moment van diagnose. 
Opvallend genoeg is het aantal blaaskanker gevallen dat toe te wijzen is aan roken in 
mannen lager dan in 2000 (nu 43% en nog 50% in 2000). Dit is waarschijnlijk te verklaren 
door het dalende aantal rokers in Westerse landen, waar blaaskanker het meest voorkomt. 
Daarnaast laat deze meta-analyse zien dat ook degene die meer dan 35 jaar voor afname 
van de vragenlijst gestopt zijn met roken nog steeds een verhoogd risico (ongeveer 1.5 
keer zo groot) hebben op blaaskanker ten opzichte van zij die nooit gerookt hebben.
In hoofdstuk 3 wordt al het wetenschappelijk bewijs samengevoegd wat er momenteel is 
naar blootstelling aan passief roken en blaaskanker risico. Aangezien er al recente analyses 
bestaan die dit hebben gedaan, hebben we in deze studie ervoor gekozen om te kijken 
naar blootstelling in specifieke fases van het leven. De resultaten van deze meta-analyse 
laten zien dat er geen noemenswaardig verhoogd (of verlaagd) risico op blaaskanker is bij 
blootstelling aan passief roken tijdens de kindertijd of tijdens het volwassen leven thuis 
of op het werk. Desalniettemin was gedetailleerde informatie over het rookgedrag van de 
actieve rokers waaraan de niet-rokers werden blootgesteld vaak onbekend en weten we 
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dus niet of er misschien wel een effect is bij blootstelling aan zware rokers. Ook keken alle 
studies naar niet-rokers die blootgesteld waren aan rokers en niet of rokers die ook nog 
blootgesteld werden aan passief roken van een partner een extra verhoogd risico hadden.
Door een unieke samenwerking tussen de “UK Department of Health” en de BCPP cohort 
studie was het mogelijk om te kijken naar de invloed van de teer, nicotine en koolstofmo-
nooxide (CO) inhoud van sigaretten op blaaskanker risico. De resultaten lieten zien dat een 
hogere dagelijkse inname van zowel teer, nicotine en CO lineair het risico op blaaskanker 
deden toenemen ten opzichte van de laagste inname groep onder rokers (hoofdstuk 4). 
Hiernaast werd geen verschil aangetoond tussen light en reguliere sigaretten. Los hiervan 
is het ook mogelijk dat individueel rookgedrag, bijvoorbeeld het wel of niet compleet 
oproken van de sigaret wat misschien vaker gebeurt bij zwaardere rokers, een vertekende 
factor geweest kan zijn in dit onderzoek en kan zorgen voor een overschatting van het 
effect van sigaret inhoud.
In hoofdstuk 5 wordt het effect van de duur van blootstelling aan roken en het aantal 
sigaretten, wat vaak sterk met elkaar samenhangt, tegelijk bekeken in het BLEND-consor-
tium. In deze studie zijn data van 15 patiënt-controle onderzoeken samengevoegd en de 
resultaten laten zien dat duur van blootstelling belangrijker is in het bepalen van risico 
dan het aantal sigaretten dat per dag gerookt wordt. Dit geeft aan dat stoppen met roken 
het meest wenselijk is en dat alleen reductie van het aantal sigaretten waarschijnlijk niet 
het gewenste positieve effect op de publieke gezondheid op zal leveren, in ieder geval 
wat betreft het verminderen van het aantal blaaskanker gevallen.
De meta-analysis in hoofdstuk 6, die resultaten van studies naar het effect van rook-
status op het moment van diagnosis op blaaskanker prognose (recidief, progressie en 
overleving) samenvat, laat zien dat blaaskanker patiënten die roken op het moment van 
diagnosis ongeveer 25% meer kans hebben op een recidief en om door blaaskanker te 
sterven binnen 5 jaar. Helaas zijn alle studies op dit moment retrospectief van aard en was 
er weinig bewijs over stoppen met roken na de diagnose op langere termijn. Hoofdstuk 
7 beschrijft de eerste prospectieve studie naar rookgedrag na de diagnose en de kans 
op blaaskanker recidieven. Opvallend genoeg was het aandeel blaaskanker patiënten dat 
stopte met roken na de diagnose te laag (14%) om betrouwbare uitspraken te kunnen 
doen op basis van deze gegevens, maar het lijkt erop dat stoppen met roken vóór de 
diagnose van blaaskanker een groter positief effect heeft op het verlagen van de kans op 




Het onderzoek gepresenteerd in dit proefschrift heeft getracht een uitgebreide uitleg te 
geven waarom rokers blaaskanker krijgen en hoe hun rookgedrag invloed kan hebben op 
hun prognose. Natuurlijk hebben succesvolle preventieprogramma’s om te voorkomen 
dat mensen starten met roken de grootste impact op het verminderen van het aantal 
blaaskanker gevallen. Desalniettemin, geven onze resultaten uit verschillende studies aan 
dat de totale duur van de blootstelling aan roken dusdanig belangrijk is dat compleet 
stoppen met roken van groot belang is om het aantal blaaskanker gevallen in een popu-
latie significant terug te dringen. Het type sigaret of blootstelling aan passief roken lijkt 
geen invloed te hebben op blaaskanker risico. Naast het verlagen van risico, zal stoppen 
met roken voor de diagnose waarschijnlijk ook ervoor zorgen dat de kans op recidieven 
na diagnose van blaaskanker ook kleiner wordt, maar meer prospectief onderzoek is 






Bladder cancer is a common malignancy in the elderly from Western countries and will 
remain to have a significant social and economic impact on both individual lives as well 
as public health in general.
The findings of this thesis will mostly impact cancer prevention as the meta-analysis 
research and the pooled analysis from the BLEND consortium provide the most detailed 
summary of the available scientific evidence on the association between smoking and 
bladder cancer risk. The results from this research indicate that merely focussing on 
decreasing the number of cigarettes smoked per day is not enough and that only a large 
proportion of regular smokers completely quitting smoking is likely to have a meaningful 
impact on lowering bladder cancer rates.
Results of this thesis have been shared, after publication, with the UK-based bladder can-
cer charity “Fight Bladder Cancer”. This charity is run by bladder cancer survivors and their 
families and aims to translate medical terms, scientific results and share tips and stories. 
By collaborating with such a patient-centred charity, I have attempted to help them keep 
their information up to date and to provide them with some of the most recent facts on 
smoking and bladder cancer. 
Additionally, the Wikipedia page for “bladder cancer” (under heading: “causes”) was up-
dated in 2016 with results from the meta-analysis estimating the population attributable 
risk of bladder cancer among smokers, which decreased since the last published figures 
in 2000.
Furthermore, results published in this thesis have been presented at the yearly Dutch 
conference for Epidemiology (WEON) and, while another paper on fluid intake and 
bladder cancer characteristics at diagnosis was presented, results were also discussed 
with several urologists at the European Association of Urology (EAU) conference 2018 in 
Copenhagen. It is important that both other researchers in the field and clinicians in the 
field are provided with the most reliable estimates of the impact of smoking on bladder 
cancer. In this way, other researchers can determine where more studies are needed and 
clinicians can use scientific facts to advise and treat their patients. 
Summarising, the valorisation of the results of this epidemiological thesis is mainly in 
updating the facts on smoking and bladder cancer that can be read online by most 
people. Furthermore, providing reliable evidence on basic epidemiological associations 
lays the foundation for more translational research and provides clinicians with fact sheets 
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me geïntroduceerd hebt in het CAT-onderwijs en dat ik je altijd mocht lastigvallen met 
vragen daarover. 
Het CAT-onderwijs is een mooi bruggetje naar de volgende collega’s waar ik veel mee 
samen heb gewerkt en waar ik een heleboel van heb mogen leren op het gebied van 
epidemiologie en onderwijs. Alle collega’s van CAT-onderwijs bedankt voor de in-
houdelijke discussies tijdens de besprekingen en in het bijzonder iedereen die meehelpt 
in het organiseren van dit onderwijs. Hiernaast wil ik Martien bedanken voor onze 
samenwerking in Venlo, het was erg leuk om samen met degene die mij mijn eerste col-
leges epidemiologie heeft gegeven nu zelf een blok te organiseren. Hetzelfde geldt voor 
Bas, bedankt voor onze discussies over onderwijs en onderzoek. Matty, Leo, Colinda en 
Piet, bedankt voor alles wat ik tijdens mijn Master-stage heb mogen leren onder jullie 
supervisie binnen de NLCS. Zonder deze ervaring had ik zeker niet zo’n vliegende start 
kunnen maken met dit promotietraject! Uiteraard is er tussen alle bedankjes richting de 
afdeling Epidemiologie een apart stukje gereserveerd in dit dankwoord voor jou Christel. 
Zonder jouw enthousiasme voor epidemiologie tijdens de Bachelor had ik misschien wel 
iets heel anders gekozen en je adviezen over belangrijke carrièrekeuzes helpen me nog 
steeds! Ook wil ik hier mijn “aangetrouwde familie” op Campus Venlo en mijn “nieuwe 
werkfamilie” bij het Leerhuis in VieCuri bedanken voor jullie support!
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Paranimf Sylvia, dankjewel dat je mijn naam hebt genoemd als potentiële collega toen je 
begon aan het parallelle joint PhD project in Birmingham. Ik kan een heel boek schrijven 
over onze (of eigenlijk vooral jouw) avonturen in Birmingham en de gesprekken in het 
kantoor achter de tralies. Zonder jou was het een heel stuk saaier geweest in Birmingham 
en waren er ook een heleboel kleine foutjes niet ontdekt in verschillende datasets. Geluk-
kig let je altijd op de allerkleinste details en dat maakte ons ook zo’n dreamteam de 
afgelopen 4 jaar!
Paranimf Jeroen, ik vind het mooi dat we inmiddels als collega-epidemiologen nog beter 
significante woordgrappen kunnen maken. Bedankt dat ik altijd bij je terecht kan om 
nieuwe onderzoeksplannen te pitchen en te horen over jouw ideeën en ik hoop dat onze 
vriendschap in de toekomst nog eens vereeuwigd zal worden op Pubmed! 
Ben, Jorn en Maikel, we zijn ondertussen al meer dan 10 jaar bevriend en wetenschap-
pelijke studies beweren dat het dan vriendschap voor altijd is. Ik denk dat de kans daarop 
bij ons groter is dan 95% en daarom verdienen de Heugemer Boys een speciale shout-out; 
als Jorn het niet doet op tv doe ik het wel via dit boekje. Andere vrienden die ik speciaal 
wil noemen zijn de bandleden van Dubbel Fout: Bas, Paul, HoiYau, Maarten en nog een 
keer Ben. We zijn de afgelopen jaren het hele land doorgereisd met onze foute medleys 
en covers wat voor mij altijd een geweldige uitlaatklep is om even alles van me af te laten 
glijden en te rocken!
Als laatste bedank ik graag mijn échte aangetrouwde familie; Fokke en Tine, Hilde & 
Wilmer (en natuurlijk Rinse & Hedser) en Jelke & Elze. Bedankt dat jullie altijd geïnter-
esseerd zijn, het hele land door willen rijden om ons te zien en voor alle Friese woorden 
die ik nog steeds bij blijf leren! Papa en Mama, of Huub en Mieke, zoals alle andere 
mensen op de wereld jullie kennen, bedankt dat ik uit zo’n veilig nestje kom en dat jullie 
altijd achter me staan. Allerliefste Alie, wat is er veel moois gebeurd in ons leven het 
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